inline xbrl viewer application relies heavily javascript need allow javascript to use this application inline viewer menu menu information save xbrl instance save xbrl zip file open html setting help section section additional search option include fact name include fact content include label include definition include dimension reference option include topic include sub topic include paragraph include publisher include section match case clear search submit search data data amount text only calculation only negative only additional item only tag tag all standard only custom only filter more filter selecting will take moment period measure axis explicit typed member explicit typed scale balance debit credit reset all filter link fact loading inline form tagged section search all search in internal section only search in external section only clear section search submit section search help getting started the inline xbrl viewer allows user to quickly easily review detail of the tagged information in inline document automatically placing top and bottom highlight border around tagged numeric fact and left and right border each block tagged fact hovering tagged fact will highlight shade all content related to the tagged fact and clicking on tagged fact will reveal tagging detail in the fact review window navigation search and filter option also provided to easily refine and identify specific type of tagged information fact review window the fact review window show the tagging detail for the currently selected fact highlighted solid blue border are four category of fact detail which viewed an value indicates there is available information for the item within the given category attribute all primary information applicable describing the tagged fact including period sign decimal dimensional detail ax and member scale measure and data type label detailed documentation definition for the tag used and label reference authoritative reference information applicable for the selected tag calculation balance and calculation hierarchy detail numeric non dimensioned item only searching there are two way to search the document fact and section to search information enter keyword in search box and select the magnifying glass icon to return matching result search operator and via and and or via or or are available to refine search fact the search fact box can be used to find tagged fact matching entered keywords by default tag name tag label and tagged content are included in search tagged fact matching the search criterion are shown with yellow colored default shading on the page and appear in the fact list select the button to the left of the magnifying glass icon to clear the search the content included in search can be increased to included tag definition dimension and authoritative reference by selecting the cog wheel icon to the left of the search box see setting for more information section the search section box can be used to filter the tagged section of the financial statement filter filter change the number of highlighted fact and item in the fact list by providing several way to review and pinpoint certain tagged information multiple filter can be used data filter filter option allow the user to refine the highlighted tagged fact by data type all display all tagged data default amount only numeric fact only text only textual fact only calculation only numeric fact participating in calculation only negative only negative numeric amount only additional item only tagged fact without corresponding html presentation hidden fact only tag filter these filter allow the user to refine the highlighted fact by tag type all display all tagged data default standard only fact with standard tag common taxonomy us_gaap ifrs dei custom only fact with extension custom tag unique to the entity document more filter additional filter allow user to further refine the highlighted fact period list of all used context year and reporting period measure list of all used unit of measure dollar applicable axis list of all used axis dimension applicable dimension applicable scale list of all used scaled option thousand million applicable balance debit credit applicable multiple filter work in conjunction with each other for example selecting the amount only data filter and custom only tag filter will highlight only numeric tagged fact using custom tag and list in the fact list active filter are displayed in the filter toolbar are selected active filter can be removed individually by unchecking or selecting all option for each filter or all at once via the reset all filter option fact list result on the toolbar select the count to the right of the word fact fact to reveal the fact list result navigable listing of all currently highlighted tagged fact the count represents the current number of fact by default all tagged fact are displayed in the fact list result the list content and count reflects the currently highlighted fact filter and search criterion refine the list to match the highlighted tagged fact navigation control are available to move the list well move the current view to the corresponding highlighted fact location automatically fact in the fact result list is selected will reveal the fact review window certain letter may appear to the right of an item in the fact result list to indicate certain property the letter appears for fact it indicates the fact is additional data hidden with potentially no corresponding html presentation if the letter appears the fact is tagged with custom tag if the letter appears the fact is tagged with dimensional information section the section toolbar item provides listing of the tagged section of the inline document section are divided three group document entity information financial statement note to the financial statement by expanding group and selecting section item in the listing inline xbrl viewer will navigate to that section when the tagged section feature is open the search section box will additionally filter the list of section to only section that match the entered criterion menu information the information menu item provides additional detail the current inline document and customizable viewer setting company and document basic company and document information tag fact and tag standard and custom information file file used additional item additional hidden data that tagged potentially corresponding location in the html save xbrl instance the save xbrl instance menu item allows an xbrl instance document xml that is extracted from the inline document to be saved locally for use by software supporting the xbrl format save xbrl zip the save xbrl zip menu item allows zip file zip that contains the provided xbrl instance document and related custom taxonomy file to be saved locally setting the setting menu item provides the ability to customize viewer feature tagged fact hover on display the hover fact review window for any tagged fact hide the hover fact review window for any tagged fact default may impact performance with certain web browser auto scrolling position this setting will have no effect on ie or safari top selecting fact from the section menu or the fact menu will automatically scroll that element to the top of the inline xbrl viewer window default center selecting fact from the section menu or the fact menu will automatically scroll that element to the middle of the inline xbrl viewer window highlight color use the save and reset button to save the selected setting or reset to default tagged data change the highlight color of the tagged fact border search result change the background color of tagged item matching the search result selected fact change the color of highlight border used to identify the currently selected fact tag shading hover change the color of the shading applied to tagged data on hover search option match case match the specific case of the entered search keyword include label extends search to include tag label include definition extends search to include tag definition include dimension extends search to include dimensional detail include reference extends search to include authoritative reference information optionally specify the reference part to include in the search topic subtopic section help this content version indicates the current build of the inline xbrl viewer application fact select page loading pfe fasb org gaap otherassetsnoncurrenthttp fasb org gaap otherassetsnoncurrenthttp fasb org gaap otherliabilitiescurrenthttp fasb org gaap otherliabilitiescurrenthttp fasb org gaap otherliabilitiesnoncurrenthttp fasb org gaap gaap usdxbrli gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap salesrevenueproductlinememberus gaap productconcentrationriskmemberpfe topsevenproductsmemberus gaap salesrevenueproductlinememberus gaap gaap salesrevenueproductlinememberpfe topsixproductsmemberus gaap gaap gaap gaap gaap gaap gaap arraymemberpfe gaap developedtechnologyrightsmemberpfe gaap developedtechnologyrightsmemberpfe arraymemberus gaap gaap licensingagreementsmemberpfe arraymemberpfe licensingagreementsdevelopedtechnologymemberpfe licensingagreementsdevelopedtechnologymemberpfe arraymemberus gaap gaap discontinuedoperationsdisposedofbysalememberpfe gaap discontinuedoperationsdisposedofbysalememberpfe purchaserofmeridianmembersrt minimummemberpfe purchaserofmeridianmemberpfe transitionserviceagreementmembersrt purchaserofmeridianmemberpfe mylanmemberpfe gaap discontinuedoperationsdisposedofbymeansotherthansalespinoffmemberpfe viatrismemberpfe mylanmemberpfe upjohnfinanceb gaap seniornotesmemberpfe gaap commercialpapermemberus gaap gaap gaap gaap discontinuedoperationsdisposedofbymeansotherthansalespinoffmemberpfe gaap discontinuedoperationsdisposedofbymeansotherthansalespinoffmemberpfe gaap discontinuedoperationsdisposedofbymeansotherthansalespinoffmemberpfe gaap discontinuedoperationsdisposedofbymeansotherthansalespinoffmemberpfe viatrismembersrt minimummemberpfe viatrismemberpfe manufacturingandsupplyagreementmembersrt viatrismemberpfe transitionserviceagreementmembersrt gaap gaap gaap epipenmemberus gaap discontinuedoperationsdisposedofbysalememberpfe upjohnincandupjohnfinancebvmemberus gaap gaap segmentdiscontinuedoperationsmemberpfe gaap gaap gskconsumerhealthcarememberpfe gskconsumerhealthcaremembersrt gskconsumerhealthcaremembersrt gskconsumerhealthcarememberus gaap viivhealthcarelimitedmemberpfe viivhealthcarelimitedmemberpfe viivhealthcarelimitedmemberpfe viivhealthcarelimitedmemberpfe viivhealthcarelimitedmemberpfe gaap licensingagreementsmemberpfe gaap researchanddevelopmentexpensememberus gaap licensingagreementsmemberpfe gaap licensingagreementsmemberpfe gaap licensingagreementsmemberus gaap researchanddevelopmentexpensememberpfe beammemberus gaap beammemberpfe beammemberus gaap gaap researchanddevelopmentexpensememberpfe beammemberus gaap beammemberus gaap gaap researchanddevelopmentexpensememberpfe arvinasincmemberus gaap arvinasincmemberus gaap gaap researchanddevelopmentexpensememberpfe arvinasincmemberus gaap arvinasincmemberus gaap arvinasincmemberus gaap myovantmemberus gaap myovantmemberus gaap myovantmemberus gaap myovantmemberus gaap gaap developedtechnologyrightsmemberpfe myovantmemberus gaap cstonememberus gaap cstonememberus gaap biontechmemberus gaap collaborativearrangementmemberpfe biontechmemberus gaap researchanddevelopmentexpensememberus gaap collaborativearrangementmemberpfe biontechmemberus gaap collaborativearrangementmemberpfe biontechmemberpfe coronavirusvaccineprogrammrnabasedmemberus gaap biontechmemberpfe coronavirusvaccineprogrammrnabasedmemberus gaap biontechmemberpfe coronavirusvaccineprogrammrnabasedmemberus gaap researchanddevelopmentexpensememberus gaap biontechmemberpfe coronavirusvaccineprogrammrnabasedmemberus gaap biontechmemberpfe coronavirusvaccineprogrammrnabasedmemberus gaap biontechmemberus gaap gaap collaborativearrangementmemberpfe gaap productmemberus gaap gaap productmemberus gaap gaap productmemberus gaap gaap collaborativearrangementmemberpfe gaap collaborativearrangementmemberpfe gaap collaborativearrangementmemberpfe gaap gaap gaap corporateenablingfunctionsmemberpfe gotomarketmodelmemberpfe manufacturingoptimizationmemberpfe manufacturingoptimizationmemberpfe focusedcompanyplanmemberpfe focusedcompanyplanmemberpfe focusedcompanyplanmemberpfe focusedcompanyplanmemberpfe businessintegrationcostsmemberpfe businessintegrationcostsmemberpfe gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap biontechmemberus gaap gaap licensingagreementsmemberus gaap gaap pumatechnologiesmemberus gaap elilillycompanymemberus gaap gaap licensingagreementsmemberus gaap mylanmemberus gaap gaap licensingagreementsmemberus gaap arraymemberus gaap inprocessresearchanddevelopmentmemberpfe gaap developedtechnologyrightsmemberpfe eucrisamemberpfe anacormemberpfe genericsterileinjectableproductmemberus gaap developedtechnologyrightsmemberpfe hospiramemberpfe gaap developedtechnologyrightsmemberpfe eucrisamemberpfe gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap moneymarketfundsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap moneymarketfundsmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap moneymarketfundsmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap moneymarketfundsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap moneymarketfundsmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap moneymarketfundsmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap shortterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap shortterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap shortterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap shortterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap shortterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap shortterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap shortterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap shortterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap shortterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap shortterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap shortterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap shortterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap interestratecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap interestratecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap interestratecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap interestratecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap interestratecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap interestratecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreignexchangecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap foreignexchangecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap foreignexchangecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreignexchangecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap foreignexchangecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap foreignexchangecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberpfe gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberpfe longterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberpfe gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberpfe longterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberpfe gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberpfe longterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberpfe gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreigngovernmentdebtsecuritiesmemberpfe longterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberpfe longterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap longterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberpfe longterminvestmentsmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberpfe longterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap longterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberpfe longterminvestmentsmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberpfe longterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap longterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberpfe longterminvestmentsmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberpfe longterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap longterminvestmentsmemberus gaap gaap fairvaluemeasurementsrecurringmemberpfe longterminvestmentsmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap othernoncurrentassetsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap othernoncurrentassetsmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap othernoncurrentassetsmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap othernoncurrentassetsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap othernoncurrentassetsmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap othernoncurrentassetsmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap othernoncurrentassetsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap othernoncurrentassetsmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap othernoncurrentassetsmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap othernoncurrentassetsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap othernoncurrentassetsmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap othernoncurrentassetsmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap othernoncurrentassetsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap othernoncurrentassetsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap othernoncurrentassetsmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap othernoncurrentassetsmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap othercurrentliabilitiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap othercurrentliabilitiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap othercurrentliabilitiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap othercurrentliabilitiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap othercurrentliabilitiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap othercurrentliabilitiesmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreignexchangecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap foreignexchangecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap foreignexchangecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap foreignexchangecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap foreignexchangecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap foreignexchangecontractmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap fairvaluemeasurementsrecurringmemberus gaap gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap estimateoffairvaluefairvaluedisclosurememberus gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap commercialpapermemberpfe gaap gaap gaap gaap gaap gaap gaap unsecureddebtmemberpfe gaap unsecureddebtmemberpfe gaap unsecureddebtmemberpfe gaap unsecureddebtmemberpfe gaap unsecureddebtmemberpfe gaap unsecureddebtmemberpfe gaap gaap gaap unsecureddebtmemberpfe gaap unsecureddebtmemberpfe gaap gaap gaap gaap gaap gaap gaap unsecureddebtmemberpfe gaap unsecureddebtmemberpfe gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap foreignexchangecontractmemberus gaap gaap foreignexchangecontractmemberus gaap gaap interestratecontractmemberus gaap gaap interestratecontractmemberus gaap gaap gaap gaap nondesignatedmemberus gaap gaap nondesignatedmemberus gaap gaap salesmemberus gaap foreignexchangecontractmemberus gaap gaap salesmemberus gaap foreignexchangecontractmemberus gaap gaap foreignexchangecontractmemberus gaap gaap foreignexchangecontractmemberus gaap otherincomedeductionsandcostofsalesmemberus gaap foreignexchangecontractmemberus gaap otherincomedeductionsandcostofsalesmemberus gaap foreignexchangecontractmemberus gaap gaap cashflowhedgingmemberus gaap foreignexchangecontractmemberus gaap gaap cashflowhedgingmemberus gaap foreignexchangecontractmemberus gaap gaap cashflowhedgingmemberpfe otherincomedeductionsandcostofsalesmemberus gaap foreignexchangecontractmemberus gaap gaap cashflowhedgingmemberpfe otherincomedeductionsandcostofsalesmemberus gaap foreignexchangecontractmemberus gaap gaap interestratecontractmemberus gaap designatedashedginginstrumentmemberus gaap gaap interestratecontractmemberus gaap designatedashedginginstrumentmemberus gaap gaap foreignexchangecontractmemberus gaap designatedashedginginstrumentmemberus gaap gaap foreignexchangecontractmemberus gaap designatedashedginginstrumentmemberus gaap otherincomedeductionsandcostofsalesmemberus gaap foreignexchangecontractmemberus gaap designatedashedginginstrumentmemberus gaap otherincomedeductionsandcostofsalesmemberus gaap foreignexchangecontractmemberus gaap designatedashedginginstrumentmemberus gaap gaap designatedashedginginstrumentmemberpfe gaap designatedashedginginstrumentmemberpfe otherincomedeductionsandcostofsalesmemberus gaap designatedashedginginstrumentmemberpfe foreigncurrencylongtermdebtmemberus gaap foreigncurrencylongtermdebtmemberus gaap otherincomedeductionsandcostofsalesmemberpfe foreigncurrencylongtermdebtmemberus gaap gaap nondesignatedmemberus gaap foreignexchangecontractmemberus gaap gaap nondesignatedmemberus gaap foreignexchangecontractmemberus gaap gaap foreignexchangecontractmemberus gaap designatedashedginginstrumentmemberus gaap gaap gaap biontechmemberpfe comirnatymemberus gaap biontechmemberpfe comirnatymemberus gaap gaap gaap gaap buildingmembersrt gaap buildingmembersrt gaap gaap minimummemberus gaap maximummemberus gaap gaap gaap gaap furnitureandfixturesmembersrt gaap furnitureandfixturesmembersrt gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap biontechmemberpfe comirnatymemberus gaap gaap gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap gaap gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmembercountry gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap gaap gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap pensionplansdefinedbenefitmembercountry gaap definedbenefitplancashandcashequivalentsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap pensionplansdefinedbenefitmembercountry usus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap pensionplansdefinedbenefitmembercountry gaap definedbenefitplancashandcashequivalentsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap pensionplansdefinedbenefitmembercountry usus gaap gaap pensionplansdefinedbenefitmemberpfe definedbenefitplanequitysecuritiesglobalequitysecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanequitysecuritiesglobalequitysecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanequitysecuritiesglobalequitysecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanequitysecuritiesglobalequitysecuritiesmembercountry gaap pensionplansdefinedbenefitmemberpfe definedbenefitplanequitysecuritiesglobalequitysecuritiesmembercountry usus gaap gaap pensionplansdefinedbenefitmemberpfe definedbenefitplanequitysecuritiesglobalequitysecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanequitysecuritiesglobalequitysecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanequitysecuritiesglobalequitysecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanequitysecuritiesglobalequitysecuritiesmembercountry gaap pensionplansdefinedbenefitmemberpfe definedbenefitplanequitysecuritiesglobalequitysecuritiesmembercountry usus gaap gaap pensionplansdefinedbenefitmemberpfe definedbenefitplanequitysecuritiesequitycommingledfundsmembercountry gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanequitysecuritiesequitycommingledfundsmembercountry gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanequitysecuritiesequitycommingledfundsmembercountry gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanequitysecuritiesequitycommingledfundsmembercountry gaap pensionplansdefinedbenefitmemberpfe definedbenefitplanequitysecuritiesequitycommingledfundsmembercountry usus gaap gaap pensionplansdefinedbenefitmemberpfe definedbenefitplanequitysecuritiesequitycommingledfundsmembercountry gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanequitysecuritiesequitycommingledfundsmembercountry gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanequitysecuritiesequitycommingledfundsmembercountry gaap pensionplansdefinedbenefitmemberus gaap definedbenefitplanequitysecuritiesequitycommingledfundsmembercountry gaap pensionplansdefinedbenefitmemberpfe definedbenefitplanequitysecuritiesequitycommingledfundsmembercountry usus gaap gaap pensionplansdefinedbenefitmemberus gaap corporatedebtsecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap gaap corporatedebtsecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap gaap corporatedebtsecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap gaap corporatedebtsecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap corporatedebtsecuritiesmembercountry usus gaap gaap pensionplansdefinedbenefitmemberus gaap corporatedebtsecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap gaap corporatedebtsecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap gaap corporatedebtsecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap ustreasurysecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap gaap ustreasurysecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap ustreasurysecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap ustreasurysecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap ustreasurysecuritiesmembercountry usus gaap gaap pensionplansdefinedbenefitmemberus gaap ustreasurysecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap gaap ustreasurysecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap ustreasurysecuritiesmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap ustreasurysecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap ustreasurysecuritiesmembercountry usus gaap gaap pensionplansdefinedbenefitmemberus gaap fixedincomesecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap gaap fixedincomesecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap gaap fixedincomesecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap fixedincomesecuritiesmembercountry usus gaap gaap pensionplansdefinedbenefitmemberus gaap fixedincomesecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap gaap fixedincomesecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap gaap fixedincomesecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap gaap fixedincomesecuritiesmembercountry gaap pensionplansdefinedbenefitmemberus gaap fixedincomesecuritiesmembercountry usus gaap partnershipinterestmemberus gaap pensionplansdefinedbenefitmembercountry partnershipinterestmemberus gaap pensionplansdefinedbenefitmemberus gaap partnershipinterestmemberus gaap pensionplansdefinedbenefitmemberus gaap partnershipinterestmemberus gaap pensionplansdefinedbenefitmembercountry usus gaap partnershipinterestmemberus gaap pensionplansdefinedbenefitmembercountry partnershipinterestmemberus gaap pensionplansdefinedbenefitmemberus gaap partnershipinterestmemberus gaap pensionplansdefinedbenefitmemberus gaap partnershipinterestmemberus gaap pensionplansdefinedbenefitmemberus gaap partnershipinterestmemberus gaap pensionplansdefinedbenefitmembercountry usus gaap gaap pensionplansdefinedbenefitmemberpfe insurancecontractsmembercountry gaap pensionplansdefinedbenefitmemberus gaap insurancecontractsmembercountry gaap pensionplansdefinedbenefitmemberus gaap insurancecontractsmembercountry gaap pensionplansdefinedbenefitmemberus gaap insurancecontractsmembercountry gaap pensionplansdefinedbenefitmemberpfe insurancecontractsmembercountry usus gaap gaap pensionplansdefinedbenefitmemberpfe insurancecontractsmembercountry gaap pensionplansdefinedbenefitmemberus gaap insurancecontractsmembercountry gaap pensionplansdefinedbenefitmemberus gaap insurancecontractsmembercountry gaap pensionplansdefinedbenefitmemberus gaap insurancecontractsmembercountry gaap pensionplansdefinedbenefitmemberpfe insurancecontractsmembercountry usus gaap gaap pensionplansdefinedbenefitmemberpfe othercommingledfundsmembercountry gaap pensionplansdefinedbenefitmemberus gaap othercommingledfundsmembercountry gaap pensionplansdefinedbenefitmemberpfe othercommingledfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap othercommingledfundsmembercountry gaap pensionplansdefinedbenefitmemberpfe othercommingledfundsmembercountry usus gaap gaap pensionplansdefinedbenefitmemberpfe othercommingledfundsmembercountry gaap pensionplansdefinedbenefitmemberus gaap othercommingledfundsmembercountry gaap pensionplansdefinedbenefitmemberpfe othercommingledfundsmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap othercommingledfundsmembercountry gaap pensionplansdefinedbenefitmemberpfe othercommingledfundsmembercountry usus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmembercountry usus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmemberus gaap gaap pensionplansdefinedbenefitmembercountry usus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap foreignplanmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap foreignplanmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberpfe gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberpfe definedbenefitplanequitysecuritiesequitycommingledfundsmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberpfe gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberpfe definedbenefitplanequitysecuritiesequitycommingledfundsmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap corporatedebtsecuritiesmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap corporatedebtsecuritiesmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap ustreasurysecuritiesmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap ustreasurysecuritiesmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap ustreasurysecuritiesmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap ustreasurysecuritiesmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap fixedincomesecuritiesmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap fixedincomesecuritiesmemberus gaap partnershipinterestmemberus gaap foreignplanmemberus gaap partnershipinterestmemberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap partnershipinterestmemberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap partnershipinterestmemberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap partnershipinterestmemberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap partnershipinterestmemberus gaap foreignplanmemberus gaap partnershipinterestmemberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap partnershipinterestmemberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap partnershipinterestmemberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap partnershipinterestmemberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberpfe gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberpfe insurancecontractsmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberpfe gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberpfe insurancecontractsmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap otheraggregatedinvestmentsmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap otheraggregatedinvestmentsmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap otheraggregatedinvestmentsmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap otheraggregatedinvestmentsmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap otheraggregatedinvestmentsmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap otheraggregatedinvestmentsmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap otherpostretirementbenefitplansdefinedbenefitmembercountry gaap definedbenefitplancashandcashequivalentsmemberus gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap otherpostretirementbenefitplansdefinedbenefitmembercountry gaap definedbenefitplancashandcashequivalentsmemberus gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap otherpostretirementbenefitplansdefinedbenefitmembercountry usus gaap gaap otherpostretirementbenefitplansdefinedbenefitmemberpfe insurancecontractsmembercountry gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap insurancecontractsmembercountry gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap insurancecontractsmembercountry gaap otherpostretirementbenefitplansdefinedbenefitmemberpfe insurancecontractsmembercountry gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap insurancecontractsmembercountry gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap insurancecontractsmembercountry gaap otherpostretirementbenefitplansdefinedbenefitmemberpfe insurancecontractsmembercountry usus gaap gaap otherpostretirementbenefitplansdefinedbenefitmembercountry gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap otherpostretirementbenefitplansdefinedbenefitmembercountry gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap otherpostretirementbenefitplansdefinedbenefitmemberus gaap gaap otherpostretirementbenefitplansdefinedbenefitmembercountry usus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberus gaap gaap definedbenefitplancashandcashequivalentsmemberus gaap pensionplansdefinedbenefitmembersrt minimummembercountry gaap definedbenefitplancashandcashequivalentsmemberus gaap pensionplansdefinedbenefitmembercountry ussrt gaap definedbenefitplanequitysecuritiesmemberus gaap pensionplansdefinedbenefitmembersrt minimummembercountry gaap definedbenefitplanequitysecuritiesmemberus gaap pensionplansdefinedbenefitmembercountry ussrt gaap pensionplansdefinedbenefitmembersrt minimummembercountry usus gaap gaap pensionplansdefinedbenefitmembercountry ussrt maximummemberus gaap gaap pensionplansdefinedbenefitmemberpfe definedbenefitplanotherinvestmentsmembersrt minimummembercountry gaap pensionplansdefinedbenefitmemberpfe definedbenefitplanotherinvestmentsmembercountry ussrt gaap definedbenefitplancashandcashequivalentsmemberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembersrt gaap definedbenefitplancashandcashequivalentsmemberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembersrt gaap definedbenefitplanequitysecuritiesmemberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembersrt gaap definedbenefitplanequitysecuritiesmemberus gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembersrt gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembersrt minimummemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmembersrt maximummemberus gaap gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberpfe definedbenefitplanotherinvestmentsmembersrt gaap foreignplanmemberus gaap pensionplansdefinedbenefitmemberpfe definedbenefitplanotherinvestmentsmembersrt gaap definedbenefitplancashandcashequivalentsmemberus gaap otherpostretirementbenefitplansdefinedbenefitmembersrt minimummembercountry gaap definedbenefitplancashandcashequivalentsmemberus gaap otherpostretirementbenefitplansdefinedbenefitmembercountry ussrt gaap otherpostretirementbenefitplansdefinedbenefitmemberpfe insurancecontractsmembersrt minimummembercountry gaap otherpostretirementbenefitplansdefinedbenefitmemberpfe insurancecontractsmembercountry ussrt gaap gaap gaap gaap minimummemberpfe totalshareholderreturnunitstsrusmembersrt minimummemberpfe maximummemberpfe gaap measurepfe gaap performancesharesmembersrt gaap performancesharesmembersrt breakthroughperformanceawardsmembersrt breakthroughperformanceawardsmembersrt gaap performancetotalshareholderreturnunitptsrusmembersrt performancetotalshareholderreturnunitptsrusmemberpfe gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap gaap patentinfringementmemberpfe eliquismemberus gaap pendinglitigationmemberpfe docetaxelmemberus gaap pendinglitigationmemberpfe epipenmemberus gaap discontinuedoperationsdisposedofbysalememberpfe gaap operatingsegmentsmemberpfe gaap operatingsegmentsmemberpfe gaap operatingsegmentsmemberpfe gaap gaap gaap reconcilingitemspurchaseaccountingadjustmentsmemberus gaap reconcilingitemspurchaseaccountingadjustmentsmemberus gaap reconcilingitemspurchaseaccountingadjustmentsmemberus gaap reconcilingitemsacquisitionrelatedcostsmemberus gaap reconcilingitemsacquisitionrelatedcostsmemberus gaap reconcilingitemsacquisitionrelatedcostsmemberus gaap reconcilingitemsothermemberus gaap reconcilingitemsothermemberus gaap reconcilingitemsothermemberus gaap nonunitedstatesmemberus gaap revenuefromcontractwithcustomermemberus gaap nonunitedstatesmemberus gaap revenuefromcontractwithcustomermemberus gaap nonunitedstatesmemberus gaap revenuefromcontractwithcustomermemberus gaap usus gaap revenuefromcontractwithcustomermemberus gaap usus gaap revenuefromcontractwithcustomermemberus gaap usus gaap revenuefromcontractwithcustomermemberus gaap jpus gaap revenuefromcontractwithcustomermemberus gaap jpus gaap revenuefromcontractwithcustomermemberus gaap jpus gaap revenuefromcontractwithcustomermemberus gaap gaap customerconcentrationriskmemberpfe mckessoninc memberus gaap gaap customerconcentrationriskmemberpfe mckessoninc memberus gaap gaap customerconcentrationriskmemberpfe mckessoninc memberus gaap gaap customerconcentrationriskmemberpfe amerisourcebergencorporationmemberus gaap gaap customerconcentrationriskmemberpfe amerisourcebergencorporationmemberus gaap gaap customerconcentrationriskmemberpfe amerisourcebergencorporationmemberus gaap cardinalhealthinc memberus gaap customerconcentrationriskmemberus gaap cardinalhealthinc memberus gaap customerconcentrationriskmemberus gaap cardinalhealthinc memberus gaap customerconcentrationriskmemberus gaap gaap customerconcentrationriskmemberus gaap accountsreceivablememberpfe gaap customerconcentrationriskmemberus gaap accountsreceivablememberpfe gaap customerconcentrationriskmemberus gaap accountsreceivablememberpfe gaap customerconcentrationriskmemberpfe comirnatymemberpfe governmentandgovernmentsponsoredmemberus gaap comirnatymemberpfe governmentandgovernmentsponsoredmemberus gaap accountsreceivablememberus gaap vaccinesmemberpfe vaccinesmemberpfe vaccinesmemberpfe comirnatymemberpfe vaccinesmemberpfe comirnatymemberpfe vaccinesmemberpfe comirnatymemberpfe vaccinesmemberpfe prevnarprevenarfamilymemberpfe vaccinesmemberpfe prevnarprevenarfamilymemberpfe vaccinesmemberpfe prevnarprevenarfamilymemberpfe vaccinesmemberpfe vaccinesmemberpfe biopharmasegmentmemberpfe vaccinesmemberpfe biopharmasegmentmemberpfe vaccinesmemberpfe biopharmasegmentmemberpfe fsmeimmunticovacmemberpfe vaccinesmemberpfe fsmeimmunticovacmemberpfe vaccinesmemberpfe fsmeimmunticovacmemberpfe vaccinesmemberpfe trumenbamemberpfe vaccinesmemberpfe trumenbamemberpfe vaccinesmemberpfe trumenbamemberpfe vaccinesmemberpfe othervaccinesproductsmemberpfe vaccinesmemberpfe othervaccinesproductsmemberpfe vaccinesmemberpfe othervaccinesproductsmemberpfe vaccinesmemberpfe oncologymemberpfe oncologymemberpfe oncologymemberpfe ibrancememberpfe oncologymemberpfe ibrancememberpfe oncologymemberpfe ibrancememberpfe oncologymemberpfe oncologymemberpfe xtandialliancerevenuesmemberpfe oncologymemberpfe xtandialliancerevenuesmemberpfe oncologymemberpfe xtandialliancerevenuesmemberpfe inlytamemberpfe oncologymemberpfe inlytamemberpfe oncologymemberpfe inlytamemberpfe oncologymemberpfe sutentmemberpfe oncologymemberpfe sutentmemberpfe oncologymemberpfe sutentmemberpfe oncologymemberpfe bosulifmemberpfe oncologymemberpfe bosulifmemberpfe oncologymemberpfe bosulifmemberpfe oncologymemberpfe xalkorimemberpfe oncologymemberpfe xalkorimemberpfe oncologymemberpfe xalkorimemberpfe oncologymemberpfe ruxiencememberpfe oncologymemberpfe ruxiencememberpfe oncologymemberpfe ruxiencememberpfe oncologymemberpfe retacritmemberpfe oncologymemberpfe retacritmemberpfe oncologymemberpfe retacritmemberpfe oncologymemberpfe zirabevmemberpfe oncologymemberpfe zirabevmemberpfe oncologymemberpfe zirabevmemberpfe oncologymemberpfe lorbrenamemberpfe oncologymemberpfe lorbrenamemberpfe oncologymemberpfe lorbrenamemberpfe oncologymemberpfe aromasinmemberpfe oncologymemberpfe aromasinmemberpfe oncologymemberpfe aromasinmemberpfe oncologymemberpfe trazimeramemberpfe oncologymemberpfe trazimeramemberpfe oncologymemberpfe trazimeramemberpfe oncologymemberpfe oncologymemberpfe besponsamemberpfe oncologymemberpfe besponsamemberpfe oncologymemberpfe besponsamemberpfe braftovimemberpfe oncologymemberpfe braftovimemberpfe oncologymemberpfe braftovimemberpfe oncologymemberpfe bavencioalliancerevenuesmemberpfe oncologymemberpfe bavencioalliancerevenuesmemberpfe oncologymemberpfe bavencioalliancerevenuesmemberpfe oncologymemberpfe mektovimemberpfe oncologymemberpfe mektovimemberpfe oncologymemberpfe mektovimemberpfe oncologymemberpfe otheroncologyproductsmemberpfe oncologymemberpfe otheroncologyproductsmemberpfe oncologymemberpfe otheroncologyproductsmemberpfe oncologymemberpfe biopharmasegmentmemberpfe biopharmasegmentmemberpfe biopharmasegmentmemberpfe eliquismemberpfe biopharmasegmentmemberpfe eliquismemberpfe biopharmasegmentmemberpfe eliquismemberpfe biopharmasegmentmemberpfe premarinfamilymemberpfe biopharmasegmentmemberpfe premarinfamilymemberpfe biopharmasegmentmemberpfe premarinfamilymemberpfe biopharmasegmentmemberpfe chantixchampixmemberpfe biopharmasegmentmemberpfe chantixchampixmemberpfe biopharmasegmentmemberpfe chantixchampixmemberpfe biopharmasegmentmemberpfe biopharmasegmentmemberpfe biopharmasegmentmemberpfe biopharmasegmentmemberpfe toviazmemberpfe biopharmasegmentmemberpfe toviazmemberpfe biopharmasegmentmemberpfe toviazmemberpfe biopharmasegmentmemberpfe biopharmasegmentmemberpfe pristiqmemberpfe biopharmasegmentmemberpfe pristiqmemberpfe biopharmasegmentmemberpfe pristiqmemberpfe allotherinternalmedicinememberpfe biopharmasegmentmemberpfe allotherinternalmedicinememberpfe biopharmasegmentmemberpfe allotherinternalmedicinememberpfe biopharmasegmentmemberpfe hospitalmemberpfe hospitalmemberpfe hospitalmemberpfe sulperazonmemberpfe hospitalmemberpfe sulperazonmemberpfe hospitalmemberpfe sulperazonmemberpfe hospitalmemberpfe medrolmemberpfe hospitalmemberpfe medrolmemberpfe hospitalmemberpfe medrolmemberpfe hospitalmemberpfe zaviceftamemberpfe hospitalmemberpfe zaviceftamemberpfe hospitalmemberpfe zaviceftamemberpfe hospitalmemberpfe fragminmemberpfe hospitalmemberpfe fragminmemberpfe hospitalmemberpfe fragminmemberpfe hospitalmemberpfe zithromaxzmaxmemberpfe hospitalmemberpfe zithromaxzmaxmemberpfe hospitalmemberpfe zithromaxzmaxmemberpfe hospitalmemberpfe vfendmemberpfe hospitalmemberpfe vfendmemberpfe hospitalmemberpfe vfendmemberpfe hospitalmemberpfe tygacilmemberpfe hospitalmemberpfe tygacilmemberpfe hospitalmemberpfe tygacilmemberpfe hospitalmemberpfe precedexmemberpfe hospitalmemberpfe precedexmemberpfe hospitalmemberpfe precedexmemberpfe hospitalmemberpfe zyvoxmemberpfe hospitalmemberpfe zyvoxmemberpfe hospitalmemberpfe zyvoxmemberpfe hospitalmemberpfe hospitalmemberpfe paxlovidmemberpfe hospitalmemberpfe paxlovidmemberpfe hospitalmemberpfe paxlovidmemberpfe hospitalmemberpfe ivigproductsmemberpfe hospitalmemberpfe ivigproductsmemberpfe hospitalmemberpfe ivigproductsmemberpfe otherantiinfectivesmemberpfe hospitalmemberpfe otherantiinfectivesmemberpfe hospitalmemberpfe otherantiinfectivesmemberpfe hospitalmemberpfe otherhospitalproductsmemberpfe hospitalmemberpfe otherhospitalproductsmemberpfe hospitalmemberpfe otherhospitalproductsmemberpfe hospitalmemberpfe inflammationandimmunologymemberpfe inflammationandimmunologymemberpfe inflammationandimmunologymemberpfe xeljanzmemberpfe inflammationandimmunologymemberpfe xeljanzmemberpfe inflammationandimmunologymemberpfe xeljanzmemberpfe inflammationandimmunologymemberpfe inflammationandimmunologymemberpfe enbrelmemberpfe inflammationandimmunologymemberpfe enbrelmemberpfe inflammationandimmunologymemberpfe enbrelmemberpfe inflammationandimmunologymemberpfe inflectraremsimamemberpfe inflammationandimmunologymemberpfe inflectraremsimamemberpfe inflammationandimmunologymemberpfe inflectraremsimamemberpfe allotherinflammationandimmunologyproductsmemberpfe inflammationandimmunologymemberpfe allotherinflammationandimmunologyproductsmemberpfe inflammationandimmunologymemberpfe allotherinflammationandimmunologyproductsmemberpfe inflammationandimmunologymemberpfe rarediseasememberpfe rarediseasememberpfe rarediseasememberpfe vyndaqelmemberpfe rarediseasememberpfe vyndaqelmemberpfe rarediseasememberpfe vyndaqelmemberpfe rarediseasememberpfe rarediseasememberpfe benefixmemberpfe rarediseasememberpfe benefixmemberpfe rarediseasememberpfe benefixmemberpfe rarediseasememberpfe genotropinmemberpfe rarediseasememberpfe genotropinmemberpfe rarediseasememberpfe genotropinmemberpfe rarediseasememberpfe refactoafxynthamemberpfe rarediseasememberpfe refactoafxynthamemberpfe rarediseasememberpfe refactoafxynthamemberpfe somavertmemberpfe rarediseasememberpfe somavertmemberpfe rarediseasememberpfe somavertmemberpfe rarediseasememberpfe allotherrarediseaseproductsmemberpfe rarediseasememberpfe allotherrarediseaseproductsmemberpfe rarediseasememberpfe allotherrarediseaseproductsmemberpfe rarediseasememberpfe biontechmemberpfe biontechmemberpfe biontechmemberpfe comirnatymemberpfe comirnatymemberpfe state security and exchange commissionwashington mark one annual report pursuant to section or of the security exchange act of the fiscal year ended december transition report pursuant to section or of the security exchange act of the transition period from to commission file number pfizer inc exact name of registrant specified in it charter state or other jurisdiction of incorporation or organization employer identification number east street new york new york address of principal executive office zip code registrant telephone number including area code security registered pursuant to section of the act title of each classtrading symbol name of each exchange on which registeredcommon stock par valuepfenew york stock note due york stock note due york stock exchangesecurities registered pursuant to section of the act noneindicate by check mark if the registrant is well known seasoned issuer defined in rule of the security act yes no indicate by check mark if the registrant is not required to file report pursuant to section or section of the act yes no indicate by check mark whether the registrant filed all report required to be filed by section or of the security exchange act of the preceding month or for shorter period that the registrant required to file such report and ha been subject to such filing requirement for the past day yes no indicate by check mark whether the registrant ha submitted electronically every interactive data file required to be submitted pursuant to rule of regulation of this chapter during the preceding month or for such shorter period that the registrant wa required to submit such file yes no indicate by check mark whether the registrant is large accelerated filer an accelerated filer non accelerated filer smaller reporting company or an emerging growth company see the definition of large accelerated filer accelerated filer smaller reporting company and emerging growth company in rule of the exchange act large accelerated filer accelerated filer non accelerated filer smaller reporting company emerging growth company if an emerging growth company indicate by check mark if the registrant ha elected not to use the extended transition period for complying with any new or revised financial accounting standard provided pursuant to section of the exchange act indicate by check mark whether the registrant ha filed report on and attestation to it management assessment of the effectiveness of it internal control over financial reporting section of the sarbanes oxley act by the registered public accounting firm that prepared or issued it audit report indicate by check mark whether the registrant is shell company defined in rule of the exchange act yes no the aggregate market value of the voting stock held by non affiliate of the registrant computed by reference to the closing price of the last business day of the registrant recently completed second fiscal quarter july wa approximately billion this excludes share of common stock held by director and executive officer at july exclusion of share held by any person not be construed to indicate that such person posse the power directly or indirectly to direct or cause the direction of the management or policy of the registrant or that such person is controlled by or under common control with the registrant the registrant ha no non voting common stock the number of share outstanding of the registrant common stock of february wa share of common stock all of one class document incorporated by referenceportions of the proxy statement for the annual meeting of shareholderspart iiitable of content pagedefined termsiavailable informationiiiforward looking information and factor that may affect future and co promotion and and and other intellectual property pressure and managed care regulation and price risk unresolved staff commentsn aitem legal mine safety disclosuresn ainformation about executive market for the company common equity related stockholder matter and issuer purchase of equity reserved management discussion and analysis of financial condition and result of quantitative and qualitative disclosure about market financial statement and supplementary change in and disagreement with accountant on accounting and financial control and other informationn aitem disclosure regarding foreign jurisdiction that prevent inspectionsn apart director executive officer and corporate executive security ownership of certain beneficial owner and management and related stockholder certain relationship and related transaction and director principal accounting fee and exhibit financial statement financial financial statement form not applicabledefined termsunless the context requires otherwise reference to pfizer the company or our in this form defined below refer to pfizer inc and it subsidiary pfizer fiscal year end for subsidiary operating outside the is of and for the year ended november for each year presented pfizer fiscal year end for subsidiary is of and for the year ended december for each year presented reference to note in this form are to the note to the consolidated financial statement in item financial statement and supplementary data in this form we also have used several other term in this form most of which are explained or defined below form kthis annual report on form for the fiscal year ended december statementproxy statement for the annual meeting of shareholder which will be filed no later day december inc aboaccumulated benefit obligation represents the present value of the benefit obligation earned through the end of the year but doe not factor in future compensation increasesaca also referred to healthcare legislation patient protection and affordable care act amended by the health care and education reconciliation actacipadvisory committee on immunization practicesakceaakcea therapeutic inc alkanaplastic lymphoma kinasealliance revenuesrevenues from alliance agreement under which we co promote product discovered or developed by other company or usanacoranacor pharmaceutical inc asraccelerated share repurchase agreementarenaarena pharmaceutical inc arrayarray biopharma inc arvinasarvinas inc astellasastellas pharma inc astellas llc and astellas pharma inc attr cmtransthyretin amyloid cardiomyopathybeambeam therapeutic inc biogenbiogen inc biohavenbiohaven pharmaceutical holding company ltd biohaven pharmaceutical ireland dac and bioshin limited collectively biohaven biontechbiontech sebiopharmapfizer biopharmaceuticals groupblabiologics license applicationbmsbristol myers squibb pfizer biontech covid vaccine also known comirnatybodboard of directorsbrcabreast cancer susceptibility genecdcu center for disease control and preventioncgmpscurrent good manufacturing practice comirnaty pfizer biontech covid vaccine also known healthcare jvgsk consumer healthcare jvcovid coronavirus disease of marketing authorisationcstonecstone pharmaceuticalsdeau drug enforcement agencydeveloped europeincludes the following market western europe scandinavian country and finlanddeveloped marketsincludes the following market developed europe japan canada south korea australia and new zealanddeveloped rest of worldincludes the following market japan canada south korea australia and new zealandeceuropean commissionemaeuropean medicine agencyemerging marketsincludes but is not limited to the following market asia excluding japan and south korea latin america central europe eastern europe the middle east africa and turkeyepsearnings per shareesopemployee stock ownership planeueuropean unioneuaemergency use authorizationexchange actsecurities exchange act of amendedfasbfinancial accounting standard boardfcpau foreign corrupt practice actfdau food and drug administrationffdcau federal food drug and cosmetic actpfizer inc form kigaapgenerally accepted accounting principlesgdfvgrant date fair valuegistgastrointestinal stromal tumorsgpdglobal product development organizationgskglaxosmithkline plchospirahospira inc ionisionis pharmaceutical inc ipr din process research and developmentircinternal revenue codeirsu internal revenue servicejakjanus kinasejvjoint venturekingking pharmaceutical llc formerly king pharmaceutical inc liborlondon interbank offered ratelillyeli lilly and companyloeloss of exclusivitymcomanaged care organizationmcrcmetastatic colorectal cancermcrpcmetastatic castration resistant prostate cancermcspcmetastatic castration sensitive prostate cancermrnamessenger ribonucleic acidmd amanagement discussion and analysis of financial condition and result of operationsmedivationmedivation llc formerly medivation inc meridianmeridian medical technology inc moody smoody investor servicemtmmark to marketmylanmylan mylan japan collaborationa pre existing strategic collaboration pfizer and mylan for generic drug in japan that terminated on december science ltd navnet asset valuendanew drug applicationnmcrpcnon metastatic castration resistant prostate cancernmpanational medical product administration in chinansclcnon small cell lung cancernysenew york stock exchangeopkoopko health inc otcover the counterpaxlovid an oral covid treatment nirmatrelvir pf tablet and ritonavir tablet pbmpharmacy benefit managerpboprojected benefit obligation represents the present value of the benefit obligation earned through the end of the year and factor in future compensation centreonepgspfizer global supplypharmaciapharmacia corporationpmdapharmaceuticals and medical device agency in japanpracpharmacovigilance risk assessment committeepsapsoriatic arthritisqcequality consistency evaluationrarheumatoid arthritisrccrenal cell carcinomar dresearch and developmentrouright of usesandozsandoz inc division of novartis ag pstandard poor ssecu security and exchange commissiontax cut and job act or tcjalegislation commonly referred to the tax cut and job act of holding agtrilliumtrillium therapeutic inc tsastransition service arrangementsuculcerative colitispfizer inc form kiiu united kingdomupjohn businesspfizer former global primarily off patent branded and generic business which included portfolio of globally recognized solid oral dose brand including lipitor lyrica norvasc celebrex and viagra well based generic platform greenstone that wa spun off on november and combined with mylan to create viatrisu united statesvalnevavalneva sevbpvolume based procurementviatrisviatris inc viivviiv healthcare limitedwhoworld health organizationwrdmworldwide research development and medicalwtoworld trade organization this form includes discussion of the covid vaccine that pfizer ha co developed with biontech and our oral covid treatment paxlovid this form may refer to the vaccine by it brand name comirnaty approved under bla or authorized under eua the vaccine is fda approved to prevent covid in individual year of age and older the vaccine is authorized by the fda to prevent covid in individual year of age and older in addition comirnaty is authorized by the fda for third dose in certain immunocompromised individual year of age and older and booster dose in individual year of age and older paxlovid ha been authorized for emergency use by the fda under an eua for the treatment of mild to moderate covid in adult and pediatric patient year of age and older weighing at least kg lb with positive result of direct sars cov viral testing and are at high risk for progression to severe covid including hospitalization or death the emergency us are only authorized for the duration of the declaration that circumstance exist justifying the authorization of emergency use of the medical product under section of the ffdca unless the declaration is terminated or authorization revoked sooner the fda ha issued euas to certain other company for product intended for the prevention or treatment of covid and may continue to during the duration of the declaration please see the eua fact sheet at www cvdvaccine com and www com this form includes discussion of certain clinical study relating to various in line product and or product candidate these study typically are part of larger body of clinical data relating to such product or product candidate and the discussion herein should be considered in the context of the larger body of data in addition clinical trial data are subject to differing interpretation and even when we view data sufficient to support the safety and or effectiveness of product candidate or new indication for an in line product regulatory authority may not share our view and may require additional data or may deny approval altogether amount in this form may not add due to rounding all percentage have been calculated using unrounded amount all trademark mentioned are the property of owner available informationour website is located at www pfizer com this form our quarterly report on form our current report on form and our proxy statement and amendment to those report filed or furnished pursuant to section or of the exchange act are or will be available free of charge on our website in text format and applicable in interactive data file format soon reasonably practicable after we electronically file this material with or furnish it to the sec throughout this form we incorporate by reference certain information from other document filed or to be filed with the sec including our proxy statement please refer to this information this form will be available on our website on or about february our proxy statement will be available on our website on or about march our environmental social and governance esg report which provides enhanced esg disclosure will be available on our website on or about march we also have pfizer investor insight website which includes article on the company it product and it pipeline located at insight pfizer com information in our esg report and on the pfizer investor insight website are not incorporated by reference into this form we may use our website mean of disclosing material information and for complying with our disclosure obligation under regulation fair disclosure promulgated by the sec these disclosure are included on our website in the about investor or news section accordingly investor should monitor these portion of our website in addition to following our press release sec filing public conference call and webcasts well our social medium channel our facebook youtube and linkedin page and twitter account pfizer and pfizer_news the information contained on our website our facebook youtube and linkedin page or our twitter account or any third party website is not incorporated by reference into this form information relating to corporate governance at pfizer including our corporate governance principle director qualification standard pfizer policy on business conduct for all of our employee including our chief executive officer chief financial officer and principal accounting officer code of business conduct and ethic for member of the board of director information concerning our director way to communicate by mail with our director information concerning our board committee committee charter charter of the lead independent director and transaction in pfizer security by director and officer are available on our website we will provide any of the foregoing information without charge upon written request to our corporate secretary pfizer inc east street new york ny we will disclose any future amendment to or waiver from provision of the pfizer policy on business conduct affecting our chief executive officer chief financial officer and principal accounting officer on our website promptly practicable may be required under applicable sec and nyse rule information relating to shareholder service including the computershare investment program book entry share ownership and direct deposit of dividend is also available on our website pfizer inc form kiiiforward looking information and factor that may affect future resultsthis form contains forward looking statement we also provide forward looking statement in other material we release to the public well public oral statement given their forward looking nature these statement involve substantial risk uncertainty and potentially inaccurate assumption we have tried wherever possible to identify such statement by using word such will may could likely ongoing anticipate estimate expect project intend plan believe assume target forecast guidance goal objective aim seek potential and other word and term of similar meaning or by using future date we include forward looking information in our discussion of the following among other topic our anticipated operating and financial performance reorganization business plan strategy and prospect expectation for our product pipeline in line product and product candidate including anticipated regulatory submission data read out study start approval clinical trial result and other developing data revenue contribution growth performance timing of exclusivity and potential benefit strategic review capital allocation objective dividend and share repurchase plan for and prospect of our acquisition disposition and other business development activity and our ability to successfully capitalize on these opportunity sale expense interest rate foreign exchange rate and the outcome of contingency such legal proceeding expectation for impact of or change to existing or new government regulation or law our ability to anticipate and respond to macroeconomic geopolitical health and industry trend pandemic act of war and other large scale crisis and manufacturing and product supply in particular forward looking information in this form includes statement relating to specific future action and effect including among others our effort to respond to covid including our development of vaccine to help prevent covid and an oral covid treatment the forecasted revenue contribution of comirnaty and the potential number of dos that we and biontech believe can be manufactured and or delivered the forecasted revenue contribution of paxlovid and the potential number of treatment course that we believe can be manufactured our expectation regarding the impact of covid on our business the expected patent term for comirnaty and paxlovid the expectation for ongoing revenue stream from comirnaty and paxlovid the expected impact of patent expiry and competition from generic manufacturer the expected pricing pressure on our product and the anticipated impact to our business the availability of raw material for the expected charge and or cost in connection with the spin off of the upjohn business and it combination with mylan the benefit expected from our business development transaction our anticipated liquidity position the anticipated cost and saving from certain of our initiative including our transforming to more focused company program our planned capital spending and the expected benefit payment and employer contribution for our benefit plan given their nature we can not assure that any outcome expressed in these forward looking statement will be realized in whole or in part actual outcome may vary materially from past result and those anticipated estimated implied or projected these forward looking statement may be affected by underlying assumption that may prove inaccurate or incomplete or by known or unknown risk and uncertainty including those described in this section and in the item risk factor section in this form therefore you are cautioned not to unduly rely on forward looking statement which speak only of the date of this form we undertake no obligation to update forward looking statement whether result of new information future event or otherwise except required by applicable security law you are advised however to consult any further disclosure we make on related subject some of the factor that could cause actual result to differ are identified below well those discussed in the item risk factor section in this form and within md we note these factor for investor permitted by the private security litigation reform act of the occurrence of any of the risk identified below or in the item risk factor section in this form or other risk currently unknown could have material adverse effect on our business financial condition or result of operation or we may be required to increase our accrual for contingency it is not possible to predict or identify all such factor consequently you should not consider the following to be complete discussion of all potential risk or uncertainty risk related to our business industry and operation and business development the outcome of activity including the ability to meet anticipated pre clinical or clinical endpoint commencement and or completion date for our pre clinical or clinical trial regulatory submission date and or regulatory approval and or launch date the possibility of unfavorable pre clinical and clinical trial result including the possibility of unfavorable new pre clinical or clinical data and further analysis of existing pre clinical or clinical data the risk that pre clinical and clinical trial data are subject to differing interpretation and assessment including during the peer review publication process in the scientific community generally and by regulatory authority and whether and when additional data from our pipeline program will be published in scientific journal publication and if so when and with modification and interpretation our ability to successfully address comment received from regulatory authority such the fda or the ema or obtain approval for new product and indication from regulator on timely basis or at all regulatory decision impacting labeling including the scope of indicated patient population product dosage manufacturing process safety and or other matter including decision relating to emerging development regarding potential product impurity the impact of recommendation by technical or advisory committee and the timing of pricing approval and product launch claim and concern that may arise regarding the safety or efficacy of in line product and product candidate including claim and concern that may arise from the outcome of post approval clinical trial which could impact marketing approval product labeling and or availability or commercial potential including uncertainty regarding the commercial or other impact of the result of the xeljanz oral surveillance study or action by regulatory authority based on analysis of oral surveillance or other data including on other jak inhibitor in our portfolio the success and impact of external business development activity including the ability to identify and execute on potential business development opportunity the ability to satisfy the condition to closing of announced transaction in the anticipated time frame or at all the ability to realize the anticipated benefit of any such transaction in the anticipated time frame or at all the pfizer inc form need for and impact of additional equity or debt financing to pursue these opportunity which could result in increased leverage and or downgrade of our credit rating challenge integrating the business and operation disruption to business and operation relationship risk related to growing revenue for certain acquired product significant transaction cost and unknown liability competition including from new product entrant in line branded product generic product private label product biosimilars and product candidate that treat or prevent disease and condition similar to those treated or intended to be prevented by our in line product and product candidate the ability to successfully market both new and existing product including biosimilars difficulty or delay in manufacturing sale or marketing supply disruption shortage or stock out at our facility or third party facility that we rely on and legal or regulatory action the impact of public health outbreak epidemic or pandemic such the covid pandemic including the impact of vaccine mandate where applicable on our business operation and financial condition and result including impact on our employee manufacturing supply chain sale and marketing and clinical trial risk and uncertainty related to our effort to develop vaccine to help prevent covid and an oral covid treatment well challenge related to their manufacturing supply and distribution trend toward managed care and healthcare cost containment and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our product interest rate and foreign currency exchange rate fluctuation including the impact of possible currency devaluation in country experiencing high inflation rate any significant issue involving our largest wholesale distributor or government customer which account for substantial portion of our revenue the impact of the increased presence of counterfeit medicine or vaccine in the pharmaceutical supply chain any significant issue related to the outsourcing of certain operational and staff function to third party and any significant issue related to our jv and other third party business arrangement uncertainty related to general economic political business industry regulatory and market condition including without limitation uncertainty related to the impact on our customer supplier and lender and counterparties to our foreign exchange and interest rate agreement of challenging global economic condition and recent and possible future change in global financial market any change in business political and economic condition due to actual or threatened terrorist activity civil unrest or military action the impact of product recall withdrawal and other unusual item including uncertainty related to regulator directed risk evaluation and assessment trade buying pattern the risk of an impairment charge related to our intangible asset goodwill or equity method investment the impact of and risk and uncertainty related to restructurings and internal reorganization well any other corporate strategic initiative and cost reduction and productivity initiative each of which requires upfront cost but may fail to yield anticipated benefit and may result in unexpected cost or organizational disruption risk related to government regulation and legal proceeding the impact of any healthcare reform or legislation or any significant spending reduction or cost control affecting medicare medicaid or other publicly funded or subsidized health program or change in the tax treatment of employer sponsored health insurance that may be implemented federal or state legislation or regulatory action and or policy effort affecting among other thing pharmaceutical product pricing intellectual property reimbursement or access or restriction on direct to consumer advertising limitation on interaction with healthcare professional and other industry stakeholder well pricing pressure for our product result of highly competitive insurance market legislation or regulatory action in market outside of the including china affecting pharmaceutical product pricing intellectual property reimbursement or access including in particular continued government mandated reduction in price and access restriction for certain biopharmaceutical product to control cost in those market the exposure of our operation globally to possible capital and exchange control economic condition expropriation and other restrictive government action change in intellectual property legal protection and remedy well political unrest unstable government and legal system and inter governmental dispute legal defense cost insurance expense settlement cost and contingency including those related to actual or alleged environmental contamination the risk and impact of an adverse decision or settlement and the adequacy of reserve related to legal proceeding the risk and impact of tax related litigation governmental law and regulation affecting our operation including without limitation change in law and regulation or their interpretation including among others change in tax law and regulation internationally and in the including among others potential adoption of global minimum taxation requirement and potential change to existing tax law by the current presidential administration and congress pfizer inc form related to intellectual property technology and security any significant breakdown or interruption of our information technology system and infrastructure including cloud service any business disruption theft of confidential or proprietary information extortion or integrity compromise resulting from cyber attack the risk that our currently pending or future patent application may not be granted on timely basis or at all or any patent term extension that we seek may not be granted on timely basis if at all and our ability to protect our patent and other intellectual property including claim of invalidity that could result in loe unasserted intellectual property claim and in response to any pressure or legal or regulatory action by various stakeholder or government that could potentially result in not seeking intellectual property protection for or agreeing not to enforce or restricted from enforcing intellectual property related to our product including our vaccine to help prevent covid and our oral covid treatment part iitem businessabout pfizerpfizer inc is research based global biopharmaceutical company we apply science and our global resource to bring therapy to people that extend and significantly improve their life through the discovery development manufacture marketing sale and distribution of biopharmaceutical product worldwide we work across developed and emerging market to advance wellness prevention treatment and cure that challenge the most feared disease of our time we collaborate with healthcare provider government and local community to support and expand access to reliable affordable healthcare around the world the company wa incorporated under the law of the state of delaware on june most of our revenue come from the manufacture and sale of biopharmaceutical product we believe that our medicine and vaccine provide significant value for healthcare provider and patient through improved treatment of disease improvement in health wellness and productivity well by reducing other healthcare cost such emergency room or hospitalization we seek to enhance the value of our medicine and vaccine and actively engage in dialogue about we can best work with patient physician and payer to prevent and treat disease and improve outcome we seek to maximize patient access and evaluate our pricing arrangement and contracting method with payer to minimize adverse impact on our revenue within the current legal and pricing structure we are committed to fulfilling our purpose breakthrough that change patient life our purpose fuel everything we do and reflects both our passion for science and our commitment to patient pfizer growth strategy is driven by five bold move that help deliver breakthrough for patient and create value for shareholder and other stakeholder unleash the power of our people deliver first in class science transform our go to market model win the digital race in pharma lead the conversation in addition pfizer continues to enhance it esg strategy which is focused on six area where we see opportunity to create meaningful impact over the next decade product innovation equitable access and pricing product quality and safety diversity equity and inclusion climate change and business ethic we are committed to strategically capitalizing on growth opportunity primarily by advancing our product pipeline and maximizing the value of our existing product but also through various business development activity we view our business development activity an enabler of our strategy and seek to generate growth by pursuing opportunity and transaction that have the potential to strengthen our business and our capability we ass our business asset and scientific capability portfolio part of our regular ongoing portfolio review process and also continue to consider business development activity that will help advance our business strategy our significant recent business development activity in include among others the july global collaboration with arvinas to develop and commercialize arv an investigational oral protac proteolysis targeting chimera estrogen receptor protein degrader the estrogen receptor is well known disease driver in most breast cancer ii the november collaboration and license agreement with biohaven to acquire right to commercialize rimegepant and zavegepant for the treatment and prevention of migraine outside of the upon approval iii the november acquisition of trillium clinical stage immuno oncology company developing innovative potential therapy for the treatment of cancer and iv the december research collaboration with beam to utilize beam in vivo base editing program which use mrna and lipid nanoparticles for three target for rare genetic disease of the liver muscle and central nervous system in addition in december we entered into definitive agreement to acquire arena clinical stage company developing innovative potential therapy for the treatment of several immuno inflammatory disease on february arena shareholder voted to approve the proposed acquisition which is targeted to close in the first half of subject to review under antitrust law and other customary closing condition for further discussion of our strategy and our business development initiative see the overview of our performance operating environment strategy and outlook section within md and note in and our business operation and financial condition and result impacted by the covid pandemic to confront the public health challenge posed by the pandemic we have made some important advance including the development of vaccine to help prevent pfizer inc form and an oral covid treatment for additional information see the overview of our performance operating environment strategy and outlook covid pandemic section within md and the item risk factor covid pandemic section in this form commercial operationsfollowing the spin off and combination of the upjohn business which wa our global primarily off patent branded and generic business with mylan in which created new global pharmaceutical company viatris and ii the formation of the consumer healthcare jv with gsk in we saw the culmination of pfizer transformation into more focused global leader in science based innovative medicine and vaccine and beginning in the fourth quarter of we operated single operating segment engaged in the discovery development manufacturing marketing sale and distribution of biopharmaceutical product worldwide at the beginning of our fiscal fourth quarter we reorganized our commercial operation and began to manage our commercial operation through new global structure consisting of two operating segment each led by single manager biopharma our innovative science based biopharmaceutical business and our global contract development and manufacturing organization and leading supplier of specialty active pharmaceutical ingredient our biopharma business includes the following therapeutic area and key product therapeutic areadescriptionkey productsvaccinesincludes innovative vaccine across all age infant adolescent and adult in pneumococcal disease meningococcal disease tick borne encephalitis and covid with pipeline focus on infectious disease with significant unmet medical need comirnaty the prevnar family nimenrix fsme immun ticovac and trumenbaoncologyincludes innovative oncology brand of biologics small molecule immunotherapy and biosimilars across wide range of cancer ibrance xtandi inlyta sutent retacrit lorbrena and braftoviinternal medicineincludes innovative brand in cardiovascular metabolic and woman health well regional brand eliquis and the premarin familyhospital includes our global portfolio of sterile injectable and anti infective medicine well an oral covid treatment sulperazon medrol zavicefta zithromax vfend panzyga and paxlovidinflammation immunologyincludes innovative brand and biosimilars for chronic immune and inflammatory disease xeljanz enbrel outside the and canada inflectra eucrisa staquis and cibinqorare diseaseincludes innovative brand for number of therapeutic area with rare disease including amyloidosis hemophilia and endocrine disease vyndaqel vyndamax benefix and genotropin each of prevnar prevenar ibrance eliquis xeljanz and enbrel recorded direct product and or alliance revenue of more than billion in and each of comirnaty and inlyta recorded direct product and or alliance revenue of more than billion in each of xtandi and vyndaqel vyndamax recorded direct product and or alliance revenue of more than billion in and comirnaty eliquis and xtandi include alliance revenue and direct sale prevnar family include revenue from prevnar prevenar pediatric and adult and prevnar adult prior to the fourth quarter of been managed within the hospital therapeutic area also on december we completed the sale of our meridian subsidiary which wa part of the hospital therapeutic area prior to it sale see note for additional information for additional information on our operating segment and product see note and for additional information on the key operational revenue driver of our business see the analysis of the consolidated statement of income section within md for discussion of the risk associated with our dependence on certain of our major product see the item risk factor concentration section in this form collaboration and co promotion we use collaboration and or co promotion arrangement to enhance our development sale and distribution of certain biopharmaceutical product which include among others the following comirnaty is an mrna based coronavirus vaccine to help prevent covid which is being jointly developed and commercialized with biontech pfizer and biontech equally share the cost of development for the comirnaty program comirnaty ha been granted an approval or an authorization in many country around the world in population varying by country we also share gross profit equally from commercialization of comirnaty and are working jointly with biontech in our respective territory to commercialize the vaccine worldwide excluding china hong kong macau and taiwan subject to regulatory authorization or approval market by market for discussion on comirnaty see the overview of our performance operating environment strategy and outlook covid pandemic section within md eliquis apixaban is part of the novel oral anticoagulant market and wa jointly developed and commercialized with bm an alternative treatment option to warfarin in appropriate patient we fund between and of all development cost depending on the study and profit and loss are shared equally except in certain country where we commercialize eliquis and pay percentage of net sale to bm in certain smaller market we have full commercialization right and bm supply the product to at cost plus percentage of the net sale to end customer xtandi enzalutamide is an androgen receptor inhibitor that block multiple step in the androgen receptor signaling pathway within tumor cell that is being developed and commercialized in collaboration with astellas we share equally in the gross profit and loss related to net sale and also share equally all xtandi commercialization cost attributable to the market subject to certain exception in addition we share certain development and other collaboration expense for international net sale we receive royalty based on tiered percentage bavencio avelumab is human anti programmed death ligand pd antibody that is being developed and commercialized in collaboration with merck kgaa we jointly fund the majority of development and commercialization cost and split profit equally related to net sale generated from any product containing avelumab orgovyx relugolix is an oral gonadotropin releasing hormone gnrh receptor antagonist for the treatment of adult patient with advanced prostate cancer that is being developed and commercialized with myovant the company are also collaborating on myfembree relugolix pfizer inc form estradiol mg and norethindrone acetate mg for heavy menstrual bleeding associated with uterine fibroid in premenopausal woman and the management of moderate to severe pain associated with endometriosis the company will equally share profit and allowable expense in the and canada for orgovyx and myfembree with myovant bearing our share of allowable expense to maximum of million in myovant will remain responsible for regulatory interaction and drug supply and continue to lead clinical development for the relugolix combination tablet revenue associated with these arrangement are included in alliance revenue except in certain market where we have direct sale and except for the majority of revenue for comirnaty which are included direct product revenue in addition we have collaboration arrangement for the development and commercialization of certain pipeline product that are in development stage including among others with biontech to develop modified mrna based vaccine for the prevention of varicella zoster shingle and ii with valneva to co develop and commercialize valneva lyme disease vaccine candidate for further discussion of collaboration and co promotion agreement see the item risk factor collaboration and other relationship with third party section in this form and note and research and developmentr is at the heart of fulfilling our purpose to deliver breakthrough that change patient life we work to translate advanced science and technology into the therapy that may be the most impactful for patient the discovery and development of drug vaccine and biological product are time consuming costly and unpredictable in addition to discovering and developing new product our effort seek to add value to our existing product by improving their effectiveness and ease of dosing and by discovering potential new indication our priority and strategy our priority include delivering pipeline of highly differentiated medicine and vaccine where we have unique opportunity to bring the most important new therapy to patient in need advancing our capability that can position for long term leadership and advancing new model for partnership with creativity flexibility and urgency to deliver innovation to patient quickly possible to that end our primarily focus on our main therapeutic area significant portion of our is internal we also seek promising chemical and biological lead molecule and innovative technology developed by others to incorporate into our discovery and development process or project well our product line we do so by entering into collaboration alliance and license agreement with university biotechnology company and other firm well through acquisition and investment these collaboration alliance and license agreement and investment allow to share knowledge risk and cost they also enable to access external scientific and technological expertise well provide the opportunity to advance our own product and in licensed or acquired product for information on certain of these collaboration alliance and license arrangement and investment see note our operation in we continued to strengthen our global operation and pursue strategy to improve productivity to achieve sustainable pipeline that is positioned to deliver value in the near term and over time our activity is conducted through various platform function that operate in parallel within our global operation including the following wrdm research unit within wrdm are generally responsible for research and early stage development asset for our business asset that have not yet achieved proof of concept and are organized by therapeutic area to enhance flexibility cohesiveness and focus we can rapidly redeploy resource within research unit and between various project to leverage necessary common skill expertise or focus gpd our gpd organization is unified center for clinical development and regulatory activity that is generally responsible for the clinical development strategy and operational execution of clinical trial for late stage clinical asset in pfizer pipeline science based platform service organization within wrdm these organization provide technical expertise and other service to various project and are organized into science based function these organization allow to react more quickly and effectively to evolving need by sharing resource among project candidate and target across therapeutic area and phase of development example of these platform organization include pharmaceutical science and medicine design and worldwide medical and safety we manage operation on total company basis through our platform function described specifically the portfolio strategy investment committee composed of senior executive is accountable for aligning resource among all of our wrdm gpd and project and for seeking to ensure optimal capital allocation across the innovative portfolio we believe that this approach also serf to maximize accountability and flexibility we do not disaggregate total expense by development phase or by therapeutic area since described above we do not manage our operation by development phase or by therapeutic area further we are able to adjust significant portion of our spending quickly we believe that any prior period information about expense by development phase or by therapeutic area would not necessarily be representative of future spending for additional information see the cost and expense research and development expense section within md and note pfizer inc form pipeline the process of drug and biological product discovery from initiation through development and to potential regulatory approval is lengthy and can take more than ten year of february we had the following number of project in various stage of development of single compound is often pursued part of multiple program while our drug candidate may or may not receive regulatory approval new candidate entering clinical development phase are the foundation for future product information concerning several of our drug candidate in development well supplemental filing for existing product is set forth in the product development section within md for information on the risk associated with see the item risk factor research and development section of this form international operationsour operation are conducted globally and we sell our product in over country emerging market are an important component of our strategy for global leadership and our commercial structure recognizes that the demographic and rising economic power of the fastest growing emerging market are becoming more closely aligned with the profile found within developed market urbanization and the rise of the middle class in emerging market provide potential growth opportunity for our product revenue from operation outside the of billion accounted for of our total revenue in revenue exceeded million in each of and country outside the in and respectively with the increase in the number of country in primarily driven by comirnaty by total revenue japan wa our largest national market outside the in for geographic breakdown of revenue see the analysis of the consolidated statement of income revenue by geography section within md and the table captioned geographic information in note our international operation are subject to risk inherent in carrying on business in other country for additional information see the item risk factor global operation and item business government regulation and price constraint section in this form sale and marketingour prescription biopharmaceutical product are sold principally to wholesaler but we also sell directly to retailer hospital clinic government agency and pharmacy in the we primarily sell our vaccine directly to the federal government cdc wholesaler individual provider office retail pharmacy and integrated delivery system outside the we primarily sell our vaccine to government and non government institution certain of these government contract may be renegotiated or terminated at the discretion of government entity in addition our contract with government and supranational organization for the sale of comirnaty and paxlovid which are on committed basis represented significant amount of revenue in we also seek to gain access for our product on formulary which are list of approved medicine available to member of healthcare program or pbms pbms use various benefit design such tiered co pay for formulary product to drive utilization of product in preferred formulary position we may also work with payer on disease management program that help to develop tool and material to educate patient and physician on key disease area for information on our significant customer see note we promote our product to healthcare provider and patient through our marketing organization we explain the approved us benefit and risk of our product to healthcare provider and patient mcos that provide insurance coverage such hospital integrated delivery system pbms and health plan and employer and government agency who hire mcos to provide health benefit to their employee in the we market directly to consumer through direct to consumer advertising that seek to communicate the approved us benefit and risk of our product while motivating people to have meaningful conversation with their doctor in addition we sponsor general advertising to educate the public on disease awareness prevention and wellness important public health issue and our patient assistance program pfizer inc form and other intellectual property rightspatents we own or license number of patent covering pharmaceutical and other product their us formulation and product manufacturing process patent for individual product extend for varying period according to the date of patent filing or grant and the legal term of patent in the various country where patent protection is obtained the scope of protection afforded by patent can vary from country to country and depends on the patent type the scope of it patent claim and the availability of legal remedy patent term extension pte may be available in some country to compensate for loss of patent term due to delay in product approval due to the regulatory requirement one of the primary consideration in limiting our operation in some country outside the is the lack of effective intellectual property protection for our product although international and free trade agreement have included some improved global protection of intellectual property right for additional information see the item business government regulation and price constraint section in this form in various market period of regulatory exclusivity may be provided for drug or vaccine upon approval the scope and term of such exclusivity will vary but in general the period will run concurrently with the term of any existing patent right associated with the drug at the time of approval based on current sale and considering the competition with product sold by our competitor the patent right we consider most significant in relation to our business whole together with the year in which the basic product patent expires are follows productu basic product patent expiration year major europe basic product patent expiration year japan basic product patent expiration year chantix prevenar vyndaqel vyndamax pending pte braftovi pending pte mektovi bavencio pending pte pending pte comirnaty paxlovid unless otherwise indicated the year pertain to the basic product patent expiration including granted ptes supplementary protection certificate spc or pediatric exclusivity period spcs are included when granted in three of five major european market france germany italy spain and the noted in parenthesis is the projected year of expiry of the earliest pending patent term extension in the or japan and or spc application in europe the term of which if granted may be shorter than originally requested due to number of factor in some instance there are later expiring patent relating to our product which may or may not protect our product from generic or biosimilar competition after the expiration of the basic patent the basic product patent for chantix expired in the in november and in europe in september the basic product patent for sutent expired in the in august and in europe in january expiry is provided by regulatory exclusivity in this market the europe patent that cover the combination of the serotype conjugate of prevenar wa revoked following an opposition and ha been withdrawn there are other europe patent and pending application covering the formulation various aspect of the manufacturing process and the combination of serotype conjugate of prevenar that remain in force eliquis wa developed and is being commercialized in collaboration with bm for eliquis in the two patent listed in the fda orange book the composition of matter patent claiming apixaban specifically and formulation patent were challenged by numerous generic company and were the subject of patent infringement litigation prior to the resolution of the litigation in our favor on both challenged patent we and bm settled with number of these generic company settled generic company while continuing to litigate against three remaining generic company remaining generic company result of the litigation the remaining generic company are not permitted to launch their product the expiration date of the formulation patent under the term of the settlement agreement the permitted date of launch for the settled generic company under these patent is april both patent may be subject to subsequent challenge while we can not predict the outcome of any potential future litigation these are the alternative that might occur if both patent are upheld in future litigation through appeal the permitted date of launch for the settled generic company under these patent would remain april if the formulation patent is held invalid or not infringed in future litigation through appeal the settled generic company and any successful future litigant would be permitted to launch on november or if both patent are held invalid or not infringed in future litigation through appeal the settled generic company and any successful future litigant could launch product immediately upon such an adverse decision refer to note for more information pfizer inc form xtandi is being developed and commercialized in collaboration with astellas which ha exclusive commercialization right for xtandi outside the pfizer receives tiered royalty percentage of international xtandi net sale vyndaqel tafamidis meglumine basic patent expiry in japan is august for treatment of polyneuropathy vynmac tafamidis wa approved in japan for treatment of cardiomyopathy with regulatory exclusivity expiring march we have exclusive right to braftovi and mektovi in the the pierre fabre group ha exclusive right to commercialize both product in europe and ono pharmaceutical co ltd ha exclusive right to commercialize both product in japan we receive royalty from the pierre fabre group and ono pharmaceutical co ltd on sale of braftovi and mektovi outside the mektovi expiry is provided by method of use patent bavencio is being developed and commercialized in collaboration with merck kgaa product not yet approved or authorized in this market an spc ha been filed for cibinqo in the with expected expiry in based on the september approval cibinqo wa approved in other major european market in december the basic product patent application for comirnaty ha been filed in these market if granted full term is expected in these market comirnaty is being developed and commercialized in collaboration with biontech pfizer doe not have co promotion right for comirnaty in germany the basic product patent application for paxlovid ha been filed in these market if granted full term is expected in these market loss of intellectual property right the loss expiration or invalidation of intellectual property right patent litigation settlement with manufacturer and the expiration of co promotion and licensing right can have material adverse effect on our revenue once patent protection ha expired or ha been lost prior to the expiration date result of legal challenge we typically lose exclusivity on these product and generic and biosimilar pharmaceutical manufacturer generally produce identical or highly similar product and sell them for lower price the date at which generic or biosimilar competition commences may be different from the date that the patent or regulatory exclusivity expires however when generic or biosimilar competition doe commence the resulting price competition can substantially decrease our revenue for the impacted product often in short period of time also if one of our product related patent is found to be invalid by judicial court or regulatory or administrative proceeding generic or biosimilar product could be introduced resulting in the erosion of sale of our existing product we continue to vigorously defend our patent right against infringement and we will continue to support effort that strengthen worldwide recognition of patent right while taking necessary step to help ensure appropriate patient access for additional information see the item risk factor competitive product intellectual property protection and third party intellectual property claim section in this form and note certain of our product have experienced patent based expiration or loss of regulatory exclusivity in certain market in the last few year and we expect certain product to face increased generic competition over the next few year for additional information on the impact of loes on our revenue see the analysis of the consolidated statement of income revenue selected product discussion section within md trademark our product are sold under brand name and logo trademark and trade dress registration generally are for fixed but renewable term and protection is provided in some country for long the mark is used while in others for long it is registered protecting our trademark is of material importance to pfizer competitionour business is conducted in intensely competitive and often highly regulated market many of our product face competition in the form of branded or generic drug or biosimilars that treat similar disease or indication the principal form of competition include efficacy safety ease of use and cost though the mean of competition vary among our product demonstrating the value of our product is critical factor for success we compete with other company that manufacture and sell product that treat or prevent disease or indication similar to those treated or prevented by our major product these competitor include other worldwide research based biopharmaceutical company smaller research company with more limited therapeutic focus and generic drug and biosimilar manufacturer our competitor also may devote substantial fund and resource to and their successful could result in erosion of the sale of our existing product and potential sale of product in development well unanticipated product obsolescence in addition several of our competitor operate without large expense and make regular practice of challenging our product patent their expiration to address competitive trend we continually emphasize innovation which is underscored by our multi billion dollar investment in well our business development transaction both designed to result in strong product pipeline our investment in research continues even after drug or vaccine approval we seek to further demonstrate the value of our product for the condition they treat or prevent well potential new application we educate patient physician payer and global health authority on the benefit and risk of our medicine and vaccine and seek to continually enhance the organizational effectiveness of our biopharmaceutical function including to accurately and ethically launch and market our product to our customer operating condition have also shifted result of increased global competitive pressure industry regulation and cost containment we continue to evaluate adapt and improve our organization and business practice in an effort to better meet customer and public need we believe that we have taken an industry leading role in evolving our approach to direct to consumer advertising interaction with and payment to healthcare professional and medical education grant we also continue to sponsor program to address patient affordability and access barrier we strive to advance fundamental health system change through our support for better healthcare solution our vaccine may face competition including from the introduction of alternative vaccine or next generation vaccine prior to or after the expiration of their patent which may adversely affect our future result our biosimilars which include biosimilars of certain inflammation immunology and oncology biologic medicine compete with branded product from competitor well other generic and biosimilars manufacturer we seek to maximize the opportunity to establish first to pfizer inc form or early market position for our biosimilars to provide customer lower cost alternative immediately when available and also to potentially provide with higher level of sale and profitability until other competitor enter the market generic product generic pharmaceutical manufacturer pose one of the biggest competitive challenge to our branded small molecule product they can market competing version of our product after the expiration or loss of our patent and often charge much le several competitor regularly challenge our product patent before their expiration generic competitor often operate without large expense well without cost of conveying medical information about product to the medical community in addition the fda approval process exempts generic from costly and time consuming clinical trial to demonstrate their safety and efficacy allowing generic manufacturer to rely on the safety and efficacy data of the innovator product in china for example we expect to continue to face intensified competition by certain generic manufacturer in and beyond which may result in price cut and volume loss of some of our product in addition generic version of competitor branded product may also compete with our product mcos that focus primarily on the immediate cost of drug often favor generic over brand name drug many government also encourage the use of generic alternative to brand name drug in their healthcare program including medicaid in the and law generally allow and in some case require pharmacist to substitute generic drug for brand name drug in small subset of state prescribing physician are able to expressly prevent such substitution biosimilars certain of our biologic product including enbrel we market enbrel outside the and canada already face or may face in the future competition from biosimilars also referred to follow on biologics biosimilars are version of biologic medicine that have been developed and proven to be highly similar to the original biologic in term of safety and efficacy and that have no clinically meaningful difference in safety purity or potency biosimilars have the potential to offer high quality lower cost alternative to innovative biologic medicine in the biosimilars referencing innovative biologic product are approved under the public health service act pricing pressure and managed care organizationscommercial pricing pressure pricing and access pressure in the commercial sector continue to be significant overall there is increasing pressure on provider to deliver healthcare at lower cost and to ensure that those expenditure deliver demonstrated value in term of health outcome many employer have adopted high deductible health plan which can increase out of pocket cost for medicine this trend is likely to continue private third party payer such health plan increasingly challenge pharmaceutical product pricing which could result in lower price lower reimbursement rate and reduction in demand for our product pricing pressure also may occur result of highly competitive insurance market healthcare provider purchaser directly or through group purchasing organization are seeking enhanced discount or implementing more rigorous bidding or purchasing review process longer term we foresee shift in focus away from fee for service payment towards outcome based payment and risk sharing arrangement that reward provider for cost reduction and improved patient outcome these new payment model can at time lead to lower price for and restricted access to new medicine at the time these model can also promote utilization of drug by encouraging physician to screen and diagnose and consider drug mean of forestalling more costly medical intervention in light of the covid pandemic and related large scale healthcare disruption we expect value based payment model may have reduced participation if the incentive to participate are reduced or eliminated financially weakened hospital may weigh their ability to take on the financial risk of downside model in contrast provider in more advanced value based model such full capitation fixed amount paid in advance per patient per unit of time period generally found their revenue remained steady during the pandemic which may ultimately encourage the growth of such model we believe medicine and vaccine are the most efficient and effective use of healthcare dollar based on the value they deliver to the overall healthcare system we work with law maker and advocate for solution that effectively improve patient health outcome lower cost to the healthcare system and help ensure access to medicine and vaccine within an efficient and affordable healthcare system this includes assessing our go to market model to address patient affordability challenge we have engaged with major payors and the government to explore opportunity to improve access and reimbursement in an effort to drive pro patient policy in addition in response to the evolving and global healthcare spending landscape we work with health authority health technology assessment and quality measurement body and major payer throughout the product development process to better understand how these entity value our compound and product further we are developing stronger internal capability focused on demonstrating the value of the medicine and vaccine that we discover or develop register and manufacture by recognizing pattern of usage of our medicine and vaccine and competitor medicine and vaccine along with pattern of healthcare cost for information on government pricing pressure see the item business government regulation and price constraint and item risk factor pricing and reimbursement section in this form managed care organization the evolution of managed care in the ha been major factor in the competitiveness of the healthcare marketplace approximately million people in the now have some form of health insurance coverage and the marketing of prescription drug and vaccine to both consumer and the entity that manage coverage in the continues to grow in importance in particular the influence of mcos ha increased in recent year due to the growing number of patient receiving coverage through mcos at the same time consolidation in the mco industry ha resulted in fewer even larger mcos which enhances those mcos ability to negotiate pricing and increase their importance to our business since mcos seek to contain and reduce healthcare expenditure their growing influence ha increased pressure on drug price well revenue mcos typically negotiate price with pharmaceutical provider by using formulary which are list of approved medicine available to mco member clinical protocol which require prior authorization for branded product if generic product is available or require the patient to first fail on one or more generic product before permitting access to branded medicine volume purchasing long term contract and their ability to influence volume and market share of prescription drug in addition by placing branded medicine on higher tier or non preferred status in their formulary mcos transfer portion of the cost to the patient resulting in significant patient out of pocket expense this financial disincentive is tool for mcos to manage drug cost and channel patient to medicine preferred by the mcos the aca ha accelerated payment reform by distributing risk across mcos and other stakeholder in care delivery with the intent of improving quality while reducing cost which creates pfizer inc form on mcos to tie reimbursement to defined outcome we are closely monitoring these newer approach and developing appropriate strategy to respond to them the breadth of the product covered by formulary can vary considerably from one mco to another and many formulary include alternative and competitive product for treatment of particular medical problem mcos also emphasize primary and preventive care out patient treatment and procedure performed at doctor office and clinic way to manage cost hospitalization and surgery typically the most expensive form of treatment are carefully managed and drug that can reduce the need for hospitalization professional therapy or surgery may become favored first line treatment for certain disease exclusion of product from formulary or other mco implemented restriction can significantly impact drug usage in the mco patient population and beyond consequently pharmaceutical company compete to gain access to formulary for their product typically on the basis of unique product feature such greater efficacy better patient ease of use or fewer side effect well the overall cost of the therapy we have been generally although not universally successful in our major product included on mco formulary however increasingly our branded product are being placed on the higher tier or in non preferred status for additional information see the item risk factor managed care trend section in this form raw materialswe procure raw material essential to our business from numerous supplier worldwide in general these material have been available in sufficient quantity to support our demand and in many case are available from multiple supplier no significant impact to our operation due to the availability of raw material is currently anticipated in however we are seeing an increase in overall demand in the industry for certain component and raw material with the potential to constrain available supply which could have future impact on our business we are continuing to monitor and implement mitigation strategy in an effort to reduce any potential risk or impact including active supplier management qualification of additional supplier and advanced purchasing to the extent possible government regulation and price constraintswe are subject to extensive regulation by government authority in the country in which we do business this includes law and regulation governing the operation of biopharmaceutical company such the approval manufacturing and marketing of product pricing including discount and rebate and health information privacy among others these law and regulation may require administrative guidance for implementation and failure to comply could subject to legal and or administrative action enforcement measure may include substantial fine and or penalty order to stop non compliant activity criminal charge warning letter product recall or seizure delay in product approval exclusion from participation in government program or contract well limitation on conducting business in applicable jurisdiction and could result in harm to our reputation and business for additional information see note compliance with these law and regulation may be costly and may require significant technical expertise and capital investment to ensure compliance while capital expenditure or operating cost for compliance with government regulation can not be predicted with certainty we do not currently anticipate they will have material effect on our capital expenditure or competitive position in the united statesdrug and biologic regulation the fda pursuant to the ffdca the public health service act and other federal statute and regulation extensively regulates pre and post marketing activity related to our biopharmaceutical product the regulation govern area such the safety and efficacy of medicine and vaccine clinical trial advertising and promotion quality control manufacturing labeling distribution post marketing safety surveillance and reporting and record keeping other federal agency including the dea also regulate certain of our product and activity for biopharmaceutical company to market drug or biologic product including vaccine in the the fda must evaluate whether the product is safe and effective for it intended use if the fda determines that the drug or biologic is safe and effective the fda will approve the product nda or bla or supplemental nda or supplemental bla appropriate drug or biologic may be subject to postmarketing commitment which are study or clinical trial that the product sponsor agrees to conduct or postmarketing requirement which are study or clinical trial that are required condition of approval in addition we are also required to report adverse event and comply with cgmps the fda regulation that govern all aspect of manufacturing quality for pharmaceutical and the drug supply chain security act the law that among other thing set forth requirement related to product tracing product identifier and verification for manufacturer wholesale distributor repackagers and dispenser to facilitate the tracing of product through the pharmaceutical distribution supply chain well advertising and promotion regulation for additional information see the item risk factor development regulatory approval and marketing of product and post authorization approval data section in this form in the context of public health emergency like the covid pandemic we may apply to the fda for an eua which if granted allows for the distribution and use of our product during the declared emergency in accordance with the condition set forth in the eua unless the eua is otherwise terminated by the government although the criterion for an eua differ from the criterion for approval of an nda or bla euas nevertheless require the development and submission of data to satisfy the relevant fda standard and number of ongoing obligation the fda generally expects eua holder to work toward submission of full application such bla or an nda soon possible biosimilar regulation the fda is responsible for approval of biosimilars innovator biologics are entitled to year of market exclusivity by statute and biosimilars application may not be submitted until four year after the approval of the reference innovator biologic sale and marketing regulation our marketing practice are subject to state law well federal law such the anti kickback statute and false claim act intended to prevent fraud and abuse in the healthcare industry the anti kickback statute generally prohibits corruptly soliciting offering receiving or paying anything of value to generate business the false claim act generally prohibits anyone from knowingly and willingly presenting or causing to be presented any claim for payment for good or service including to government payer such medicare and medicaid that are false or fraudulent and generally treat claim generated through kickback false or fraudulent the federal government and state also regulate sale and marketing activity and financial interaction between manufacturer and healthcare provider requiring disclosure to government authority and the public of such interaction and the adoption of compliance standard or program state pfizer inc form general have also taken action to regulate the marketing of prescription drug under state consumer protection and false advertising law pricing reimbursement and access regulation pricing and reimbursement for our product depend in part on government regulation any significant effort at the federal or state level to reform the healthcare system by changing the way healthcare is provided or funded or more directly impose control on drug pricing government reimbursement and access to medicine and vaccine on public and private insurance plan could have material impact on in addition in order to have our product covered by medicaid we must offer discount or rebate on purchase of pharmaceutical product under various federal and state program we also must report specific price to government agency the calculation necessary to determine the price reported are complex and the failure to do so accurately may expose to enforcement measure see the discussion regarding rebate in the analysis of the consolidated statement of income revenue by geography section within md and note government and private payer routinely seek to manage utilization and control the cost of our product and there is considerable public and government scrutiny of pharmaceutical pricing effort by state and the federal government to regulate price or payment for pharmaceutical product including proposed action to facilitate drug importation limit reimbursement to lower international reference price require deep discount and require manufacturer to report and make public price increase and sometimes written justification for the increase could adversely affect our business if implemented we expect to see continued focus by congress and the biden administration on regulating pricing which could result in legislative and regulatory change designed to control cost for example there is proposed legislation that if enacted would allow medicare to negotiate price for certain prescription drug well require that penalty be paid by manufacturer who raise drug price faster than inflation in addition change to the medicaid program or the federal drug pricing program which imposes ceiling on price that drug manufacturer can charge for medication sold to certain health care facility could have material impact on our business for example certain change issued in final rule by the center for medicare medicaid service cm in december to the medicaid drug rebate program could increase our medicaid rebate obligation and increase the discount we extend to covered entity additional change to the program are undergoing review and their status is unclear for additional information see the item risk factor pricing and reimbursement section in this form majority of state use preferred drug list to manage access to pharmaceutical product under medicaid including some of our product for example access to our product under the medicaid managed care program typically is determined by the health plan with which state medicaid agency contract to provide service to beneficiary state seek to control healthcare cost related to medicaid and other state healthcare program including the implementation of supplemental rebate agreement under the medicaid drug rebate program tied to patient outcome state budget were impacted le by the covid pandemic than expected and are generally growing we expect state to seek cost cutting within medicaid which may focus on managed care capitation payment and or formulary management state may also advance drug pricing initiative with focus on affordability review board financial penalty related to pricing practice manufacturer pricing and reporting requirement well regulation of prescription drug assistance or copay accumulator program in the commercial market payer may promote generic drug and biosimilars more aggressively to generate saving and attempt to stimulate additional price competition in addition we expect that consolidation and integration among pharmacy chain wholesaler and pbms will increase pricing pressure in the industry for additional information see the item risk factor managed care trend section in this form anti corruption the fcpa prohibits corporation and their representative from offering promising authorizing or making payment to any foreign government official government staff member political party or political candidate to obtain or retain business abroad the scope of the fcpa includes interaction with certain healthcare professional in many country other country have enacted similar anti corruption law and or regulation data privacy the collection and use of personal data by is increasingly important to our business and is subject to various federal and state privacy and data security law and regulation including oversight by various regulatory and other governmental body such law and regulation continue to evolve and are increasingly being enforced vigorously outside the united statesnew drug approval in the eu the ema conduct the scientific evaluation supervision and safety monitoring of our innovative medicinal product and employ centralized procedure for approval for the eu and the european economic area eea country in the the medicine and healthcare product regulatory agency is the sole regulatory authority in japan the pmda is involved in wide range of regulatory activity including clinical study approval post marketing review and pharmaceutical safety in china the nmpa is the primary regulatory authority for approving and supervising medicine health authority in many middle and lower income country require marketing approval by recognized regulatory authority the fda or ema before they begin to conduct their application review process and or issue their final approval pharmacovigilance in the eu the ema prac is responsible for reviewing and making recommendation on product safety issue outside developed market pharmacovigilance requirement vary and are generally not extensive but there is trend toward increasing regulation pricing and reimbursement certain government including in the different eu member state the japan china canada and south korea provide healthcare at low to zero direct cost to consumer at the point of care and have significant power to regulate pharmaceutical price or patient reimbursement level to control cost for the government sponsored healthcare system particularly under recent global financing pressure government globally may use variety of measure to control cost including proposing price reform or legislation cross country collaboration and procurement price cut mandatory rebate health technology assessment forced localization condition of market access international reference pricing the practice of country linking it regulated medicine price to those of other country qce process and vbp in addition the international patchwork of price regulation differing economic condition and incomplete value assessment across country ha led to varying access to quality medicine in many market and some third party trade in our product between country several important multilateral organization such the who are increasing scrutiny of international pharmaceutical pricing through policy recommendation and sponsorship of program such the oslo medicine initiative which is planning high level meeting in to agree on who europe member state commitment to ensure affordability for high priced medicine in november the ec published it new pharmaceutical strategy for europe which envisions broad range of new initiative and legislation including significant focus on affordability and access to medicine pfizer inc form china pricing pressure have increased in recent year because of an overall focus on healthcare cost containment with government official emphasizing improved health outcome healthcare reform and decreased drug price key indicator of progress towards reform for patented product drug price have decreased dramatically result of adding innovative drug including oncology medicine to the national reimbursement drug list nrdl in the off patent space numerous local generic have been officially deemed bioequivalent under qce process that required domestically manufactured generic drug to pas test to ass their bioequivalence to qualified reference drug typically the originator drug centralized vbp program tender process where certain portion of included molecule volume are guaranteed to tender winner and is intended to contain healthcare cost by driving utilization of generic that have passed qce ha resulted in dramatic price cut for off patent medicine furthermore the chinese government ha discussed moving toward effort to unify the reimbursement price between qce approved generic medicine and the applicable original medicine which the government currently plan to implement within the next few year we and most off patent originator have mostly not been successful in the vbp bidding process the government ha indicated that additional post loe drug could be subjected to vbp qualification in future round while certain detail of future qce expansion have been made available we are unable to determine the impact on our business and financial condition until the initiation of these future round healthcare provider transparency and disclosure several country have implemented law requiring or industry trade association have recommended disclosure of transfer of value made by pharmaceutical company to healthcare provider and or healthcare organization such academic teaching hospital intellectual property reliable patent protection and enforcement around the world are among the key factor we consider for continued business and investment the wto agreement on trade related aspect of intellectual property right wto trip requires participant country to provide patent and other intellectual property related protection for pharmaceutical product by law with an exemption provided for least developed country until while some country have made improvement we still face patent grant enforcement and other intellectual property challenge in many country while the global intellectual property policy environment ha generally improved following wto trip and bilateral multilateral trade agreement our growth and ability to bring new product innovation to patient depends on further progress in intellectual property protection in certain developed international market government maintain relatively effective intellectual property policy however in the eu pursuant to the ongoing review of pharmaceutical intellectual property and regulatory incentive legislative change may result in the reduction of certain protection in several emerging market country government have used intellectual property policy tool to force innovator to accept le than fair value for medicine well to advance industrial policy and localization goal discussion are ongoing at the wto that seek to limit intellectual property protection within the context of the covid pandemic response considerable political and economic pressure ha weakened current intellectual property protection in some country and ha led to policy such more restrictive standard for obtaining patent and more difficult procedure for patenting biopharmaceutical invention restriction on patenting certain type of invention revocation of patent law or regulation that promote or provide broad discretion to issue compulsory license weak intellectual property enforcement and failure to implement effective regulatory data protection our industry advocacy effort focus on seeking fair and transparent business environment for foreign manufacturer underscoring the importance of strong intellectual property system for local innovative industry and helping improve patient access to innovative medicine and vaccine data privacy outside of the many country have privacy and data security law and regulation concerning the collection and use of personal data including but not limited to the eu general data protection regulation and china personal information protection law the legislative and regulatory framework for privacy and data protection issue worldwide is also rapidly evolving country continue to adopt new and updated privacy and data security law the interpretation and application of such law and regulation remain uncertain and continue to evolve in addition enforcement of such law and regulation is increasing environmental mattersour operation are affected by national state and or local environmental law we have made and intend to continue to make the expenditure necessary for compliance with applicable law we also are cleaning up environmental contamination from past industrial activity at certain site we incurred capital and operational expenditure in for environmental compliance purpose and for the clean up of certain past industrial activity follows million in environment related capital expenditure and million in other environment related expense while capital expenditure or operating cost for environmental compliance can not be predicted with certainty we do not currently anticipate they will have material effect on our capital expenditure or competitive position see also note climate change present risk to our operation including the potential for additional regulatory requirement and associated cost the potential for more frequent and severe weather event and water availability challenge that may impact our facility and those of our supplier we can not provide assurance that physical risk to our facility or supply chain due to climate change will not occur in the future we periodically review our vulnerability to potential weather related risk and other natural disaster and update our assessment accordingly based on our review we do not believe these potential risk are material to our operation at this time human capitalour purpose is breakthrough that change patient life these breakthrough are delivered through the relentless collaboration of our talented workforce of december we employed approximately people worldwide with approximately based in the woman compose approximately of our global workforce and approximately of our based employee are individual with ethnically diverse background our continued success link directly to the commitment engagement and performance of our employee it is important that we not only attract and retain the best and brightest diverse talent but also ensure they remain engaged and can thrive in an environment that is committed to helping them grow succeed and contribute directly to achieving our purpose part of these effort we strive for an inclusive and empowering work environment adopting practice to simplify process and remove needle complexity rewarding both performance and leadership skill pfizer inc form career growth and internal mobility and offering competitive compensation and benefit program that encourage mental and physical well being core value to fully realize pfizer purpose we have established clear set of goal regarding what we need to achieve for patient and how we will go about achieving them the how is represented by four simple powerful company value courage excellence equity and joy each value defines our company and our culture courage breakthrough start by challenging convention especially in the face of uncertainty or adversity this happens when we think big speak up and are decisive excellence we can only change patient life when we perform at our best together this happens when we focus on what matter agree who doe what and measure outcome equity every person deserves to be seen heard and cared for this happens when we are inclusive act with integrity and reduce health care disparity joy we give to our work and it also give to we find joy when we take pride recognize one another and have fun diversity equity and inclusion at pfizer every person deserves to be seen heard and cared for and we work to further this goal by bringing together people with different background perspective and experience our commitment to equity consist of specific action to help foster more inclusive environment within pfizer including among others building more inclusive colleague experience through representation and meaningful connection ii advancing equitable health outcome by evaluating our work through the lens of the community we serve iii providing resource on allyship and the science behind inclusion to support all colleague in having courageous conversation about equity race and the avoidance of bias iv working to help transform society with external diversity equity and inclusion partnership including deploying capital engaging diverse supplier and amplifying equity initiative and working to help ensure demographic of clinical trial correlate to those of the country where trial are taking place colleague engagement to attract develop and inspire the brightest talent we aim to support our colleague by engaging and partnering with them to help ensure they feel they are part of community we understand the importance of continuously listening and responding to colleague feedback and our annual engagement survey pfizer pulse provides forum for our colleague to give structured feedback about their colleague experience through this survey we measure and track key area of the overall colleague experience and equip leader with actionable insight for discussion and follow up regular topic in the survey include employee engagement such colleague commitment to and advocacy for pfizer ii purpose including how colleague work connects with our purpose iii inclusion such having climate in which diverse perspective are valued and iv growth including the ability for colleague to gain new experience that align with their individual career goal in we continued to maintain low turnover rate relative to the pharmaceutical industry and in our pfizer pulse survey on average of colleague reported feeling engaged measured by pride in working at pfizer willingness to recommend pfizer great place to work and intent to stay in addition of the colleague agreed that their daily work contributes to our purpose while we are slightly behind in our bold move goal to create room for meaningful work we continue to make progress on simplifying process and removing needle complexity we have committed to tangible action and principle that incorporate the similar behavior and mindset we used to develop covid vaccine in an accelerated timeline these behavior include working with urgency and overcoming bureaucracy well believing in our purpose trusting in one another and being transparent performance leadership and growth we are committed to helping our colleague reach their full potential by rewarding both their performance and leadership skill and by providing opportunity for growth and development our performance management approach called performance and leadership insight is based on six month semester during which our colleague and their manager set goal receive feedback and meet to discus performance these conversation are meant to help colleague grow and develop by evaluating performance what the colleague achieved measured by outcome leadership how they achieved it taking into account pfizer value of courage excellence equity and joy and identifying area of growth that help move colleague towards fulfilling their career goal and their potential our commitment to colleague development consist of specific action to encourage non linear career growth path for all colleague including common language around growth along with guiding framework to help colleague identify their next best growth experience ii tool and resource to encourage growth conversation and offer transparency on the source of growth available and iii variety of program including mentoring job rotation experiential project role skill based volunteering and learning resource focused on various topic including leadership and management skill and industry and job specific learning well general business manufacturing finance and technology skill health safety and well being protecting the health safety and well being of colleague and contingent worker all of are essential to delivering our business objective is an integral part of how we operate our global environment health safety ehs policy and supporting standard outline our approach to assessment evaluation elimination and mitigation of ehs risk across our operation covid pandemic preparedness and response continues to be key focus to help ensure on site worker at our commercial manufacturing and research site remain safe and healthy while continuing to support work from home arrangement for colleague who can work remotely part of these effort we implemented vaccination program for colleague and their family in the and other country where employer vaccination program were possible ii partnered with and launched thrive global wellness and organizational change initiative with primary focus on colleague mental health and wellness and iii hosted educational webinars and information session on mental health and well being nutrition and work life balance through our employee assistance program provider pay equity our commitment to pay equity for all colleague is based in our value of equity and our intention to continue to build diverse and inclusive workforce we are committed to equitable pay practice at pfizer for employee based on role education experience performance and location and we conduct and report publicly on pay equity on an annual basis additional information regarding our human capital program and initiative is available in the about career section of pfizer website and our esg report item risk factorsthis section describes the material risk to our business which should be considered carefully in addition to the other information in this report and our other filing with the sec investor should be aware that it is not possible to predict or identify all such factor and that the following is pfizer inc form meant to be complete discussion of all potential risk or uncertainty additionally our business is subject to general risk applicable to any company such economic condition geopolitical event extreme weather and natural disaster if known or unknown risk or uncertainty materialize our business operation financial condition operating result including component of our financial result cash flow prospect reputation or credit rating could be adversely affected now and in the future potentially in material way the following discussion of risk factor contains forward looking statement discussed in the forward looking information and factor that may affect future result section in this form risk related to our business industry and operation managed care trendsprivate payer such health plan and other managed care entity such pbms continue to take action to manage the utilization and cost of drug the negotiating power of mcos and other private third party payer ha increased due to consolidation and they along with government increasingly employ formulary to control cost and encourage utilization of certain drug including through the use of formulary inclusion or favorable formulary placement these initiative have increased consumer interest and input in medication choice they pay for larger portion of their prescription cost and may cause them to favor lower cost generic alternative we may fail to obtain or maintain timely or adequate pricing or formulary placement of our product or fail to obtain such formulary placement at favorable pricing the growing availability and use of innovative specialty pharmaceutical medicine that treat rare or life threatening condition which typically have smaller patient population combined with their relative higher cost compared to other type of pharmaceutical product also ha generated increased payer interest in developing cost containment strategy targeted to this sector third party payer also use additional measure such new to market block exclusion list indication based pricing and value based pricing contracting to improve their cost containment effort such payer are also increasingly imposing utilization management tool such clinical protocol requiring prior authorization for branded product if generic product is available or requiring the patient to first fail on one or more generic product before permitting access to branded medicine the private third party payer market consolidates further and more drug become available in generic form we may face greater pricing pressure from private third party payer they continue to drive more of their patient to use lower cost generic alternative also business arrangement in this area are subject to high degree of government scrutiny and available safe harbor under applicable federal and state fraud and abuse law are subject to change through legislative and regulatory action well evolving judicial interpretation our approach to these arrangement may also be informed by such government and industry guidance competitive productscompetitive product launch may erode future sale of our product including our existing product and those currently under development or result in unanticipated product obsolescence such launch continue to occur and potentially competitive product are in various stage of development we can not predict with accuracy the timing or impact of the introduction of competitive product that treat disease and condition like those treated by our in line product and product candidate in addition competition from manufacturer of generic drug including from generic version of competitor branded product that lose their market exclusivity is major challenge for our branded product certain of our product have experienced significant generic competition over the last few year for additional information see the item business patent and other intellectual property right section in this form in china we expect to continue to face intense competition by certain generic manufacturer which may result in price cut and volume loss of some of our product in addition our patented product may face generic competition before patent exclusivity expires including upon the at risk launch despite pending patent infringement litigation against the generic product by manufacturer of generic version of one of our patented product generic manufacturer have filed application with the fda seeking approval of product candidate that they claim do not infringe our patent or claim that our patent are not valid these include candidate that would compete with among other product ibrance and xeljanz our licensing and collaboration partner also face challenge by generic drug manufacturer to patent covering product for which we have license or co promotion right we may become subject to competition from biosimilars referencing our biologic product if competitor are able to obtain marketing approval for such biosimilars we also commercialize biosimilar product that compete with product of others including other biosimilar product the entry to the market of competing biosimilars is expected to increase pricing pressure on our biosimilar product uptake of our biosimilars may be lower due to various factor such anti competitive practice access challenge where our product may not receive appropriate coverage reimbursement access or remains in disadvantaged position relative to an innovator product physician reluctance to prescribe biosimilars for existing patient taking the innovative product or misaligned financial incentive for additional information on competition our product face see the item business competition section in this form concentrationwe recorded direct product and or alliance revenue of more than billion for each of nine product that collectively accounted for of our total revenue in in particular comirnaty accounted for of our total revenue in for additional information see note and if these product or any of our other major product were to experience loss of patent protection if applicable change in prescription or vaccination growth rate material product liability litigation unexpected side effect or safety concern regulatory proceeding negative publicity affecting doctor or patient confidence pressure from existing competitive product change in labeling pricing and access pressure or supply shortage or if new more effective product should be introduced the adverse impact on our revenue could be significant in particular certain of our product have experienced patent based expiration or loss of regulatory exclusivity in certain market in the last few year and patent covering number of our best selling product are or have been the subject of pending legal challenge for additional information on our patent see the item business patent and other intellectual property right section in this form for comirnaty and pfizer inc form while we believe that these product have the potential to provide ongoing revenue stream for pfizer for the foreseeable future revenue of these product following the covid pandemic may not be at the similar level those being generated during the pandemic for information on additional risk associated with comirnaty and paxlovid see the covid pandemic section below in addition we sell our prescription pharmaceutical product principally through wholesaler in the for additional information see note if one of our significant biopharmaceutical wholesaler should encounter financial or other difficulty it might decrease the amount of business the wholesaler doe with and or we might be unable to timely collect all the amount that the wholesaler owes or at all which could negatively impact our result of operation in addition we expect that consolidation and integration of pharmacy chain and wholesaler will increase competitive and pricing pressure on pharmaceutical manufacturer including research and development the discovery and development of new product well the development of additional us for existing product are necessary for the continued strength of our business our product line must be replenished over time to offset revenue loss when product lose exclusivity or market share well to provide for earnings growth primarily through internal or through collaboration acquisition jv licensing or other arrangement growth depends in large part on our ability to identify and develop new product or new indication for existing product that address unmet medical need and receive reimbursement from payer however balancing current growth investment for future growth and the delivery of shareholder return remains major challenge the cost of product development continue to be high are regulatory requirement in many therapeutic area which may affect the number of candidate we are able to fund well the sustainability of the portfolio decision made early in the development process of drug or vaccine candidate can have substantial impact on the marketing strategy and payer reimbursement possibility if the candidate receives regulatory approval we try to plan clinical trial prudently and to reasonably anticipate and address challenge but there is no assurance that an optimal balance between trial conduct speed and desired outcome will be achieved additionally our product candidate can fail at any stage of the process and may not receive regulatory approval even after many year of we may fail to correctly identify indication for which our science is promising or allocate investment resource efficiently and failure to invest in the right technology platform therapeutic area product class geographic market and or licensing opportunity could adversely impact the productivity of our pipeline further even if we identify area with the greatest commercial potential the scientific approach may not succeed despite the significant investment required for and the product may not be competitive expected because of the highly dynamic market environment and the hurdle in term of access and reimbursement for example our gene therapy product candidate are based on novel technology with only few gene therapy approved to date which make it difficult to predict the time and cost of development and the ability to obtain regulatory approval further gene therapy may face difficulty in gaining the acceptance of patient or the medical community global operationswe operate on global scale and could be affected by currency fluctuation capital and exchange control global economic condition including inflation expropriation and other restrictive government action change in intellectual property legal protection and remedy trade regulation tax law and regulation and procedure and action affecting approval production pricing and marketing of reimbursement for and access to our product well impact of political or civil unrest or military action including the current conflict between russia and ukraine terrorist activity unstable government and legal system inter governmental dispute public health outbreak epidemic pandemic natural disaster or disruption related to climate change some emerging market country may be particularly vulnerable to period of financial or political instability or significant currency fluctuation or may have limited resource for healthcare spending result of these and other factor our strategy to grow in emerging market may not be successful and growth rate in these market may not be sustainable government financing and economic pressure can lead to negative pricing pressure in various market where government take an active role in setting price access criterion through health technology assessment or other mean of cost control for additional information on government pricing pressure see the item business government regulation and price constraint section in this form we continue to monitor the global trade environment and potential trade conflict and impediment that could impact our business if trade restriction or tariff reduce global economic activity potential impact could include declining sale increased cost volatility in foreign exchange rate decline in the value of our financial asset and pension plan investment required increase of our pension funding obligation increased government cost control effort delay or failure in the performance of customer supplier and other third party on whom we may depend for the performance of our business and the risk that our allowance for doubtful account may not be adequate we operate in many country and transact in over different currency change in the value of those currency relative to the dollar or high inflation in these country can impact our revenue cost and expense and our financial guidance significant portion of our revenue cost and expense well our substantial international net asset are exposed to exchange rate change of our total revenue were derived from international operation including from europe and from china japan and the rest of asia future change in exchange rate or economic condition and the impact they may have on our result of operation financial condition or business are difficult to predict for additional information about our exposure to foreign currency risk see the analysis of financial condition liquidity capital resource and market risk section within md in addition our borrowing pension benefit and postretirement benefit obligation and interest bearing investment are subject to risk from change in interest and exchange rate the risk related to interest bearing investment and borrowing and the measure we have taken to help contain them are discussed in the analysis of financial condition liquidity capital resource and market risk section within md and note for additional detail on critical accounting estimate and assumption for our benefit plan see the significant accounting policy and application of critical accounting estimate and assumption benefit plan section within md and note from time to time we issued variable rate debt based on libor or undertook interest rate swap that contain variable element based on libor the financial conduct authority announced in that it will no longer compel bank to submit rate used to calculate libor after this deadline wa extended until june for number of key dollar benchmark maturity including the month and month pfizer inc form rate the federal reserve ha selected the secured overnight funding rate sofr the preferred alternate rate and the transition away from libor will continue despite the extended timeline we are planning for this transition and will amend any contract to accommodate the sofr rate where required we do not expect the transition to have significant impact on our business or financial condition product manufacturing sale and marketing riskswe could encounter difficulty or delay in our supply chain product manufacturing and distribution network well sale or marketing due to regulatory action shut down work stoppage or strike approval delay withdrawal recall penalty supply disruption shortage or stock out at our facility or third party facility that we rely on reputational harm the impact to our facility due to health pandemic or natural or man made disaster including result of climate change product liability or unanticipated cost example of such difficulty or delay include the inability to increase production capacity commensurate with demand challenge related to component material to maintain supply and or appropriate quality standard throughout our supply network and or comply with applicable regulation inability to supply certain product due to voluntary product recall is the case with chantix and supply chain disruption at our facility or at supplier or vendor in addition we engage contract manufacturer and from time to time our contract manufacturer may face difficulty or are unable to manufacture our product at the necessary quantity or quality level regulatory agency periodically inspect our manufacturing facility well third party facility that we rely on to evaluate compliance with cgmp or other applicable requirement failure to comply with these requirement may subject to possible legal or regulatory action such warning letter suspension of manufacturing seizure of product injunction debarment product recall delay or denial of product approval import ban or denial of import certification in july and august pfizer recalled lot of chantix in the due to the presence of nitrosamine nitroso varenicline at or above the fda interim acceptable intake limit in september pfizer expanded it voluntary recall in the to include all lot of chantix we currently also have voluntary recall across multiple market and global pause in shipment of chantix technical solution are being pursued to reduce nitrosamine level in chantix to enable return to market nitrosamines are impurity common in water and food and everyone is exposed to some level of nitrosamines in response to request from various regulatory authority manufacturer across the pharmaceutical industry including pfizer are evaluating their product portfolio for the potential for the presence or formation of nitrosamines this may lead to additional recall or other market action for pfizer product collaboration and other relationship with third party we depend on third party collaborator service provider and others in the research development manufacturing and commercialization of our product and product candidate and also enter into jv and other business development transaction to achieve expected longer term benefit we may make substantial upfront payment part of these transaction which may negatively impact our reported earnings or cash flow we rely heavily on these party for multiple aspect of our drug development manufacturing and commercialization activity but we do not control many aspect of those activity we also outsource certain service including activity related to transaction processing accounting information technology manufacturing clinical trial recruitment and execution clinical lab service non clinical research safety service integrated facility management and other area failure by one or more of the third party collaborator service provider and others to complete activity on schedule or in accordance with our expectation or to meet their contractual or other obligation to failure of one or more of these party to comply with applicable law or regulation or any disruption in the relationship between and these party could delay or prevent the development approval manufacturing or commercialization of our product and product candidate expose to suboptimal quality of service delivery or deliverable result in repercussion such missed deadline or other timeliness issue erroneous data and supply disruption and could also result in non compliance with legal or regulatory requirement or industry standard or subject to reputational harm all with potential negative implication for our product pipeline and business further our alliance revenue will be adversely affected by the termination or expiration of collaboration and co promotion agreement that we have entered into and that we may enter into from time to time for information on additional risk specific to our consumer healthcare jv see the consumer healthcare jv with gsk section below counterfeit productsour reputation and promising pipeline render our medicine and vaccine prime target for counterfeiter counterfeit medicine and vaccine pose significant risk to patient health and safety because of the condition under which they are manufactured often in unregulated unlicensed uninspected and unsanitary site well the lack of regulation of their content failure to mitigate this threat could adversely impact pfizer patient potentially causing them harm this in turn may result in the loss of patient confidence in the pfizer name and in the integrity of our medicine and vaccine and potentially impact our business through lost sale product recall and possible litigation the prevalence of counterfeit medicine is an industry wide issue due to variety of factor including the adoption of commerce which increased during the covid pandemic greatly enhancing consumer ability to obtain prescription and other medical treatment via the internet in lieu of traditional brick and mortar pharmacy or authorized full service internet pharmacy the internet expose patient to greater risk it is preferred vehicle for dangerous counterfeit offer and scam because of consumer misplaced trust with certain commerce retailer coupled with the anonymity the internet affords counterfeiter while counterfeiter generally target any medicine or vaccine boasting strong demand we have observed heightened counterfeit and fraud attempt to our covid vaccine well other product potentially utilized in the treatment of covid we consistently invest in an enterprise wide strategy to aggressively combat counterfeit threat by educating patient and health care provider about the risk investing in innovative technology to detect and disrupt sophisticated internet offer and scam proactively monitoring and interdicting supply with the help of law enforcement and advising legislator and regulator however our effort and those of others may not be entirely successful and the presence of counterfeit medicine may continue to increase pfizer inc form related to government regulation and legal proceeding pricing and reimbursementu and international governmental regulation that mandate price control or limitation on patient access to our product or establish price paid by government entity or program for our product impact our business and our future result could be adversely affected by change in such regulation or policy the adoption of restrictive price control in new jurisdiction more restrictive control in existing jurisdiction or the failure to obtain or maintain timely or adequate pricing could also adversely impact revenue we expect pricing pressure will continue globally in the pharmaceutical product pricing is subject to government and public scrutiny and call for reform and many of our product are subject to increasing pricing pressure result we expect to see continued focus by the federal government on regulating pricing which could result in legislative and regulatory change designed to control cost some state have implemented and others are considering patient access constraint or cost cutting under the medicaid program and some are considering measure that would apply to broader segment of their population that are not medicaid eligible state legislature also have continued to focus on addressing drug cost generally by increasing price transparency or limiting drug price increase measure to regulate price or payment for pharmaceutical product including legislation on drug importation could adversely affect our business for additional information on pricing and reimbursement see the item business government regulation and price constraint section in this form we encounter similar regulatory and legislative issue in most other country in which we operate in certain market such in eu member state the japan china canada and south korea government have significant power large single payer to regulate price access criterion or impose other mean of cost control particularly result of recent global financing pressure for example the qce and vbp tender process in china ha resulted in dramatic price cut for off patent medicine for additional information regarding these government initiative see the item business government regulation and price constraint section in this form we anticipate that these and similar initiative will continue to increase pricing pressure in china and elsewhere in the future in addition in many country with respect to our vaccine we participate in tender process for selection in national immunization program failure to secure participation in national immunization program or to obtain acceptable pricing in the tender process could adversely affect our business we also anticipate pricing pressure will be amplified by covid induced budget deficit and focus on pricing for covid treatment and vaccine healthcare regulationthe healthcare industry is highly regulated and subject to frequent and substantial change any significant effort at the federal or state level to reform the healthcare system by changing the way healthcare is provided or funded could have material impact on for additional information on healthcare regulation see the item business government regulation and price constraint section in this form other federal or state legislative or regulatory action and or policy effort could adversely affect our business including among others general budget control action change in patent law the importation of prescription drug to the at price that are regulated by foreign government revision to reimbursement of biopharmaceuticals under government program that could reference international price or require new discount limitation on interaction with healthcare professional and other industry stakeholder or the use of comparative effectiveness methodology that could be implemented in manner that focus primarily on cost difference and minimizes the therapeutic difference among pharmaceutical product and restricts access to innovative medicine reduction of federal spending on entitlement program including medicare and medicaid may affect payment for our product or service provided using our product any other significant spending reduction or cost control affecting medicare medicaid or other publicly funded or subsidized health program that may be implemented could have an adverse impact on our result of operation development regulatory approval and marketing of productsthe discovery and development of drug vaccine and biological product are time consuming costly and unpredictable the outcome is inherently uncertain and involves high degree of risk due to the following factor among others the process from early discovery to design and adequate implementation of clinical trial to regulatory approval can take many year product candidate can and do fail at any stage of the process including the result of unfavorable pre clinical and clinical trial result or unfavorable new pre clinical or clinical data and further analysis of existing pre clinical or clinical data including result that may not support further clinical development of the product candidate or indication we may need to amend our clinical trial protocol or conduct additional clinical trial under certain circumstance for example to further ass appropriate dosage or collect additional safety data we may not be able to meet anticipated pre clinical or clinical endpoint commencement and or completion date for our pre clinical or clinical trial regulatory submission date regulatory approval date and or launch date we may not be able to successfully address all the comment received from regulatory authority such the fda and the ema or be able to obtain approval for new product and indication from regulator regulatory approval of our product depend on myriad factor including regulatory determination to the product safety and efficacy in the context of public health emergency like the covid pandemic regulator evaluate various factor and criterion to potentially allow for marketing authorization on an emergency or conditional basis additionally clinical trial and other product data are subject to differing interpretation and assessment by regulatory authority result of regulatory interpretation and assessment or other development that occur during the review process and even after product is authorized or approved for marketing product commercial potential could be adversely affected by potential emerging concern or regulatory decision regarding or impacting labeling or marketing manufacturing process safety and or other matter including decision relating to emerging development regarding potential product impurity we may not be able to receive or maintain favorable recommendation by technical or advisory committee such the acip or any fda advisory committee that may be convened to review our application such euas ndas or blas which may impact the potential marketing and use of our product further claim and concern that may arise regarding the safety and efficacy of in line product and product candidate can negatively impact product sale and potentially lead to product recall or withdrawal including regulator directed risk evaluation and pfizer inc form and or consumer fraud product liability and other litigation and claim further regulatory agency requirement may result in more challenging expensive and lengthy regulatory approval process than anticipated due to request for among other thing additional or more extensive clinical trial prior to granting approval or increased post approval requirement for these and other reason discussed in this risk factor section we may not obtain the approval we expect within the timeframe we anticipate or at all post authorization approval dataas condition to granting marketing authorization or approval of product the fda may require additional clinical trial or other study the result generated in these trial could result in the loss of marketing approval change in labeling and or new or increased concern about the side effect efficacy or safety regulatory agency in country outside the often have similar regulation and may impose comparable requirement post marketing study and clinical trial whether conducted by or by others whether mandated by regulatory agency or conducted voluntarily and other emerging data about product such adverse event report may also adversely affect the availability or commercial potential of our product further if safety or efficacy concern are raised about product in the same class one of our product those concern could implicate the entire class and this in turn could have an adverse impact on the availability or commercial viability of our product well other product in the class the potential regulatory and commercial implication of post marketing study result typically can not immediately be determined for example in december in light of the result from the completed required postmarketing safety study of xeljanz oral surveillance the label for xeljanz wa revised update include new boxed warning for major adverse cardiovascular event mace and updated boxed warning regarding mortality malignancy and thrombosis with corresponding update to applicable warning and precaution in addition indication for the treatment of adult with moderately to severely active ra or active psa and patient who are two year of age and older with active polyarticular course juvenile idiopathic arthritis have been revised xeljanz is now indicated in patient who have had inadequate response or intolerance to one or more tumor necrosis factor blocker in addition at the request of the ec the prac of the ema ha adopted referral procedure under article of regulation ec no to ass safety information relating to oral jak inhibitor authorized for inflammatory disease including xeljanz and cibinqo which is ongoing we continue to work with regulatory agency to review the full result and analysis of oral surveillance and their impact on product labeling the term of our eua for comirnaty require that we conduct post authorization observational study in patient at least year of age or older who received booster dose or other population of interest including healthcare worker pregnant woman immunocompromised individual and subpopulation with specific comorbidities additionally in relation to the fda approval for comirnaty we are required to complete certain postmarketing study requirement and commitment by identified in the august approval letter the term of our eua for paxlovid require monitoring for convergence of global viral variant of sars cov and potential assessment of paxlovid activity against identified global variant of interest additionally in relation to the potential fda approval for paxlovid we are required to complete certain other analysis and study identified in the december authorization letter legal matterswe are and may be involved in various legal proceeding including patent litigation product liability and other product related litigation including personal injury consumer off label promotion security antitrust and breach of contract claim commercial and other asserted and unasserted matter environmental government investigation employment tax litigation and other legal proceeding that arise from time to time in the ordinary course of our business litigation is inherently unpredictable and excessive verdict do occur although we believe that our claim and defense in matter in which we are defendant are substantial we could in the future incur judgment enter into settlement or revise our expectation regarding the outcome of certain matter and such development could have material adverse effect on our result of operation claim against our patent include challenge to the coverage and or validity of our patent on various product or process there can be no assurance to the outcome of these matter and loss in any of these case could result in loss of patent protection for the product at issue which could lead to significant loss of sale of that product and could materially affect future result of operation government investigation and action could result in substantial fine and or criminal charge and civil penalty limitation on our ability to conduct business in applicable jurisdiction corporate integrity or deferred prosecution agreement and other disciplinary action well reputational harm including result of increased public interest in the matter in addition in qui tam lawsuit in which the government decline to intervene the relator may still pursue suit for the recovery of civil damage and penalty on behalf of the government our sale and marketing activity and the pricing of our product are subject to extensive regulation under the ffdca the medicaid drug rebate program the fcpa and other federal and state statute including those discussed elsewhere in this form well the anti kickback statute anti bribery law the false claim act and similar law in international jurisdiction in addition to the potential for change to relevant law the compliance and enforcement landscape is informed by government litigation settlement precedent advisory opinion and special fraud alert our approach to certain practice may evolve over time in light of these type of development requirement or industry standard in the and certain jurisdiction abroad require pharmaceutical manufacturer to track and disclose financial interaction with healthcare professional and healthcare provider and can increase government and public scrutiny of such financial interaction if an interaction is found to be improper government enforcement action and penalty could result like many company in our industry we have from time to time received and may receive in the future inquiry and subpoena and other type of information demand from government authority in addition we have been subject to claim and other action related to our business activity brought by governmental authority well consumer and private payer in some instance we have incurred significant expense civil payment fine and other adverse consequence result of these claim action and inquiry such claim action and inquiry may relate to alleged non compliance with law and regulation associated with the dissemination of product approved and unapproved information potentially resulting in government enforcement action and reputational damage this risk may be heightened by digital marketing including social medium mobile application and blogger outreach in connection with the resolution of government investigation concerning independent copay assistance organization that provide financial assistance to medicare patient in we entered into corporate integrity agreement cia with the office of the inspector general of the department of health and human service which is effective for period of five year in the cia we agreed to implement and or maintain certain compliance program element to promote compliance with federal healthcare program requirement breach of the cia could result in severe sanction against pfizer inc form and certain of our subsidiary are also subject to numerous contingency arising in the ordinary course of business relating to legal claim and proceeding including environmental contingency amount recorded for legal and environmental contingency can result from complex series of judgment about future event and uncertainty and can rely heavily on estimate and assumption while we have accrued for worldwide legal liability no guarantee exists that additional cost will not be incurred beyond the amount accrued for additional information including information regarding certain legal proceeding in which we are involved in see note risk related to intellectual property technology and security intellectual property protectionour success largely depends on our ability to market technologically competitive product we rely and expect to continue to rely on combination of intellectual property including patent trademark trade dress copyright trade secret and domain name protection law well confidentiality and license agreement to protect our intellectual property and proprietary right if we fail to obtain and maintain adequate intellectual property protection we may not be able to prevent third party from launching generic or biosimilar version of our branded product from using our proprietary technology or from marketing product that are very similar or identical to our currently pending or future patent application may not result in issued patent or be granted on timely basis similarly any term extension that we seek may not be granted on timely basis if at all for example in may the brazilian supreme court voted to invalidate article of brazil patent law which guaranteed minimum year patent term from patent grant and to give retroactive effect to such decision in addition our issued patent may not contain claim sufficiently broad to protect against claim regarding validity enforceability scope and effective term made by party with similar technology or product or provide with any competitive advantage including exclusivity in particular product area further legal or regulatory action by various stakeholder or government could potentially result in not seeking intellectual property protection for or agreeing not to enforce or being restricted from enforcing intellectual property related to our product discussion are ongoing at the wto regarding the role of intellectual property in the context of the covid pandemic response this includes proposal that would release wto member from their obligation under wto trip to grant and enforce various type of intellectual property protection on health product and technology in relation to the prevention containment or treatment of covid in may and in november the biden administration called on country to waive intellectual property protection on covid vaccine the scope of our patent claim also may vary between country individual country have distinct patent law and our ability to enforce our patent depends on the law of each country it enforcement practice and the extent to which certain country engage in policy or practice that weaken country intellectual property framework law or regulation that promote or provide broad discretion to issue compulsory license in country that provide some form of regulatory exclusivity mechanism exist permitting some form of challenge to our patent by competitor or generic drug marketer prior to or immediately following the expiration of such regulatory exclusivity and generic company are employing aggressive strategy such at risk launch that challenge our patent right most of the suit involve claim by generic drug manufacturer that patent covering our product us process or dosage form are invalid and or do not cover the product of the generic or biosimilar drug manufacturer independent action have been filed alleging that our assertion of or attempt to enforce patent right with respect to certain product constitute unfair competition and or violation of antitrust law such claim may also be brought counterclaim to action we bring to enforce our patent we are also party to other patent damage suit in various jurisdiction pursuant to which generic drug manufacturer payer government or other party are seeking damage from for alleged delay of generic entry we also are often involved in other proceeding such inter partes review post grant review examination or opposition proceeding before the patent and trademark office the european patent office or other foreign counterpart relating to our intellectual property or the intellectual property right of others also if one of our patent or competitor patent is found to be invalid in such proceeding generic or biosimilar product could be introduced into the market resulting in the erosion of sale of our existing product for additional information including information regarding certain legal proceeding in which we are involved see note further if we are unable to maintain our existing license agreement or other agreement pursuant to which third party grant right to intellectual property our operating result and financial condition could be adversely affected we currently hold trademark registration and have trademark application pending in many jurisdiction any of which may be the subject of governmental or third party objection which could prevent the maintenance or issuance of the trademark our product mature our reliance on our trademark and trade dress to differentiate from our competitor increase and result our business could be adversely affected if we are unable to prevent third party from adopting registering or using trademark and trade dress that infringe dilute or otherwise violate our right we seek to protect our proprietary information including our trade secret and proprietary know how by requiring our employee consultant other advisor and other third party to execute proprietary information and confidentiality agreement upon the commencement of their relationship with despite these effort and precaution we may be unable to prevent third party from copying or otherwise obtaining and using our trade secret or our other intellectual property without authorization and legal remedy may not adequately compensate for the damage caused by such unauthorized use further others may independently and lawfully develop substantially similar or identical product that circumvent our intellectual property by mean of alternative design or process or otherwise third party intellectual property claimsa properly functioning intellectual property regime is essential to our business model we are committed to respecting the valid intellectual property right of other company but the patent granting process is imperfect accordingly the pursuit of valid business opportunity may require to challenge intellectual property right held by others that we believe were improperly granted including challenge through negotiation and litigation and such challenge may not always be successful part of our business depends upon identifying biosimilar opportunity and launching product to take advantage of those opportunity which may involve litigation associated cost and time delay and may ultimately not be successful these opportunity may arise in situation where patent protection of equivalent branded product ha expired or been declared invalid or where product do not infringe the patent of others in some circumstance we may take action such litigation asserting that our product do not infringe patent of existing product or that those patent are invalid or unenforceable in order to achieve first to market or early market position for our product third party may claim that our product infringe one or more patent owned or controlled by them claim of intellectual property infringement can be costly and time consuming to resolve may delay or prevent product launch and may result in significant royalty payment or damage pfizer inc form example our in therapeutic area may not be first and another company or entity may have obtained relevant patent before we are involved in patent related dispute with third party over our attempt to market pharmaceutical product once we have final regulatory approval of the related product we may decide to commercially market these product even though associated legal proceeding including any appeal have not been resolved at risk launch if one of our marketed product is found to infringe valid patent right of third party such third party may be awarded significant damage or royalty payment or we may be prevented from further sale of that product such damage may be enhanced much three fold if we or one of our subsidiary is found to have willfully infringed valid patent right of third party information technology and security significant disruption of information technology system or breach of information security could adversely affect our business we extensively rely upon sophisticated information technology system including cloud service to operate our business we produce collect process store and transmit large amount of confidential information including personal information and intellectual property and we deploy and operate an array of technical and procedural control to maintain the confidentiality integrity and availability of such confidential information we have outsourced significant element of our operation including significant element of our information technology infrastructure and result we manage relationship with many third party provider who may or could have access to our confidential information we rely on technology developed supplied and or maintained by third party that may make vulnerable to supply chain style cyber attack further technology and security vulnerability of acquisition business partner or third party provider may not be identified during due diligence or soon enough to mitigate exploitation the size and complexity of our information technology and information security system and those of our third party provider and the large amount of confidential information that is present on them make such system potentially vulnerable to service interruption or to security breach from inadvertent or intentional action by our employee or contingent worker provider or malicious attacker global pharmaceutical company our system and asset are the target of frequent cyber attack such cyber attack are of ever increasing level of sophistication and are made by group and individual with wide range of motif including but not limited to industrial espionage and expertise including organized criminal group hacktivists nation state and others due to the nature of some of these attack there is risk that they may remain undetected for period of time while we have invested in the protection of data and information technology our effort may not prevent service interruption extortion theft of confidential or proprietary information compromise of data integrity or unauthorized information disclosure any such interruption or breach of our system could adversely affect our business operation and or result in the loss of confidential information or intellectual property and could result in financial legal business and reputational harm to we maintain cyber liability insurance however this insurance may not be sufficient to cover the financial legal business or reputational loss that may result from an interruption or breach of our system risk related to business development business development activitieswe expect to enhance our in line product and product pipeline through various form of business development which can include alliance license jv collaboration equity or debt based investment disposition divestments merger and acquisition the success of these activity is dependent on the availability and accurate cost benefit evaluation of appropriate opportunity competition from others that are seeking similar opportunity and our ability to successfully identify structure and execute transaction including the ability to satisfy closing condition in the anticipated timeframes or at all and successfully integrate acquisition pursuing these opportunity may require to obtain additional equity or debt financing which could result in increased leverage and or downgrade of our credit rating where we acquire debt or equity security all or part of the consideration for business development activity the value of those security will fluctuate and may depreciate we may not control company in which we invest and result we will have limited ability to determine it management operational decision and policy further while we seek to mitigate risk and liability of such transaction through among other thing due diligence there may be risk and liability that such effort fail to discover that are not disclosed to or that we inadequately ass the success of any of our acquisition will depend when applicable on our ability to realize anticipated benefit from integrating these business with we for example may fail to achieve cost saving anticipated with certain of these acquisition or such cost saving within the expected time frame similarly the accretive impact anticipated from certain of these acquisition may not be realized or may be delayed integration of these business may result in the loss of key employee the disruption of ongoing business including third party relationship or inconsistency in standard control procedure and policy we also may fail to generate the expected revenue growth for the acquired business expected revenue from acquired product and product candidate also may be constrained by development outside of our control unsuccessful clinical trial regulatory hurdle and commercialization challenge may adversely impact revenue and income contribution from product and product candidate including those acquired in these acquisition spin off and combination of upjohn with mylanwe may not realize some or all of the expected benefit of the spin off and combination the transaction of the upjohn business with mylan which resulted in the creation of viatris in november due to many factor including among others strategic adjustment required to reflect the nature of our business following the transaction increased risk resulting from becoming company that is more focused innovative science based biopharmaceutical product business and the possibility that we may not achieve our strategic objective in addition we have agreed to provide certain transition service to viatris generally for an initial period of month following the completion of the transaction with certain possibility for extension these obligation under the transition service agreement may divert our focus and resource that would otherwise be invested into maintaining or growing our business consumer healthcare jv with gskin we and gsk combined our respective consumer healthcare business into jv that operates globally under the gsk consumer healthcare name although we have certain consent board representation and other governance right we are minority owner of the jv and do not control the jv it management or it policy result our ability to realize the anticipated benefit of the transaction depend upon gsk operation and management of the jv in addition the jv is subject to risk that are different than the risk associated with our business many of these risk are outside gsk or the jv control and could materially impact the business financial condition and result of operation of the jv pfizer inc form june gsk announced that it intends to demerge at least of it ownership interest in the jv in mid subject to gsk shareholder approval following the demerger the jv is expected to be an independent listed company on the london stock exchange with american depositary receipt to be listed in the in which pfizer would initially hold ownership interest and gsk may hold up to ownership interest notwithstanding gsk announcement the demerger may not be completed within expected time period or at all and both the timing and success of the demerger or any other separation and public listing transaction will be subject to prevailing market condition and other factor at the time of such transaction any future distribution or sale of our stake in the jv will similarly be subject to prevailing market condition and other factor at the time of such transaction our ability to complete any such future distribution or sale may also be impacted by the size of our retained stake at the time the uncertainty relating to any separation and public listing transaction including the announced demerger their implementation their timing and their yet to be determined effect on the jv business may subject and the jv to risk and uncertainty that may adversely affect our business and financial result general risk covid pandemicour business operation and financial condition and result have been and may continue to be impacted by the covid pandemic to varying degree the pandemic ha presented number of risk and challenge for our business including among others impact due to travel limitation and mobility restriction manufacturing disruption and delay supply chain disruption and shortage including challenge related to reliance on third party supplier resulting in reduced availability of material or component used in the development manufacturing distribution or administration of our product disruption to pipeline development and clinical trial including difficulty or delay in enrolling certain clinical trial retaining clinical trial participant accessing needed supply and accruing sufficient number of case in certain clinical trial decreased product demand due to reduced number of in person meeting with prescribers patient visit with physician vaccination and elective surgery resulting in fewer new prescription or refill of existing prescription and reduced demand for product used in procedure reduced product demand result of unemployment or increased focus on covid vaccination challenge presented by reallocating personnel and manufacturing and other resource to assist in responding to the pandemic cost associated with the covid pandemic including practice intended to reduce the risk of transmission increased supply chain cost and additional cost incurred in our effort to develop vaccine to help prevent covid and an oral covid treatment challenge related to our business development initiative including potential delay or disruption related to regulatory approval interruption or delay in the operation of regulatory authority which may delay potential approval of new product we are developing potential label expansion for existing product and the launch of newly approved product challenge operating in virtual work environment increased cyber incident such phishing social engineering and malware attack challenge related to our intellectual property both domestically and internationally including in response to any pressure or legal or regulatory action that could potentially result in not seeking intellectual property protection for licensing or agreeing not to enforce or being restricted from enforcing intellectual property right related to our product including our vaccine to help prevent covid and an oral covid treatment challenge related to conducting oversight and monitoring of regulated activity in remote or virtual environment challenge related to our human capital and talent development including challenge in attracting hiring and retaining highly skilled and diverse workforce challenge related to vaccine mandate and other challenge presented by disruption to our normal operation in response to the pandemic well uncertainty regarding the duration and severity of the pandemic and it impact and government or regulatory action to contain the virus or control the supply of medicine and vaccine we also face risk and uncertainty related to our effort to develop and commercialize vaccine to help prevent covid and an oral covid treatment well challenge related to their manufacturing supply and distribution including among others uncertainty inherent in including the ability to meet anticipated clinical endpoint commencement and or completion date for clinical trial regulatory submission date regulatory approval date and or launch date well risk associated with pre clinical and clinical data including the phase or phase data for or any other vaccine candidate in the program or paxlovid or any other future covid treatment in any of our study in pediatrics adolescent or adult or real world evidence including the possibility of unfavorable new pre clinical clinical or safety data and further analysis of existing pre clinical clinical or safety data or further information regarding the quality of pre clinical clinical or safety data including by audit or inspection the ability to produce comparable clinical or other result for or paxlovid including the rate of effectiveness and or efficacy safety and tolerability profile observed to date in additional analysis of the phase trial for or paxlovid and additional study in real world data study or in larger more diverse population following commercialization the ability of or any future vaccine to prevent or paxlovid or any other future covid treatment to be effective against covid caused by emerging virus variant the risk that more widespread use of the vaccine or paxlovid will lead to new information about efficacy safety or other development including the risk of additional adverse reaction some of which may be serious the risk that pre clinical and clinical trial data are subject to differing interpretation and assessment including during the peer review publication process in the scientific community generally and by regulatory authority whether and when additional data from the mrna vaccine program paxlovid or other program will be published in scientific journal publication and if so when and with what modification and interpretation whether regulatory authority will be satisfied with the design of and result from these and any future pre clinical and clinical study whether and when submission to request emergency use or conditional marketing authorization for or any potential future vaccine in additional population for booster dose for or any potential future vaccine including potential future annual booster or re vaccination and or biologics license and or eua application or amendment to any such application may be filed in particular jurisdiction for or any other potential vaccine and if obtained whether or when such eua or license will expire or terminate whether and when submission to request emergency use or conditional marketing authorization for paxlovid or any other future covid treatment and or any drug application for any indication for paxlovid or any other future covid treatment may be filed in any jurisdiction and if obtained whether or when such eua or license will expire or terminate whether and when any application that may be pending or filed for or other vaccine that may result from the program paxlovid or any other future covid treatment or any other covid program may be approved by particular regulatory authority which will depend on myriad factor including making determination to whether the vaccine or drug benefit outweigh it known risk and determination of the vaccine or drug efficacy and if approved whether it will be commercially successful pfizer inc form decision by regulatory authority impacting labeling or marketing manufacturing process safety and or other matter that could affect the availability or commercial potential of vaccine or drug including development of product or therapy by other company disruption in the relationship between and our collaboration partner clinical trial site or third party supplier including our relationship with biontech the risk that other company may produce superior or competitive product the risk that demand for any product may be reduced or no longer exist the possibility that covid will diminish in severity or prevalence or disappear entirely risk related to the availability of raw material to manufacture or test any such product challenge related to our vaccine formulation dosing schedule and attendant storage distribution and administration requirement including risk related to storage and handling after delivery by the risk that we may not be able to successfully develop other vaccine formulation booster dos or potential future annual booster or re vaccination or new variant specific vaccine the risk that we may not be able to recoup cost associated with our and manufacturing effort risk associated with any change in the way we approach or provide research funding for the program paxlovid or any other covid program challenge and risk associated with the pace of our development program the risk that we may not be able to maintain or scale up manufacturing capacity on timely basis or maintain access to logistics or supply channel commensurate with global demand for our vaccine or any treatment for covid which would negatively impact our ability to supply the estimated number of dos of our vaccine or treatment course of paxlovid within the projected time period whether and when additional supply or purchase agreement will be reached uncertainty regarding the ability to obtain recommendation from vaccine or treatment advisory or technical committee and other public health authority and uncertainty regarding the commercial impact of any such recommendation pricing and access challenge for such product challenge related to public confidence or awareness of our covid vaccine or paxlovid including challenge driven by misinformation access concern about clinical data integrity and prescriber and pharmacy education trade restriction potential third party royalty or other claim related to our covid vaccine or paxlovid and competitive development further the covid pandemic and the volatile global economic condition stemming from the pandemic could precipitate or amplify the other risk that we identify in this risk factor section which could adversely affect our business operation and financial condition and result we are continuing to monitor the latest development regarding the covid pandemic and it effect on our business operation and financial condition and result and have made certain assumption regarding the covid pandemic for purpose of our operational planning and financial projection including assumption regarding the duration severity and the global macroeconomic impact of the pandemic well covid vaccine and oral covid treatment supply and contract which remain dynamic despite careful tracking and planning we are unable to accurately predict the extent of the impact of the pandemic on our business operation and financial condition and result due to the uncertainty of future development in particular we believe the ultimate impact on our business operation and financial condition and result will be affected by the speed and extent of the continued spread of the coronavirus globally the emergence of additional virus variant the duration of the pandemic new information regarding the severity and incidence of covid the safety efficacy and availability of vaccine and treatment for covid the rate at which the population becomes vaccinated against covid the global macroeconomic impact of the pandemic and governmental or regulatory action to contain the virus or control supply of medicine and vaccine the pandemic may also affect our business operation or financial condition and result in manner that is not presently known to or that we currently do not consider presenting significant risk market fluctuation in our equity and other investmentschanges in fair value of certain equity investment need to be recognized in net income that may result in increased volatility of our income for additional information see note and the analysis of financial condition liquidity capital resource and market risk section within md our pension benefit obligation and postretirement benefit obligation are subject to volatility from change in fair value of equity investment and other investment risk in the asset funding these plan for additional information see the significant accounting policy and application of critical accounting estimate and assumption benefit plan section within md and note cost and expense control and nonordinary eventsgrowth in cost and expense change in product and geographic mix and the impact of acquisition divestiture restructurings internal reorganization product withdrawal recall and other unusual event that could result from evolving business strategy evaluation of asset realization and organizational restructuring could adversely affect future result such risk and uncertainty include in particular our ability to realize the projected benefit of our cost reduction and productivity initiative other corporate strategic initiative and any acquisition divestiture or other initiative well potential disruption of ongoing business intangible asset goodwill and equity method investmentsour consolidated balance sheet contains significant amount of intangible asset including ipr and goodwill for ipr asset the risk of failure is significant and there can be no certainty that these asset ultimately will yield successful product our ability to realize value on these significant investment is often contingent upon among other thing regulatory approval and market acceptance such we expect that many of these ipr asset will become impaired and or be written off at some time in the future if the associated effort is abandoned or is curtailed for goodwill all reporting unit can confront event and circumstance that can lead to goodwill impairment charge such among other thing unanticipated competition an adverse action or assessment by regulator significant adverse change in legal matter or in the pfizer inc form climate and or failure to replace the contribution of product that lose exclusivity our other intangible asset including developed technology right and brand face similar risk for impairment our equity method investment may also be subject to impairment charge that may result from the occurrence of unexpected adverse event or management decision that impact our estimate of expected cash flow to be generated from these investment we may recognize impairment charge result of weak economic environment event related to particular customer or asset type challenging market condition or decision by management any such impairment charge of our intangible asset goodwill and equity method investment may be significant for additional detail see the significant accounting policy and application of critical accounting estimate and assumption section within md change in law and accounting standardsour future result could be adversely affected by change in law and regulation or their interpretation including among others change in accounting standard tax law and regulation internationally and in the including among other thing any potential adoption of global minimum taxation requirement and any potential change to existing tax law and regulation by the biden administration and congress competition law privacy law and environmental law in the and other country for additional information on change in tax law or rate or accounting standard see the provision benefit for tax on income and new accounting standard section within md and note item propertieswe own and lease space globally for sale and marketing customer service regulatory compliance manufacturing and distribution and corporate enabling function in many location our business and operation are co located to achieve synergy and operational efficiency our global headquarters are located in new york city we continue to advance our global workplace strategy to provide workplace that enable collaboration and foster innovation of december we had owned and leased property amounting to approximately million square foot we expect to relocate our global headquarters to the spiral an office building in the hudson yard neighborhood of new york city with occupancy expected beginning in the second half of in april we entered into an agreement to lease space at this property in july we completed the sale of our current headquarters in new york city we remain in lease back arrangement with the buyer while we complete our relocation our pgs platform function is headquartered in various location with leadership team primarily in new york city and in peapack new jersey of december pgs had responsibility for plant around the world including in belgium germany india ireland italy japan singapore and the which manufacture product for our business pgs expects to exit three of these site over the next several year pgs also operates multiple distribution facility around the world in general we believe that our property including the principal property described above are well maintained adequate and suitable for their current requirement and for our operation in the foreseeable future see note for amount invested in land building and equipment item legal proceedingscertain legal proceeding in which we are involved are discussed in note information about our executive officersthe executive officer of the company are set forth in this table each hold the office or office indicated until or successor is chosen and qualified at the regular meeting of the bod to be held on the date of the annual meeting of shareholder or until his or her earlier death resignation or removal each of the executive officer is member of the pfizer executive leadership team nameagepositionalbert of the board since january and chief executive officer since january chief operating officer from january until december group president pfizer innovative health from june until december group president global innovative pharma business responsible for vaccine oncology and consumer healthcare since from february until june president and general manager of established product business unit from december until december our director since february william vice president global business service and transformation since june senior vice president of global business operation from june until june senior vice president of global tax from until june frank financial officer executive vice president since january chief financial officer and executive vice president global supply from june until december chief financial officer executive vice president business operation and global supply from november until june executive vice president business operation and chief financial officer from december until october senior vice president and chief financial officer from september until december director of zoetis inc and humana inc and chair of the humana inc board of director audit committee mikael scientific officer president worldwide research development and medical since january president of worldwide research and development from december until december senior vice president president of worldwide research and development from may until december senior vice president president of pfizer biotherapeutics research development group from october until may director of agilent technology inc and vimian group ab pfizer inc form digital and technology officer executive vice president since january chief information officer and senior vice president of quest diagnostics incorporated from to senior vice president of laboratory corporation of america holding from until march director of tegna inc angela president pfizer biopharmaceuticals group since january group president pfizer essential health from january until december global president pfizer inflammation and immunology from january until december regional head vaccine from january until december vice president emerging market for the primary care therapeutic area from september until december director of united parcel service inc rady compliance quality and risk officer executive vice president since january executive vice president chief compliance and risk officer from december until december senior vice president and associate general counsel from october until december douglas counsel executive vice president since december corporate secretary from january until february executive vice president chief compliance and risk officer from february until december executive vice president chief compliance officer from december until february aamir business innovation officer executive vice president since august various geographic leadership role with mckinsey company from to previously co led mckinsey company global pharmaceutical medical product practice from to michael global supply officer executive vice president since january president of pfizer global supply from until vice president of pfizer global supply from until vice president of the biotechnology unit from until payal people experience officer executive vice president since january chief human resource officer executive vice president from june to december from may until june served senior vice president of human resource for multiple operating unit vice president of human resource vaccine oncology consumer from until sahni ha served in number of position in the human resource organization with increasing responsibility since joining pfizer in sally corporate affair officer executive vice president since january executive vice president corporate affair formerly policy external affair and communication from december until december senior vice president policy external affair and communication from december until december director of wpp plc part iiitem market for the company common equity related stockholder matter and issuer purchase of equity security the principal market for our common stock is the nyse our common stock currently trade on the nyse under the symbol pfe of february there were holder of record of our common stock the following summarizes purchase of our common stock during the fourth quarter of periodtotal numberof sharespurchased average pricepaid per share total number ofshares purchased aspart of publicly announced planapproximate value of sharesthat may yet be purchased under the plan october through october november through november december through december see note represents share of common stock surrendered to the company to satisfy tax withholding obligation in connection with the vesting of award under our long term incentive program and ii the open market purchase by the trustee of share of common stock in connection with the reinvestment of dividend paid on common stock held in trust for employee who deferred receipt of performance share award pfizer inc form group performance graphthe following graph assumes investment on december and reinvestment of all dividend in each of the company common stock the index and composite peer group of the major and european based pharmaceutical company which are abbvie inc amgen inc astrazeneca plc bristol myers squibb company eli lilly and company glaxosmithkline plc johnson johnson merck co inc novartis ag roche holding ag and sanofi sa five year performance group item reserved pfizer inc form management discussion and analysis of financial condition and result of operationsoverview of our performance operating environment strategy and outlookfinancial highlightsthe following is summary of certain financial performance metric in billion except per share data total revenue net cash flow from operation billionan increase of compared to increase of compared to reported diluted eps adjusted diluted eps non gaap an increase of compared to increase of compared to for additional information regarding adjusted diluted eps which is non gaap financial measure including reconciliation of certain gaap reported to non gaap adjusted information see the non gaap financial measure adjusted income section within md reference to operational variance pertain to period over period change that exclude the impact of foreign exchange rate although foreign exchange rate change are part of our business they are not within our control and since they can mask positive or negative trend in the business we believe presenting operational variance excluding these foreign exchange change provides useful information to evaluate our result our business and strategymost of our revenue come from the manufacture and sale of biopharmaceutical product with the formation of the consumer healthcare jv in and the spin off of our former upjohn business in the fourth quarter of pfizer transformed into more focused global leader in science based innovative medicine and vaccine and beginning in the fourth quarter of operated single operating segment engaged in the discovery development manufacturing marketing sale and distribution of biopharmaceutical product worldwide at the beginning of our fiscal fourth quarter of we reorganized our commercial operation and began to manage our commercial operation through new global structure consisting of two operating segment biopharma and biopharma is the only reportable segment on december we completed the sale of our meridian subsidiary and beginning in the fourth quarter of the financial result of meridian are reflected discontinued operation for all period presented beginning in the fourth quarter of the financial result of the upjohn business and the mylan japan collaboration were reflected discontinued operation for all period presented prior period information ha been restated to reflect our current organizational structure see note and item business commercial operation of this form for additional information we expect to incur cost of approximately million in connection with separating upjohn of which approximately ha been incurred since inception and through december these charge include cost and expense related to separation of legal entity and transaction cost transforming to more focused company we have undertaken effort to ensure our cost base and support model align appropriately with our new operating structure while certain direct cost transferred to the consumer healthcare jv and to the upjohn business in connection with the spin off there are indirect cost which not transfer we are taking step to restructure our corporate enabling function to appropriately support our business and pgs platform function in addition we are transforming our commercial go to market model in the way we engage patient and physician see the cost and expense restructuring charge and other cost associated with acquisition and cost reduction productivity initiative section of this md we believe we have strong pipeline and are well positioned for future growth is at the heart of fulfilling our purpose to deliver breakthrough that change patient life we work to translate advanced science and technology into the therapy that may be the most impactful for patient innovation drug discovery and development are critical to our success in addition to discovering and developing new pfizer inc form our effort seek to add value to our existing product by improving their effectiveness and ease of dosing and by discovering potential new indication see the item business research and development section of this form for our priority and strategy we seek to leverage strong pipeline organize around expected operational growth driver and capitalize on trend creating long term growth opportunity including an aging global population that is generating increased demand for innovative medicine and vaccine that address patient unmet need advance in both biological science and digital technology that are enhancing the delivery of breakthrough new medicine and vaccine and the increasingly significant role of hospital in healthcare system our business development initiativeswe are committed to strategically capitalizing on growth opportunity primarily by advancing our own product pipeline and maximizing the value of our existing product but also through various business development activity we view our business development activity an enabler of our strategy and seek to generate growth by pursuing opportunity and transaction that have the potential to strengthen our business and our capability we ass our business asset and scientific capability portfolio part of our regular ongoing portfolio review process and also continue to consider business development activity that will help advance our business strategy our significant recent business development activity that closed or are targeted to close in include acquisition of arenain december we and arena announced that the company entered into definitive agreement under which we will acquire arena clinical stage company developing innovative potential therapy for the treatment of several immuno inflammatory disease under the term of the agreement we will acquire all outstanding share of arena for per share in an all cash transaction for total equity value of approximately billion on february arena shareholder voted to approve the proposed acquisition which is targeted to close in the first half of subject to review under antitrust law and other customary closing condition collaboration with biohavenin november we entered into collaboration and license agreement and related sublicense agreement with biohaven pharmaceutical holding company ltd biohaven pharmaceutical ireland dac and bioshin limited collectively biohaven pursuant to which we acquired right to commercialize rimegepant and zavegepant for the treatment and prevention of migraine outside of the subject to regulatory approval rimegepant is currently commercialized in the israel and the under the brand name nurtec odt with certain additional application pending outside of the biohaven will continue to lead globally and we have the exclusive right to commercialization globally outside of the upon the closing of the transaction which occurred on january we paid biohaven million including an upfront payment of million and an equity investment of million biohaven is also eligible to receive up to million in non commercialization milestone payment in addition to tiered double digit royalty on net sale outside of the in addition to the milestone payment and royalty above we will also reimburse biohaven for the portion of certain additional milestone payment and royalty due to third party in accordance with preexisting biohaven agreement which are attributed to ex sale for additional information including discussion of recent significant business development activity see note our performancerevenuesrevenues increased billion or to billion in from billion in reflecting an operational increase of billion or well favorable impact of foreign exchange of billion or excluding direct sale and alliance revenue of comirnaty and sale of paxlovid revenue increased operationally reflecting strong growth in eliquis biosimilars vyndaqel vyndamax the hospital therapeutic area inlyta and xtandi partially offset by decline in the prevnar family chantix champix enbrel and sutent the following outline the component of the net change in revenue see the analysis of the consolidated statement of income revenue by geography and revenue selected product discussion section within md for more information including discussion of key driver of our revenue performance for information regarding the primary indication or class of certain product see note pfizer inc form from continuing operation before provision benefit for tax on incomethe increase in income from continuing operation before provision benefit for tax on income of billion in compared to wa primarily attributable to higher revenue ii net periodic benefit credit in versus net periodic benefit cost in iii lower asset impairment charge and iv higher net gain on equity security partially offset by increase in cost of sale research and development expense and selling informational and administrative expense see the analysis of the consolidated statement of income within md and note for additional information for information on our tax provision and effective tax rate see the provision benefit for tax on income section within md and note our operating environmentwe like other business in our industry are subject to certain industry specific challenge these include among others the topic listed below see also the item business government regulation and price constraint and item risk factor section of this form regulatory environment pipeline productivityour product line must be replenished to offset revenue loss when product lose exclusivity or market share or to respond to healthcare and innovation trend well to provide for earnings growth result we devote considerable resource to our activity which while essential to our growth incorporate high degree of risk and cost including whether particular product candidate or new indication for an in line product will achieve the desired clinical endpoint or safety profile will be approved by regulator or will be successful commercially we conduct clinical trial to provide data on safety and efficacy to support the evaluation of product overall benefit risk profile for particular patient population in addition after product ha been approved or authorized and launched we continue to monitor it safety long it is available to patient this includes postmarketing trial that may be conducted voluntarily or pursuant to regulatory request to gain additional medical knowledge for the entire life of the product we collect safety data and report safety information to the fda and other regulatory authority regulatory authority may evaluate potential safety concern and take regulatory action in response such updating product labeling restricting it use communicating new safety information to the public or in rare case requiring to suspend or remove product from the market the commercial potential of in line product may be negatively impacted by post marketing development intellectual property right and collaboration licensing rightsthe loss expiration or invalidation of intellectual property right patent litigation settlement with manufacturer and the expiration of co promotion and licensing right can have material adverse effect on our revenue certain of our product have experienced patent based expiration or loss of regulatory exclusivity in certain market in the last few year and we expect certain product to face increased generic competition over the next few year while additional patent expiry will continue we expect moderate impact of reduced revenue due to patent expiry from through we continue to vigorously defend our patent right against infringement and we will continue to support effort that strengthen worldwide recognition of patent right while taking necessary step to help ensure appropriate patient access for additional information on patent right we consider most significant to our business whole see the item business patent and other intellectual property right section in this form for discussion of recent development with respect to patent litigation see note regulatory environment pricing and access government and other payer group pressuresthe pricing of medicine by pharmaceutical manufacturer and the cost of healthcare which includes medicine medical service and hospital service continues to be important to payer government patient and other stakeholder federal and state government and private third party payer in the continue to take action to manage the utilization of drug and cost of drug including increasingly employing formulary to control cost by taking into account discount in connection with decision about formulary inclusion or favorable formulary placement we consider number of factor impacting the pricing of our medicine and vaccine within the we often engage with patient doctor and healthcare plan we also often provide significant discount from the list price to insurer including pbms and mcos the price that patient pay in the for prescribed medicine and vaccine is ultimately set by healthcare provider and insurer government globally may use variety of measure to control cost including proposing pricing reform or legislation cross country collaboration and procurement price cut mandatory rebate health technology assessment forced localization condition of market access international reference pricing the practice of country linking it regulated medicine price to those of other country qce process and vbp in the we expect to see continued focus by congress and the biden administration on regulating pricing which could result in legislative and regulatory change designed to control cost for example there is proposed legislation that if enacted would allow medicare to negotiate price for certain prescription drug well require that penalty be paid by manufacturer who raise drug price faster than inflation also certain change proposed by the cm in december to the medicaid program and drug pricing program which imposes ceiling on price that drug manufacturer can charge for medication sold to certain health care facility could increase our medicaid rebate obligation and increase the discount we extend to covered entity if they go into effect additional change to the program are undergoing review and their status is unclear we anticipate that these and similar initiative will continue to increase pricing pressure globally for additional information see the item business pricing pressure and managed care organization and government regulation and price constraint section in this form product supplywe periodically encounter supply delay disruption or shortage including due to voluntary product recall such our recent chantix recall for information on our recent chantix recall and risk related to product manufacturing see the item risk factor product manufacturing sale and marketing risk section in this form the global economic environmentin addition to the industry specific factor discussed above we like other business of our size and global extent of activity are exposed to economic cycle certain factor in the global economic environment that may impact our global operation include among other thing currency fluctuation capital and exchange control global economic condition including inflation restrictive government action change in intellectual property legal protection and remedy trade regulation tax law and regulation and procedure and action affecting approval pfizer inc form pricing and marketing of reimbursement for and access to our product well impact of political or civil unrest or military action including the current conflict between russia and ukraine terrorist activity unstable government and legal system inter governmental dispute public health outbreak epidemic pandemic natural disaster or disruption related to climate change government pressure can lead to negative pricing pressure in various market where government take an active role in setting price access criterion or other mean of cost control covid pandemicthe covid pandemic ha impacted our business operation and financial condition and result our response to covid ha helped lead the global effort to confront the covid pandemic by advancing vision for industry wide collaboration while making significant investment in breakthrough science and global manufacturing comirnaty we have collaborated with biontech to jointly develop comirnaty mrna based coronavirus vaccine to help prevent covid the fda ha approved comirnaty in the to prevent covid in individual year of age and older two dose primary series g per dose comirnaty is the first covid vaccine to be granted approval by the fda and had previously been available to this patient population in the under an eua since december the vaccine is also available to individual to year old under an eua granted by the fda in g per dose for child through year of age october and g per dose for individual year of age and older may the fda ha also authorized for emergency use third dose of comirnaty in certain immunocompromised individual year of age and older and ii comirnaty booster dose in individual year of age and older comirnaty ha also been granted an approval or an authorization in many other country around the world in population varying by country we continue to evaluate our vaccine including for additional pediatric indication and the short and long term efficacy of comirnaty we are also studying vaccine candidate to potentially prevent covid caused by new and emerging variant such the omicron variant or an updated vaccine needed in we manufactured more than three billion dos and in fiscal delivered billion dos around the world pfizer and biontech expect we can manufacture up to four billion dos in total by the end of the company have entered into agreement to supply pre specified dos of comirnaty in with multiple developed and emerging country around the world and are continuing to deliver dos of comirnaty to government under such agreement we also signed agreement with multiple country to supply comirnaty dos in and are currently negotiating similar potential agreement with multiple other country we anticipate delivering at least two billion dos to low and middle income country by the end of one billion that wa delivered in and one billion expected to be delivered in with the possibility to increase those delivery if more order are placed by these country for one billion of the aforementioned dos to low and middle income country are being supplied to the government at not for profit price to be donated to the world poorest nation at no charge to those country of february we forecasted approximately billion in revenue for comirnaty in with gross profit to be split evenly with biontech which includes dos expected to be delivered in fiscal under contract signed of late january paxlovid in december the fda authorized the emergency use of paxlovid novel oral covid treatment which is sars protease inhibitor and is co administered with low dose of ritonavir for the treatment of mild to moderate covid in adult and pediatric patient year of age and older weighing at least kg lb with positive result of direct sars cov viral testing and who are at high risk for progression to severe covid including hospitalization or death the fda based it decision on clinical data from the phase epic hr evaluation of protease inhibition for covid in high risk patient which enrolled non hospitalized adult aged and older with confirmed covid who are at increased risk of progressing to severe illness paxlovid ha been granted an authorization or approval in many other country we continue to evaluate paxlovid in other population including in patient with confirmed diagnosis of sars cov infection who are at standard risk low risk of hospitalization or death phase epic sr evaluation of protease inhibition for covid in standard risk patient and in adult living in the same household someone with confirmed covid infection phase epic pep evaluation of protease inhibition for covid in post exposure prophylaxis we have entered into agreement with multiple country to supply pre specified course of paxlovid such the and and have initiated bilateral outreach to approximately country around the world additionally we have signed voluntary non exclusive license agreement with the medicine patent pool mpp for paxlovid under the term of the agreement mpp can grant sublicenses to qualified generic medicine manufacturer worldwide to manufacture and supply paxlovid to low and middle income country covering up to approximately of the world population pfizer plan to manufacture up to million treatment course by the end of depending on the global need which will be driven by advance purchase agreement with million course expected to be produced in the first half of and the remaining million course expected to be produced in the second half of of february we forecasted approximately billion of revenue for paxlovid in which includes treatment course expected to be delivered in fiscal primarily relating to supply contract signed or committed of late january iv protease inhibitor in february we discontinued the global clinical development program for pf an intravenously administered sars cov main protease inhibitor being evaluated in adult hospitalized with severe covid this decision wa made based on totality of information including careful review of early data and thorough assessment of the candidate potential to successfully fulfill patient need dosing of pf in the national institute of health ongoing accelerating covid therapeutic intervention and vaccine activ study ha ceased impact of covid on our business and operationsas part of our on going monitoring and assessment we have made certain assumption regarding the pandemic for purpose of our operational planning and financial projection including assumption regarding the duration severity and the global macroeconomic impact of the pandemic pfizer inc form well covid vaccine and oral covid treatment supply and contract which remain dynamic despite careful tracking and planning we are unable to accurately predict the extent of the impact of the pandemic on our business operation and financial condition and result due to the uncertainty of future development we are focused on all aspect of our business and are implementing measure aimed at mitigating issue where possible including by using digital technology to assist in operation for our commercial manufacturing and corporate enabling function globally apart from our introduction of comirnaty and paxlovid our business and operation have been impacted by the pandemic in various way our portfolio of product experienced varying impact from the pandemic in for example certain of our vaccine such the prevnar family were impacted by disruption to healthcare activity related to covid including the prioritization of primary and booster vaccination campaign for covid for some product such vyndaqel vyndamax we continued to see postponement of elective and diagnostic procedure in due to covid which may subside in covid vaccination and booster rate continue to increase and or if covid case subside on the other hand some product such ibrance saw accelerating demand in the delay in diagnosis and treatment initiation caused by the covid pandemic show sign of recovery across several international market for detail on the impact of the covid pandemic on certain of our product see the analysis of the consolidated statement of income revenue by geography and revenue selected product discussion section within this md in engagement with healthcare professional started to return to pre pandemic level and we continue to review and ass epidemiological data to inform in person engagement with healthcare professional and to help ensure the safety of our colleague customer and community part of our commitment to engaging our customer in the manner they prefer we are also taking hybrid approach of virtual and in person engagement and saw customer response to both approach during the pandemic we adapted our promotional platform by amplifying our digital capability to reach healthcare professional and customer to provide critical education and information including increasing the scale of our remote engagement most of our colleague who are able to perform their job function outside of our facility continue to temporarily work remotely while certain colleague in the pgs and wrdm organization continue to work onsite and are subject to strict protocol intended to reduce the risk of transmission of december more than of our employee population had been fully vaccinated or received an approved exception also in and to date we have not seen significant disruption to our supply chain and all of our manufacturing site globally have continued to operate at or near normal level however we are seeing an increase in overall demand in the industry for certain component and raw material potentially constraining available supply which could have future impact on our business we are continuing to monitor and implement mitigation strategy in an effort to reduce any potential risk or impact including active supplier management qualification of additional supplier and advanced purchasing to the extent possible certain of our clinical trial were impacted by the covid pandemic in which included in some case challenge related to recruiting clinical trial participant and accruing case in certain study our clinical trial also progressed in this challenging environment through innovation such decentralized visit telemedicine and home visit to accommodate participant ability to maintain scheduled visit well working with supplier to manage the shortage of certain clinical supply we will continue to pursue effort to maintain the continuity of our operation while monitoring for new development related to the pandemic future development could result in additional favorable or unfavorable impact on our business operation or financial condition and result if we experience significant disruption in our manufacturing or supply chain or significant disruption in clinical trial or other operation or if demand for our product is significantly reduced result of the covid pandemic we could experience material adverse impact on our business operation and financial condition and result for additional information please see the item risk factor covid pandemic section of this form significant accounting policy and application of critical accounting estimate and assumptionsfollowing is discussion about the critical accounting estimate and assumption impacting our consolidated financial statement also see note for description of our significant accounting policy see note of these policy the following are considered critical to an understanding of our consolidated financial statement they require the application of the most subjective and the most complex judgment acquisition note fair value note revenue note asset impairment note tax asset and liability and income tax contingency note pension and postretirement benefit plan note and legal and environmental contingency note for discussion of recently adopted accounting standard and change in accounting principle related to our pension and postretirement plan see note and acquisitionswe account for acquired business using the acquisition method of accounting which requires among other thing that most asset acquired and liability assumed be recognized at their estimated fair value of the acquisition date for further detail on acquisition accounting see note historically intangible asset have been the most significant fair value within our business combination for further information on our process to estimate the fair value of intangible asset see asset impairment below revenuesour gross product revenue are subject to variety of deduction which generally are estimated and recorded in the same period that the revenue are recognized such variable consideration represents chargebacks rebate sale allowance and sale return these deduction represent estimate of the related obligation and such knowledge and judgment are required when estimating the impact of these revenue deduction on gross sale for reporting period historically adjustment to these estimate to reflect actual result or updated expectation have not been material to our overall business and generally have been le than of revenue product specific rebate however can have significant impact on year over year individual product revenue growth trend if any of our ratio factor assessment experience or judgment are not indicative or accurate estimate of our future experience our result could be materially affected the potential of our estimate to vary sensitivity differs by program product type of customer and geographic location however estimate associated with medicare medicaid and performance based contract rebate are most at risk for material adjustment because of the extensive time delay pfizer inc form the recording of the accrual and it ultimate settlement an interval that can generally range up to one year because of this lag our recording of adjustment to reflect actual amount can incorporate revision of several prior quarter rebate accrual are product specific and therefore for any period are impacted by the mix of product sold well the forecasted channel mix for each individual product for further information see the analysis of the consolidated statement of income revenue deduction section within md and note asset impairmentswe review all of our long lived asset for impairment indicator throughout the year we perform impairment testing for indefinite lived intangible asset and goodwill at least annually and for all other long lived asset whenever impairment indicator are present when necessary we record charge for impairment of long lived asset for the amount by which the fair value is le than the carrying value of these asset our impairment review process are described in note example of event or circumstance that may be indicative of impairment include significant adverse change in legal factor or in the business climate that could affect the value of the asset for example successful challenge of our patent right would likely result in generic competition earlier than expected significant adverse change in the extent or manner in which an asset is used such restriction imposed by the fda or other regulatory authority that could affect our ability to manufacture or sell product an expectation of loss or reduced profit associated with an asset this could result for example from change in government reimbursement program that result in an inability to sustain projected product revenue and profitability this also could result from the introduction of competitor product that impact projected revenue growth well the lack of acceptance of product by patient physician and payer for ipr project this could result from among other thing change in outlook based on clinical trial data delay in the projected launch date or additional expenditure to commercialize the product identifiable intangible assetswe use an income approach specifically the discounted cash flow method to determine the fair value of intangible asset other than goodwill we start with forecast of all the expected net cash flow associated with the asset which incorporates the consideration of terminal value for indefinite lived asset and we apply an asset specific discount rate to arrive at net present value amount some of the more significant estimate and assumption that impact our fair value estimate include the amount and timing of the projected net cash flow which includes the expected impact of competitive legal and or regulatory force on the projection and the impact of technological advancement and risk associated with ipr asset well the selection of long term growth rate the discount rate which seek to reflect the various risk inherent in the projected cash flow and the tax rate which seek to incorporate the geographic origin of the projected cash flow while all intangible asset other than goodwill can face event and circumstance that can lead to impairment those that are most at risk of impairment include ipr asset approximately billion of december and newly acquired or recently impaired indefinite lived brand asset ipr asset are high risk asset given the uncertain nature of newly acquired and recently impaired indefinite lived asset are more vulnerable to impairment the asset are recorded at fair value and are then subsequently measured at the lower of fair value or carrying value at the end of each reporting period such immediately after acquisition or impairment even small decline in the outlook for these asset can negatively impact our ability to recover the carrying value and can result in an impairment charge goodwillour goodwill impairment review work of december concluded that none of our goodwill wa impaired and we do not believe the risk of impairment is significant at this time in our review we first ass qualitative factor to determine whether it is more likely than not that the fair value of reporting unit is le than it carrying amount qualitative factor that we consider include for example macroeconomic and industry condition overall financial performance and other relevant entity specific event if we conclude that it is more likely than not that the fair value of reporting unit is le than it carrying value we then perform quantitative fair value test when we are required to determine the fair value of reporting unit we typically use the income approach the income approach is forward looking approach to estimating fair value and relies primarily on internal forecast within the income approach we use the discounted cash flow method we start with forecast of all the expected net cash flow for the reporting unit which includes the application of terminal value and then we apply reporting unit specific discount rate to arrive at net present value amount some of the more significant estimate and assumption inherent in this approach include the amount and timing of the projected net cash flow which includes the expected impact of technological risk and competitive legal and or regulatory force on the projection well the selection of long term growth rate the discount rate which seek to reflect the various risk inherent in the projected cash flow and the tax rate which seek to incorporate the geographic diversity of the projected cash flow for all of our reporting unit there are number of future event and factor that may impact future result and that could potentially have an impact on the outcome of subsequent goodwill impairment testing for list of these factor see the forward looking information and factor that may affect future result and the item risk factor section in this form benefit plansfor description of our different benefit plan see note our assumption reflect our historical experience and our judgment regarding future expectation that have been deemed reasonable by management the judgment made in determining the cost of our benefit plan can materially impact our result of operation pfizer inc form following provides at the end of each year the expected annual rate of return on plan asset for the following year ii the actual annual rate of return on plan asset achieved in each year and iii the weighted average discount rate used to measure the benefit obligation at the end of each year for our pension plan and our international pension plan pension plansexpected annual rate of return on plan actual annual rate of return on plan discount rate used to measure the plan international pension plansexpected annual rate of return on plan actual annual rate of return on plan discount rate used to measure the plan for detailed assumption associated with our benefit plan see note expected annual rate of return on plan assetsthe assumption for the expected annual rate of return on all of our plan asset reflect our actual historical return experience and our long term assessment of forward looking return expectation by asset class which is used to develop weighted average expected return based on the implementation of our targeted asset allocation in our respective plan the expected annual rate of return on plan asset for our plan and the majority of our international plan is applied to the fair value of plan asset at each year end and the resulting amount is reflected in our net periodic benefit cost in the following year the following illustrates the sensitivity of net periodic benefit cost to basis point decline in our assumption for the expected annual rate of return on plan asset holding all other assumption constant in million pre tax assumptionchangeincrease in net periodicbenefit costsexpected annual rate of return on plan basis point decline actual return on plan asset wa approximately billion during discount rate used to measure plan obligationsthe weighted average discount rate used to measure the plan obligation for our defined benefit plan is determined at least annually and evaluated and modified required to reflect the prevailing market rate of portfolio of high quality fixed income investment rated aa aa or better that reflect the rate at which the pension benefit could be effectively settled the discount rate used to measure the plan obligation for our international plan is determined at least annually by reference to investment grade corporate bond rated aa aa or better including when there is sufficient data yield curve approach these discount rate determination are made in consideration of local requirement the measurement of the plan obligation at the end of the year will affect the amount of service cost interest cost and amortization expense reflected in our net periodic benefit cost in the following year the following illustrates the sensitivity of net periodic benefit cost and benefit obligation to basis point decline in our assumption for the discount rate holding all other assumption constant in million pre tax assumptionchangedecrease in net periodic benefit costsincrease to benefit obligationsdiscount basis point decline change in the discount rate used in measuring our plan obligation of december resulted in decrease in the measurement of our aggregate plan obligation by approximately million income tax asset and liabilitiesincome tax asset and liability include income tax valuation allowance and accrual for uncertain tax position for additional information see note and well the analysis of financial condition liquidity capital resource and market risk section within md contingencieswe and certain of our subsidiary are subject to numerous contingency arising in the ordinary course of business including tax legal contingency and guarantee and indemnification for additional information see note and pfizer inc form of the consolidated statement of incomerevenues by geographythe following present worldwide revenue by geography year ended december change worldwideu internationalworldwideu international million segment biopharma pfizer consumer healthcare total revenue following provides an analysis of the change in worldwide revenue by geographic area in million worldwideu internationaloperational growth decline growth from comirnaty eliquis biosimilars vyndaqel vyndamax the hospital therapeutic area inlyta and xtandi partially offset by decline from the prevnar family while xeljanz and ibrance were flat see the analysis of the consolidated statement of income revenue selected product discussion within md for additional analysis growth from primarily reflecting manufacturing of legacy upjohn product for viatris under manufacturing and supply agreement and certain comirnaty related manufacturing activity performed on behalf of biontech see the analysis of the consolidated statement of income revenue selected product discussion within md for additional lower revenue for chantix champix enbrel and sutent the decrease for chantix champix wa driven by the voluntary recall across multiple market in the second half of and the ongoing global pause in shipment of chantix due to the presence of nitroso varenicline above an acceptable level of intake set by various global regulator the ultimate timing for resolution of which may vary by country and the negative impact of the covid pandemic resulting in decline in patient visit to doctor for preventive health purpose the decrease for enbrel internationally primarily reflects continued biosimilar competition which is expected to continue the decrease for sutent primarily reflects lower volume demand in the resulting from it loss of exclusivity in august well continued erosion result of increased competition in certain international developed market other operational factor net operational growth favorable impact of foreign revenue increase decrease emerging market revenue increased billion or in to billion from billion in reflecting an operational increase of billion or and favorable impact from foreign exchange of approximately the operational increase in emerging market wa primarily driven by revenue from comirnaty and growth from certain product in the hospital therapeutic area eliquis and partially offset by decline from the prevnar family pfizer inc form following provides an analysis of the change in worldwide revenue by geographic area in million worldwideu internationaloperational growth decline growth from vyndaqel vyndamax eliquis biosimilars ibrance inlyta xeljanz xtandi the hospital therapeutic area and the prevnar family growth from in international market driven by growth of certain key account well new contract manufacturing impact of completion of the consumer healthcare jv transaction revenue in reflect seven month of consumer healthcare business domestic operation and eight month of international operation and none in lower revenue for enbrel internationally primarily reflecting continued biosimilar competition in most developed europe market well in japan and brazil all of which is expected to continue decline from chantix champix reflecting the negative impact of the covid pandemic resulting in decline in patient visit to doctor for preventive health purpose well the loss of patent protection in the in november other operational factor net operational growth decline unfavorable impact of foreign exchange revenue increase decrease revenue for included an estimated unfavorable impact of approximately million or due to covid primarily reflecting lower demand for certain product in china and unfavorable disruption to wellness visit for patient in the which negatively impacted prescribing pattern for certain product partially offset by increased demand for certain sterile injectable product and increased adult uptake for the prevnar family in certain international market resulting from greater vaccine awareness for respiratory illness and revenue for comirnaty emerging market revenue decreased million or in to billion from billion in and were relatively flat operationally reflecting an unfavorable impact of foreign exchange of on emerging market revenue the relatively flat operational performance wa primarily driven by growth from eliquis the prevnar family ibrance and zavicefta offset by lower revenue for consumer healthcare reflecting the july completion of the consumer healthcare jv transaction revenue deductionsour gross product revenue are subject to variety of deduction which generally are estimated and recorded in the same period that the revenue are recognized these deduction represent estimate of related obligation and such knowledge and judgment are required when estimating the impact of these revenue deduction on gross sale for reporting period historically adjustment to these estimate to reflect actual result or updated expectation have not been material to our overall business and generally have been le than of revenue product specific rebate however can have significant impact on year over year individual product revenue growth trend the following present information about revenue deduction year ended december million rebate medicaid and related state program performance based contract sale sale return and cash total revenue deduction are primarily function of product sale volume mix of product sold contractual or legislative discount and rebate for information on our accrual for revenue deduction including the balance sheet classification of these accrual see note pfizer inc form selected product discussionbiopharmarevenue million year ended dec operational result commentarycomirnaty driven by global uptake following growing number of regulatory approval and temporary authorization int worldwide eliquis operationally global growth driven primarily by continued increased adoption in non valvular atrial fibrillation and oral anti coagulant market share gain well favorable adjustment related to the medicare coverage gap provision resulting from lower than previously expected discount in prior period int worldwide ibrance operationally flat performance driven primarily by accelerating demand internationally the delay in diagnosis and treatment initiation caused by the covid pandemic show sign of recovery across several international market offset by decline in the primarily driven by an increase in the proportion of patient accessing ibrance through our patient assistance program int worldwide prevnar family operationally decline primarily resulting from the normalization of demand in germany and certain other developed market following significantly increased adult demand in resulting from greater vaccine awareness for respiratory illness due to the covid pandemic the adult indication due to disruption to healthcare activity related to covid including the prioritization of primary and booster vaccination campaign for covid in the the continued impact of the lower remaining unvaccinated eligible adult population in the and the june change to the acip recommendation for the prevnar adult indication to shared clinical decision making and decline in the pediatric indication internationally due to disruption to healthcare activity related to covid this decline wa partially offset by growth in the pediatric indication driven by government purchasing pattern which wa partially offset by disruption to healthcare activity related to covid int worldwide xeljanz operationally flat performance decline in the wa offset by operational growth internationally the decline in the wa primarily driven by the negative impact of data from long term safety study which resulted in jak class labeling issued by the fda in december an unfavorable change in channel mix toward lower priced channel despite increase in underlying demand driven by growth in our uc and psa indication and continued investment to improve formulary positioning and unlock access to additional patient life the decline in the wa offset by operational growth internationally mainly driven by continued uptake in the uc indication in certain developed market int worldwide vyndaqel vyndamax operationally growth primarily driven by continued strong uptake of the attr cm indication in the developed europe and japan int worldwide xtandi operationally growth primarily driven by strong demand across the mcrpc nmcrpc and mcspc indication int worldwide inlyta operationally growth primarily reflects continued adoption in developed europe and the of combination of certain immune checkpoint inhibitor and inlyta for the first line treatment of patient with advanced rcc int worldwide pfizer inc form million year ended dec operational result commentarybiosimilars operationally growth primarily driven by recent oncology monoclonal antibody biosimilar launch and growth from retacrit in the int worldwide hospital operationally growth primarily driven by the anti infectives portfolio in international market primarily result of recent launch of zavicefta and cresemba int worldwide pfizer centreonerevenue million year ended dec changeoperating operational result operationally growth primarily reflects manufacturing of legacy upjohn product for viatris under manufacturing and supply agreement and certain comirnaty related manufacturing activity performed on behalf of biontech int worldwide comirnaty includes direct sale and alliance revenue related to sale of the pfizer biontech covid vaccine which are recorded within our vaccine therapeutic area it doe not include revenue for certain comirnaty related manufacturing activity performed on behalf of biontech which are included in the contract development and manufacturing organization revenue related to these manufacturing activity totaled million for and million in calculation is not meaningful or result are equal to or greater than see the item business patent and other intellectual property right section in this form for information regarding the expiration of various patent right note for discussion of recent development concerning patent and product litigation relating to certain of the product discussed above and note for additional information regarding the primary indication or class of the selected product discussed above cost and expensescosts and expense follow year ended december change million of sale percentage of selling informational and administrative research and development amortization of intangible restructuring charge and certain acquisition related other income deduction net calculation is not meaningful or result are equal to or greater than cost of of sale increased billion primarily due to the impact of comirnaty which includes charge for the gross profit split with biontech and applicable royalty expense increased sale volume of other product driven mostly by and the unfavorable impact of foreign exchange and hedging activity on intercompany inventory the increase in cost of sale percentage of revenue wa primarily due to all of the factor discussed above partially offset by an increase in alliance revenue which have no associated cost of sale of sale increased million primarily due to increased sale volume an increase in royalty expense due to an increase in sale of related product an unfavorable impact of incremental cost incurred in response to the covid pandemic andpfizer inc form an unfavorable impact of foreign exchange and hedging activity on intercompany inventory partially offset by the favorable impact of the july completion of the consumer healthcare jv transaction the increase in cost of sale percentage of revenue wa primarily due to all of the factor discussed above partially offset by an increase in alliance revenue which have no associated cost of sale selling informational and administrative si expense increased billion mostly due to increased product related spending across multiple therapeutic area cost related to comirnaty driven by higher provision for healthcare reform fee based on sale and an increase in cost related to implementing our cost reduction productivity initiative partially offset by lower spending on chantix following the loss of patent protection in the in november expense decreased billion mostly due to the favorable impact of the july completion of the consumer healthcare jv transaction lower spending for corporate enabling function lower spending on sale and marketing activity due to the impact of the covid pandemic and lower investment across the internal medicine and inflammation immunology portfolio partially offset by an increase in cost related to implementing our cost reduction productivity initiative and an increase in business and legal entity alignment cost research and development expense increased billion primarily due to charge for acquired ipr related to our acquisition of trillium net increase in charge for upfront and milestone payment on collaboration and licensing arrangement driven by payment to arvinas and beam and increased investment across multiple therapeutic area including additional spending related to the development of the oral covid treatment program expense increased billion mainly due to cost related to our collaboration agreement with biontech to co develop covid vaccine including an upfront payment to biontech and premium paid on our equity investment in biontech net increase in upfront payment mainly related to myovant and valneva and increased investment towards building new capability and driving automation partially offset by net reduction of upfront and milestone payment associated with the acquisition of therachon and akcea in amortization of intangible of intangible asset increased million primarily due to amortization of capitalized comirnaty sale milestone to biontech of intangible asset decreased billion mainly due the non recurrence of amortization of fully amortized asset and the impairment of eucrisa in the fourth quarter of partially offset by the increase in amortization of intangible asset from our acquisition of array for additional information see note and restructuring charge and other cost associated with acquisition and cost reduction productivity initiativestransforming to more focused company programfor description of our program well the anticipated and actual cost see note the program saving discussed below may be rounded and represent approximation in connection with restructuring our corporate enabling function we expect gross cost saving of billion or net cost saving excluding merit and inflation growth and certain real estate cost increase of million to be achieved primarily from through in connection with transforming our marketing strategy we expect net cost saving of billion to be achieved primarily from pfizer inc form through in connection with manufacturing network optimization we expect net cost saving of million to be achieved primarily from through certain qualifying cost for this program were recorded in and and in the fourth quarter of and are reflected certain significant item and excluded from our non gaap measure of adjusted income see the non gaap financial measure adjusted income section of this md in addition to this program we continuously monitor our operation for cost reduction and or productivity opportunity especially in light of the loss of exclusivity and the expiration of collaborative arrangement for various product other income deduction income net increased billion mainly due to net periodic benefit credit recorded in versus net periodic benefit cost recorded in lower asset impairment charge higher net gain on equity security and net gain on asset disposal in versus net loss in deduction net decreased billion mainly due to lower asset impairment charge lower business and legal entity alignment cost higher consumer healthcare jv equity method income lower charge for certain legal matter and higher income from collaboration out licensing arrangement and sale of compound product right partially offset by higher net loss on asset disposal see note for additional information provision benefit for tax on income year ended december change million benefit for tax on income effective tax rate on continuing indicates calculation not meaningful or result is equal to or greater than for information about our effective tax rate and the event and circumstance contributing to the change between period well detail about discrete element that impacted our tax provision see note discontinued operationsfor information about our discontinued operation see note product development comprehensive update of pfizer development pipeline wa published of february and is available at www pfizer com science drug product pipeline it includes an overview of our research and list of compound in development with targeted indication and phase of development well mechanism of action for some candidate in phase and all candidate from phase through registration the following provides information about significant marketing application related regulatory action by and filing pending with the fda and regulatory authority in the eu and japan the table below includes only approval for product that have occurred in the last twelve month and doe not include approval that may have occurred prior to that time the table includes filing with regulatory decision pending even if the filing occurred outside of the last twelve month period pfizer inc form areaapproved filed eujapancomirnaty pf immunization to prevent covid year of age and older blaaug to prevent covid year of age eua may may to prevent covid booster eua sep oct nov to prevent covid year of age euaoct nov avelumab first line maintenance urothelial cancerapprovedjan enzalutamide mcspcapprovedapril abrocitinib atopic dermatitisapprovedjan tofacitinib ankylosing spondylitisapproveddec relugolix fixed dose combination uterine fibroid combination with estradiol and norethindrone acetate combination with estradiol and norethindrone acetate filedsep lorviqua lorlatinib first line alk positive nsclcapprovedmar somatrogon pediatric growth hormone deficiencyfiledjan apexxnar vaccine immunization to prevent invasive and non invasive pneumococcal infection adult vaccine immunization to prevent tick borne encephalitisapproved aug nirmatrelvir pf ritonavir covid infection high risk population eua dec jan feb acute migrainefiled feb preventionfiled feb for the the filing date is the date on which the fda accepted our submission for the eu the filing date is the date on which the ema validated our submission being developed in collaboration with biontech prior to bla comirnaty for age and up wa available in the pursuant to an eua from the fda on december in december supplemental bla wa submitted to the fda requesting to expand the approval of comirnaty to include individual age through year in february following request from the fda rolling submission seeking to amend the eua to include child month through year of age month to year of age wa initiated we wait for data evaluating third g dose given at least two month after the second dose of the two dose series in this age group booster dose received eua from the fda on september for individual year of age and older individual through year of age at high risk of severe covid and individual through year of age with frequent institutional or occupational exposure to sars cov in addition in october the fda authorized for emergency use booster dose to eligible individual who have completed primary vaccination with different authorized covid vaccine subsequently the fda expanded the booster eua in november to include individual year of age and older ii in december to include individual year of age and older and iii in january to include individual year of age and older well individual through year of age who have been determined to have certain kind of immunocompromise booster dose received conditional marketing authorization from the ema in october for individual year of age and older and may be given to individual year and older with severely weakened immune system at least day after their second dose booster dose received approval in japan in november for year of age and older being developed in collaboration with merck kgaa germany being developed in collaboration with astellas being developed in collaboration with myovant being developed in collaboration with opko in january pfizer and opko received complete response letter crl from the fda for the bla for somatrogon pfizer is evaluating the crl and will work with the fda to determine an appropriate path forward in the in october the cdc acip voted to recommend prevnar for routine use in adult specifically the acip voted to recommend the following adult year of age or older who have not previously received pneumococcal conjugate vaccine or whose previous vaccination history is unknown should receive pneumococcal conjugate vaccine either pneumococcal valent conjugate vaccine or pneumococcal valent conjugate vaccine if is used this should be followed by dose of pneumococcal polysaccharide vaccine and ii adult aged year of age or older with certain underlying medical condition or other risk factor who have not previously received pneumococcal conjugate vaccine or whose previous vaccination history is unknown should receive pneumococcal conjugate vaccine either or if is used this should be followed by dose of the pfizer inc form were published in the morbidity and mortality weekly report on january the publication also note for adult who have received pneumococcal conjugate vaccine but have not completed their recommended pneumococcal vaccine series with one dose of prevnar may be used if is not available in december the fda authorized the emergency use of paxlovid for the treatment of mild to moderate covid in adult and pediatric patient year of age and older weighing at least kg lb with positive result of direct sars cov viral testing and who are at high risk for progression to severe covid including hospitalization or death in january the ema approved the cma of paxlovid for treating covid in adult who do not require supplemental oxygen and who are at increased risk of the disease becoming severe under commercialization arrangement with biohaven in september the fda issued drug safety communication dsc related to xeljanz xeljanz xr and two competitor arthritis medicine in the same drug class based on it completed review of the oral surveillance trial the dsc stated that the fda will require revision to the boxed warning for each of these medicine to include information about the risk of serious heart related event cancer blood clot and death in addition the dsc indicated the fda intention to limit approved us of these product to certain patient who have not responded or can not tolerate one or more tumor necrosis factor tnf blocker in december in light of the result from the completed required postmarketing safety study of xeljanz oral surveillance the label for xeljanz wa revised in addition at the request of the ec the prac of the ema ha adopted referral procedure under article of regulation ec no to ass safety information relating to oral jak inhibitor authorized for inflammatory disease including xeljanz and cibinqo which is ongoing for additional information see item risk factor post authorization approval data in china the following product received regulatory approval in the last twelve month cresemba for fungal infection and besponsa for second line acute lymphoblastic leukemia both in december the following provides information about additional indication and new drug candidate in late stage development product candidateproposed disease arealate stage clinical program for additional us and dosage formsfor in line and in registration productsibrance palbociclib er metastatic breast cancerxtandi enzalutamide non metastatic high risk castration sensitive prostate cancertalzenna talazoparib combination with xtandi enzalutamide for first line mcrpccombination with xtandi enzalutamide for dna damage repair ddr deficient mcspcpf vaccine immunization to prevent invasive and non invasive pneumococcal infection pediatric somatrogon pf adult growth hormone deficiencybraftovi encorafenib and erbitux cetuximab first line mutant mcrcmyfembree relugolix fixed dose combination combination with estradiol and norethindrone acetate for contraceptive efficacybraftovi encorafenib and mektovi binimetinib and keytruda pembrolizumab mutant metastatic or unresectable locally advanced melanomacomirnaty pf immunization to prevent covid child to year of age immunization to prevent covid infant month to month paxlovid nirmatrelvir pf ritonavir covid infection standard risk population covid infection post exposure prophylaxis new drug candidate in late stage developmentaztreonam avibactam pf treatment of infection caused by gram negative bacteriafidanacogene elaparvovec pf hemophilia bgiroctocogene fitelparvovec pf hemophilia apf vaccine immunization to prevent primary clostridioides difficile infectionpf vaccine immunization to prevent serogroups meningococcal infection adolescent and young adult pf vaccine immunization to prevent respiratory syncytial virus infection maternal immunization to prevent respiratory syncytial virus infection older adult pf cardiomyopathy due to lamin gene mutationritlecitinib pf alopecia areatasasanlimab pf combination with bacillus calmette guerin for non muscle invasive bladder cancerfordadistrogene movaparvovec pf duchenne muscular dystrophymarstacimab pf hemophiliaelranatamab pf multiple myeloma double class exposed omicron based mrna vaccine immunization to prevent covid adult being developed in collaboration with the alliance foundation trial llc being developed in collaboration with astellas being developed in collaboration with opko erbitux is registered trademark of imclone llc in the eu we are developing in collaboration with the pierre fabre group in japan we are developing in collaboration with ono pharmaceutical co ltd being developed in collaboration with myovant keytruda is registered trademark of merck sharp dohme corp being developed in collaboration with biontech pfizer inc form being developed in collaboration with spark therapeutic inc being developed in collaboration with sangamo therapeutic inc in february pfizer and merck kgaa darmstadt germany merck kgaa provided an update on the phase javelin lung trial which assessed the safety and efficacy of two dosing regimen of avelumab monotherapy compared with platinum based doublet chemotherapy first line treatment in patient with metastatic nsclc whose tumor express pd while avelumab showed clinical activity in this population the study did not meet the primary endpoint of overall survival and progression free survival in the high pd population for either of the avelumab dosing regimen evaluated the safety profile for avelumab in this trial wa consistent with that observed in the overall javelin clinical development program avelumab is not approved for the treatment of any patient with nsclc the outcome of the javelin lung trial ha no bearing on any of avelumab currently approved indication full result of the study will be shared at future date in the fourth quarter of enrollment wa stopped in study phase placebo controlled randomized observer blind study to evaluate the safety tolerability and immunogenicity of against covid in healthy pregnant woman year of age and older this study wa developed prior to availability or recommendation for covid vaccination in pregnant woman the environment changed during and by september covid vaccine were recommended by applicable recommending body acip in the for pregnant woman in all participating planned country and result the enrollment rate declined significantly with the declining enrollment the study had insufficient sample size to ass the primary immunogenicity objective and continuation of this placebo controlled study could no longer be justified due to global recommendation this proposal wa shared with and agreed to by fda and ema for additional information about our organization see the item business research and development section of this form non gaap financial measure adjusted incomeadjusted income is an alternative measure of performance used by management to evaluate our overall performance in conjunction with other performance measure such we believe that investor understanding of our performance is enhanced by disclosing this measure we use adjusted income certain component of adjusted income and adjusted diluted eps to present the result of our major operation the discovery development manufacture marketing sale and distribution of biopharmaceutical product worldwide prior to considering certain income statement element follows measuredefinitionrelevance of metric to our business performanceadjusted incomenet income attributable to pfizer inc common shareholder before the impact of purchase accounting for acquisition acquisition related item discontinued operation and certain significant item provides investor useful information to evaluate the normal recurring operational activity and their component on comparable year over year basis assist in modeling expected future performance on normalized basis provides investor insight into the way we manage our budgeting and forecasting how we evaluate and manage our recurring operation and how we reward and compensate our senior management adjusted cost of sale adjusted selling informational and administrative expense adjusted research and development expense adjusted amortization of intangible asset and adjusted other income deduction netcost of sale selling informational and administrative expense research and development expense amortization of intangible asset and other income deduction net each before the impact of purchase accounting for acquisition acquisition related item discontinued operation and certain significant item which are component of the adjusted income measureadjusted diluted epseps attributable to pfizer inc common shareholder diluted before the impact of purchase accounting for acquisition acquisition related item discontinued operation and certain significant item most directly comparable gaap measure the short term incentive plan for substantially all non sale force employee worldwide are funded from pool based on our performance measured in significant part by three metric one of which is adjusted diluted eps which is derived from adjusted income and account for of the bonus pool funding tied to financial performance additionally the payout for performance share award is determined in part by adjusted net income which is derived from adjusted income the bonus pool funding which is largely based on financial performance may be modified by our performance measured by four metric relating to our pipeline and may be further modified by our compensation committee assessment of other factor adjusted income and it component and adjusted diluted eps are non gaap financial measure that have no standardized meaning prescribed by gaap and therefore are limited in their usefulness to investor because of their non standardized definition they may not be comparable to the calculation of similar measure of other company and are presented to permit investor to more fully understand how management ass performance limitation of these measure is that they provide view of our operation without including all event during period and do not provide comparable view of our performance to peer these measure are not and should not be viewed substitute for their directly comparable gaap measure of net income attributable to pfizer inc common shareholder component of net income attributable to pfizer inc common shareholder and eps attributable to pfizer inc common shareholder diluted respectively see the accompanying reconciliation of certain gaap reported to non gaap adjusted information certain line item for and below we also recognize that internal measure of performance these measure have limitation and we do not restrict our performance management process solely to these measure we also use other tool designed to achieve the highest level of performance for example our organization ha productivity target upon which it effectiveness is measured in addition total shareholder return both on an absolute basis and relative to publicly traded pharmaceutical index play significant role in determining payouts under certain of our incentive compensation plan pfizer inc form accounting adjustmentsadjusted income excludes certain significant purchase accounting impact resulting from business combination and net asset acquisition these impact can include the incremental charge to cost of sale from the sale of acquired inventory that wa written up to fair value amortization related to the increase in fair value of the acquired finite lived intangible asset and to much lesser extent depreciation related to the increase decrease in fair value of the acquired fixed asset amortization related to the increase in fair value of acquired debt and the fair value change for contingent consideration therefore the adjusted income measure includes the revenue earned upon the sale of the acquired product without considering the acquisition cost of those product the exclusion of amortization attributable to acquired intangible asset provides management and investor an alternative view of our result by providing degree of parity to internally developed intangible asset for which cost have been expensed however we have not factored in the impact of any other difference that might have occurred if we had discovered and developed those intangible asset on our own such different cost timeline or resulting sale accordingly this approach doe not intend to be representative of the result that would have occurred if we had discovered and developed the acquired intangible asset internally acquisition related itemsadjusted income excludes acquisition related item which are comprised of transaction integration restructuring charge and additional depreciation cost for business combination because these cost are unique to each transaction and represent cost that were incurred to restructure and integrate business result of an acquisition we have made no adjustment for resulting synergy the significant cost incurred in connection with business combination result primarily from the need to eliminate duplicate asset activity or employee natural result of acquiring fully integrated set of activity for this reason we believe that such cost incurred can be viewed differently in the context of an acquisition from those cost incurred in other more normal business context the integration and restructuring cost for business combination may occur over several year with the more significant impact typically ending within three year of the relevant transaction because of the need for certain external approval for some action the span of time needed to achieve certain restructuring and integration activity can be lengthy discontinued operationsadjusted income excludes the result of discontinued operation well any related gain or loss on the disposal of such operation we believe that this presentation is meaningful to investor because while we review our therapeutic area and product line for strategic fit with our operation we do not build or run our business with the intent to discontinue part of our business restatement due to discontinued operation do not impact compensation or change the adjusted income measure for the compensation in respect of the restated period but are presented for consistency across all period certain significant itemsadjusted income excludes certain significant item representing substantive and or unusual item that are evaluated individually on quantitative and qualitative basis certain significant item may be highly variable and difficult to predict furthermore in some case it is reasonably possible that they could reoccur in future period for example although major non acquisition related cost reduction program are specific to an event or goal with defined term we may have subsequent program based on reorganization of the business cost productivity or in response to loe or economic condition legal charge to resolve litigation are also related to specific case which are fact and circumstance specific and in some case may also be the result of litigation matter at acquired company that were inestimable not probable or unresolved at the date of acquisition gain and loss on equity security have very high degree of inherent market volatility which we do not control and can not predict with any level of certainty and because we do not believe including these gain and loss assist investor in understanding our business or is reflective of our core operation and business unusual item represent item that are not part of our ongoing business item that either result of their nature or size we would not expect to occur part of our normal business on regular basis item that would be non recurring or item that relate to product we no longer sell see the reconciliation of gaap reported to non gaap adjusted information certain line item below for non inclusive list of certain significant item beginning in we exclude pension and postretirement actuarial remeasurement gain and loss from our measure of adjusted income because of their inherent market volatility which we do not control and can not predict with any level of certainty and because we do not believe including these gain and loss assist investor in understanding our business or is reflective of our core operation and business pfizer inc form of gaap reported to non gaap adjusted information certain line presented will not in all case aggregate to total in million except per common share datacost of salesselling informational and administrative expensesresearch and development expensesamortization of intangible assetsother income deduction netnet income attributable to pfizer inc common shareholder earnings per common share attributable to pfizer inc common shareholder dilutedgaap reported purchase accounting adjustment acquisition related item discontinued operation certain significant item restructuring charge credit and implementation cost and additional depreciation asset restructuring certain asset impairment upfront and milestone payment on collaborative and licensing arrangement gain loss on equity security actuarial valuation and other pension and postretirement plan gain loss asset acquisition of ipr other income tax provision non gaap item non gaap adjusted presented will not in all case aggregate to total in million except per common share datacost of salesselling informational and administrative expensesresearch and development expensesamortization of intangible assetsother income deduction netnet income attributable to pfizer inc common shareholder earnings per common share attributable to pfizer inc common shareholder dilutedgaap reported purchase accounting adjustment acquisition related item discontinued operation certain significant item restructuring charge credit and implementation cost and additional depreciation asset restructuring certain asset impairment upfront and milestone payment on collaborative and licensing arrangement gain loss on equity security actuarial valuation and other pension and postretirement plan gain loss asset acquisition of ipr other income tax provision non gaap item non gaap adjusted pfizer inc form presented will not in all case aggregate to total in million except per common share datacost of salesselling informational and administrative expensesresearch and development expensesamortization of intangible assetsother income deduction netnet income attributable to pfizer inc common shareholder earnings per common share attributable to pfizer inc common shareholder dilutedgaap reported purchase accounting adjustment acquisition related item discontinued operation certain significant item restructuring charge credit and implementation cost and additional depreciation asset restructuring certain asset impairment upfront and milestone payment on collaborative and licensing arrangement gain loss on equity security actuarial valuation and other pension and postretirement plan gain loss gain on completion of consumer healthcare jv transaction asset acquisition of ipr other income tax provision non gaap item non gaap adjusted item that reconcile gaap reported to non gaap adjusted balance are shown pre tax and include discontinued operation our effective tax rate for gaap reported income from continuing operation were in in and in see note our effective tax rate on non gaap adjusted income were in in and in purchase accounting adjustment include item such the incremental charge to cost of sale from the sale of acquired inventory that wa written up to fair value amortization related to the increase in fair value of the acquired finite lived intangible asset depreciation related to the increase decrease in fair value of the acquired fixed asset amortization related to the increase in fair value of acquired debt and the fair value change for contingent consideration for all year presented primarily consists of amortization of intangible asset relates primarily to the spin off of our upjohn business and our sale of meridian see note includes employee termination cost asset impairment and other exit cost related to our cost reduction and productivity initiative not associated with acquisition see note primarily includes intangible asset impairment charge for million is related to ipr asset acquired from array and million is related to eucrisa for billion is related to eucrisa see note primarily includes the following charge for an upfront payment to arvinas and premium paid on our equity investment in arvinas totaling million million upfront payment to beam and million net upfront payment to biontech ii for payment of million representing the expense portion of an upfront payment to myovant an upfront payment to valneva of million an upfront payment to biontech and premium paid on our equity investment in biontech totaling million well million milestone payment to akcea and iii for an upfront license fee payment of million to akcea gain loss on equity security and actuarial valuation and other pension and postretirement plan gain loss are removed from adjusted earnings due to their inherent market volatility primarily includes payment for acquired ipr for includes billion charge related to our acquisition of trillium which wa accounted for an asset acquisition and million charge related to an asset acquisition completed in the second quarter of for included million charge related to our acquisition of therachon which wa accounted for an asset acquisition for the total of million primarily includes charge representing our equity method accounting pro rata share of restructuring charge and cost of preparing for separation from gsk of million recorded by the consumer healthcare jv and ii charge for certain legal matter of million for the total of million primarily included charge of million which represent our equity method accounting pro rata share of transaction specific restructuring and business combination accounting charge recorded by the consumer healthcare jv and ii loss on asset disposal of million for the total of billion primarily included million of business and legal entity alignment cost for consulting legal tax and advisory service associated with the design planning and implementation of our then new business structure effective in the beginning of ii charge for certain legal matter of million iii charge of million for external incremental cost such transaction cost and cost to separate our consumer healthcare business into separate legal entity associated with the formation of the consumer healthcare jv iv net loss on early retirement of debt of million and charge of million representing our equity method accounting pro rata share of restructuring and business combination accounting charge recorded by the consumer healthcare jv for amount in selling informational and administrative expense of million primarily include cost for consulting legal tax and advisory service associated with non recurring internal reorganization of legal entity pfizer inc form of the consolidated statement of cash flowscash flow from continuing operation year ended december million of changecash provided by used in operating activity from continuing operation change wa driven primarily by higher net income adjusted for non cash item the payment for the acquisition of trillium decrease in contribution to pension plan and the impact of timing of receipt and payment in the ordinary course of business mostly from an increase in cash flow from other current liability driven by billion accrual for the gross profit split due to biontech ii an increase in royalty payable well iii an increase in deferred revenue for advance payment in for comirnaty the change in other adjustment net is mostly due to an increase in unrealized gain on equity security change wa driven mainly by higher net income adjusted for non cash item advanced payment in for comirnaty recorded in deferred revenue the upfront cash payment associated with our acquisition of therachon in and the upfront cash payment associated with our licensing agreement with akcea in partially offset by an increase in benefit plan contribution the change also reflects the impact of timing of receipt and payment in the ordinary course of business the change in other adjustment net wa driven primarily by an increase in equity method dividend received partially offset by an increase in equity income and increase in net unrealized gain on equity security investing activity from continuing operation change wa driven mainly by billion increase in purchase of short term investment with original maturity of greater than three month and billion increase in net purchase of short term investment with original maturity of three month or le partially offset by billion increase in redemption of short term investment with original maturity of greater than three month change wa driven mostly by billion decrease in net proceeds from short term investment with original maturity of three month or le and billion in net purchase of short term investment with original maturity of greater than three month in compared to billion net proceeds from short term investment with original maturity of greater than three month in partially offset by the cash used to acquire array net of cash acquired of billion in financing activity from continuing operation change wa driven mostly by billion net reduction in repayment of short term borrowing with maturity of greater than three month billion decrease in net payment on short term borrowing with maturity of three month or le and billion reduction in repayment of long term debt partially offset by billion decrease in proceeds from issuance of long term debt change wa driven mostly by billion net payment of short term borrowing in compared to billion net proceeds raised from short term borrowing in and an increase in cash dividend paid of million partially offset by decrease in purchase of common stock of billion lower repayment on long term debt of billion and an increase in issuance of long term debt of million cash flow from discontinued operationscash flow from discontinued operation primarily relate to our former meridian subsidiary upjohn business and the mylan japan collaboration see note in net cash provided by financing activity from discontinued operation primarily reflects issuance of long term debt analysis of financial condition liquidity capital resource and market riskdue to our significant operating cash flow which is key strength of our liquidity and capital resource and our primary funding source well our financial asset access to capital market revolving credit agreement and available line of credit we believe that we have and will maintain the ability to meet our liquidity need to support ongoing operation our capital allocation objective and our contractual and other obligation for the foreseeable future pfizer inc form focus effort to optimize operating cash flow through achieving working capital efficiency that target account receivable inventory account payable and other working capital excess cash from operating cash flow is invested in money market fund and available for sale debt security which consist of primarily high quality highly liquid well diversified debt security we have taken and will continue to take conservative approach to our financial investment and monitoring of our liquidity position in response to market change we typically maintain cash and cash equivalent balance and short term investment which together with our available revolving credit facility are in excess of our commercial paper and other short term borrowing additionally we may obtain funding through short term or long term source from our access to the capital market banking relationship and relationship with other financial intermediary to meet our liquidity need diverse source of fund related disclosure presented in this form kinternal source operating cash flowsconsolidated statement of cash flow operating activity and the analysis of the consolidated statement of cash flow within md cash and cash equivalentsconsolidated balance sheet money market fundsnote available for sale debt securitiesnote source short term funding commercial papernote revolving credit facilitiesnote line of creditnote term funding long term debtnote equityconsolidated statement of equity and note additional information about the source and us of our fund and capital resource for the year ended december and see the analysis of the consolidated statement of cash flow in this md in august we completed public offering of billion aggregate principal amount of senior unsecured sustainability note we are using the net proceeds to finance or refinance in whole or in part follows expense related to our covid vaccine capital expenditure in connection with the manufacture and distribution of covid vaccine and our other project that have environmental and or social benefit for additional information see note credit ratingsthe cost and availability of financing are influenced by credit rating and increase or decrease in our credit rating could have beneficial or adverse effect on financing our long term debt is rated high quality by both and moody in november upon the completion of the upjohn separation both moody and lowered our long term debt rating one notch to and respectively and our short term rating remained unchanged continues to rate our long term debt rating outlook stable since november while moody recently upgraded our long term debt rating outlook to positive in december the current rating assigned to our commercial paper and senior unsecured long term debt name of rating agencypfizer short term ratingpfizer long term ratingoutlook watchmoody sp pa stablea security rating is not recommendation to buy sell or hold security and the rating is subject to revision or withdrawal at any time by the rating organization each rating should be evaluated independently of any other rating capital allocation frameworkour capital allocation framework is devised to facilitate the achievement of medical breakthrough through investment and business development activity and ii returning capital to shareholder through dividend and share repurchase see the overview of our performance operating environment strategy and outlook our business and strategy section of this md our current and projected dividend provide return to shareholder while maintaining sufficient capital to invest in growing our business our dividend are not restricted by debt covenant while the dividend level remains decision of pfizer bod and will continue to be evaluated in the context of future business performance we currently believe that we can support future annual dividend increase barring significant unforeseen event in december our bod declared first quarter dividend of per share payable on march to shareholder of record at the close of business on january the first quarter cash dividend will be our consecutive quarterly dividend see note for information on the share of our common stock purchased and the cost of purchase under our publicly announced share purchase plan including our accelerated share repurchase agreement at december our remaining share purchase authorization wa approximately billion off balance sheet arrangement contractual and other obligationsin the ordinary course of business we enter into off balance sheet arrangement that may result in contractual and other obligation and ii in connection with the sale of asset and business and other transaction we often indemnify our counterparties against certain liability that pfizer inc form arise in connection with the transaction or that are related to event and activity for more information on guarantee and indemnification see note additionally certain of our co promotion or license agreement give our licensors or partner the right to negotiate for or in some case to obtain under certain financial condition co promotion or other right in specified country with respect to certain of our product furthermore collaboration licensing or other arrangement may give rise to potential milestone payment payment under these agreement generally become due and payable only upon the achievement of certain development regulatory and or commercialization milestone which may span several year and which may never occur our significant contractual and other obligation of december consisted of long term debt including current portion see note and related interest payment estimated cash payment related to the tcja repatriation estimated tax liability see note estimated future payment related to the tcja repatriation tax liability that will occur after december total billion of which an estimated million is to be paid in the next twelve month and an estimated billion is to be paid in period thereafter certain commitment totaling billion of which an estimated billion is to be paid in the next twelve month and billion in period thereafter see note purchase of property plant and equipment see note in we expect to spend approximately billion on property plant and equipment and future minimum rental commitment under non cancelable operating lease see note global economic conditionsour venezuela and argentina operation function in hyperinflationary economy the impact to pfizer is not considered material for additional information on the global economic environment see the item risk factor global operation section in this form market riskwe are subject to foreign exchange risk interest rate risk and equity price risk the objective of our financial risk management program is to minimize the impact of foreign exchange rate and interest rate movement on our earnings we address such exposure through combination of operational mean and financial instrument for more information on how we manage our foreign exchange and interest rate risk see note and well the item risk factor global operation section in this form for key currency in which we operate our sensitivity analysis of such risk are discussed below foreign exchange risk the fair value of our financial instrument holding are analyzed at year end to determine their sensitivity to foreign exchange rate change in this analysis holding all other assumption constant and assuming that change in one currency rate relative to the dollar would not have any effect on another currency rate relative to the dollar if the dollar were to appreciate against all other currency by of december the expected adverse impact on our net income would not be significant interest rate risk the fair value of our financial instrument holding are analyzed at year end to determine their sensitivity to interest rate change in this analysis holding all other assumption constant and assuming parallel shift in the interest rate curve for all maturity and for all instrument if there were one hundred basis point decrease in interest rate of december the expected adverse impact on our net income would not be significant equity price risk we hold equity security with readily determinable fair value in life science company result of certain business development transaction while we are holding such security we are subject to equity price risk and this may increase the volatility of our income in future period due to change in the fair value of equity investment from time to time we will sell such equity security based on our business consideration which may include limiting our price risk our equity security with readily determinable fair value are analyzed at year end to determine their sensitivity to equity price rate change in this sensitivity analysis the expected adverse impact on our net income would not be significant liborfor information on interest rate risk and libor see the item risk factor global operation section in this form we do not expect the transition to an alternative rate to have material impact on our liquidity or financial resource pfizer inc form accounting standardsrecently adopted accounting standardsee note recently issued accounting standard not adopted of december descriptioneffective dateeffect on the financial statementsreference rate reform provides temporary optional expedient and exception to the guidance for contract hedging relationship and other transaction that reference libor or another reference rate expected to be discontinued after because of reference rate reform the new guidance provides the following optional expedient simplify accounting analysis under current gaap for contract modification simplify the assessment of hedge effectiveness and allow hedging relationship affected by reference rate reform to continue allow one time election to sell or transfer debt security classified held to maturity that reference rate affected by reference rate reform election can be adopted prospectively at any time through december we are assessing the impact but currently we do not expect this new guidance to have material impact on our consolidated financial statement accounting for contract asset and contract liability from contract with customer requires contract asset and contract liability acquired in business combination to be recognized and measured by the acquirer on the acquisition date in accordance with asc this new guidance will generally result in the acquirer recognizing contract asset and contract liability at the same amount that were recorded by the acquiree previously these amount were recognized by the acquirer at fair value of the acquisition date january early adoption is permitted we do not expect this new guidance to have material impact on our consolidated financial statement item quantitative and qualitative disclosure about market riskthe information required by this item is incorporated by reference to the discussion in the analysis of financial condition liquidity capital resource and market risk section within md pfizer inc form financial statement and supplementary datareport of independent registered public accounting firmto the board of director and shareholderspfizer inc opinion on the consolidated financial statementswe have audited the accompanying consolidated balance sheet of pfizer inc and subsidiary company the company of december and the related consolidated statement of income comprehensive income equity and cash flow for each of the year in the three year period ended december and the related note collectively the consolidated financial statement in our opinion the consolidated financial statement present fairly in all material respect the financial position of the company of december and and the result of it operation and it cash flow for each of the year in the three year period ended december in conformity with generally accepted accounting principle we also have audited in accordance with the standard of the public company accounting oversight board united state pcaob the company internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission and our report dated february expressed an unqualified opinion on the effectiveness of the company internal control over financial reporting change in accounting principle discussed in note to the consolidated financial statement the company ha elected to change it method of accounting for pension and postretirement plan in to immediately recognize actuarial gain and loss in the consolidated statement of income basis for opinionthese consolidated financial statement are the responsibility of the company management our responsibility is to express an opinion on these consolidated financial statement based on our audit we are public accounting firm registered with the pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statement are free of material misstatement whether due to error or fraud our audit included performing procedure to ass the risk of material misstatement of the consolidated financial statement whether due to error or fraud and performing procedure that respond to those risk such procedure included examining on test basis evidence regarding the amount and disclosure in the consolidated financial statement our audit also included evaluating the accounting principle used and significant estimate made by management well evaluating the overall presentation of the consolidated financial statement we believe that our audit provide reasonable basis for our opinion critical audit mattersthe critical audit matter communicated below are matter arising from the current period audit of the consolidated financial statement that were communicated or required to be communicated to the audit committee and that relate to account or disclosure that are material to the consolidated financial statement and involved our especially challenging subjective or complex judgment the communication of critical audit matter doe not alter in any way our opinion on the consolidated financial statement taken whole and we are not by communicating the critical audit matter below providing separate opinion on the critical audit matter or on the account or disclosure to which they relate evaluation of the medicare medicaid and performance based contract rebate accrualas discussed in note to the consolidated financial statement the company record estimated deduction for medicare medicaid and performance based contract rebate collectively rebate reduction to gross product revenue the accrual for rebate is recorded in the same period that the corresponding revenue are recognized the length of time between when sale is made and when the rebate is paid by the company can be long one year which increase the need for significant management judgment and knowledge of market condition and practice in estimating the accrual we identified the evaluation of the rebate accrual critical audit matter because the evaluation of the product specific experience ratio assumption involved especially challenging auditor judgment the product specific experience ratio assumption relates to estimating which of the company revenue transaction will ultimately be subject to related rebate the following are the primary procedure we performed to address this critical audit matter we evaluated the design and tested the operating effectiveness of certain internal control over the company rebate accrual process related to the development of the product specific experience ratio assumption we estimated the rebate accrual using internal information and historical data and compared the result to the company estimated rebate accrual we evaluated the company ability to accurately estimate the accrual for rebate by comparing historically recorded accrual to the actual amount that wa ultimately paid by the company evaluation of gross unrecognized tax benefitsas discussed in note and the company tax position are subject to audit by local taxing authority in each respective tax jurisdiction and the resolution of such audit may span multiple year since tax law is complex and often subject to varied interpretation and judgment it is uncertain whether some of the company tax position will be sustained upon audit of december the company ha recorded gross unrecognized tax benefit excluding associated interest of billion pfizer inc form of independent registered public accounting firmwe identified the evaluation of the company gross unrecognized tax benefit critical audit matter because high degree of audit effort including specialized skill and knowledge and complex auditor judgment wa required in evaluating the company interpretation of tax law and it estimate of the ultimate resolution of it tax position the following are the primary procedure we performed to address this critical audit matter we evaluated the design and tested the operating effectiveness of an internal control over the company liability for unrecognized tax position process related to interpretation of tax law evaluation of which of the company tax position may not be sustained upon audit and estimation and recording of the gross unrecognized tax benefit we involved tax and valuation professional with specialized skill and knowledge who assisted in evaluating the company interpretation of tax law including the assessment of transfer pricing practice in accordance with applicable tax law and regulation we inspected settlement with applicable taxing authority including assessing the expiration of statute of limitation we tested the calculation of the liability for uncertain tax position including an evaluation of the company assessment of the technical merit of tax position and estimate of the amount of tax benefit expected to be sustained evaluation of product and other product related litigationas discussed in note and to the consolidated financial statement the company is involved in product liability and other product related litigation which can include personal injury consumer off label promotion security antitrust and breach of contract claim among others certain of these pending product and other product related legal proceeding could result in loss that could be substantial the accrued liability and or disclosure for the pending product and other product related legal proceeding requires complex series of judgment by the company about future event which involves number of uncertainty we identified the evaluation of product and other product related litigation critical audit matter challenging auditor judgment wa required to evaluate the company judgment about future event and uncertainty the following are the primary procedure we performed to address this critical audit matter we evaluated the design and tested the operating effectiveness of certain internal control over the company product liability and other product related litigation process including control related to the evaluation of information from external and internal legal counsel forward looking expectation and new legal proceeding or other legal proceeding not currently reserved or disclosed we read letter received directly from the company external and internal legal counsel that described the company probable or reasonably possible legal contingency to pending product and other product related legal proceeding we inspected the company minute from meeting of the audit committee which included the status of key litigation matter we evaluated the company ability to estimate it monetary exposure to pending product and other product related legal proceeding by comparing historically recorded liability to actual monetary amount incurred upon resolution of prior legal matter we analyzed relevant publicly available information about the company it competitor and the industry we have not been able to determine the specific year that we or our predecessor firm began serving the company auditor however we are aware that we or our predecessor firm have served the company auditor since at least new york new yorkfebruary inc form statement of incomepfizer inc and subsidiary company year ended december million except per common share data cost and expense cost of sale selling informational and administrative expense research and development expense amortization of intangible restructuring charge and certain acquisition related gain on completion of consumer healthcare jv transaction other income deduction net income from continuing operation before provision benefit for tax on provision benefit for tax on income from continuing discontinued operation net of tax net income before allocation to noncontrolling le net income attributable to noncontrolling net income attributable to pfizer inc common shareholder earnings per common share basic income from continuing operation attributable to pfizer inc common shareholder discontinued operation net of tax net income attributable to pfizer inc common shareholder earnings per common share diluted income from continuing operation attributable to pfizer inc common shareholder discontinued operation net of tax net income attributable to pfizer inc common shareholder weighted average share weighted average share exclusive of amortization of intangible asset except disclosed in note see accompanying note pfizer inc form statement of comprehensive incomepfizer inc and subsidiary companiesyear ended december million income before allocation to noncontrolling interest foreign currency translation adjustment net reclassification adjustment unrealized holding gain loss on derivative financial instrument reclassification adjustment for gain loss included in net income unrealized holding gain loss on available for sale security net reclassification adjustment for gain loss included in net income benefit plan prior service cost credit and other reclassification adjustment related to amortization of prior service cost and other net reclassification adjustment related to curtailment of prior service cost and other net other other comprehensive income loss before tax tax provision benefit on other comprehensive income loss other comprehensive income loss before allocation to noncontrolling interest comprehensive income loss before allocation to noncontrolling interest le comprehensive income loss attributable to noncontrolling comprehensive income loss attributable to pfizer inc reclassified into other income deduction net and cost of sale see note reclassified into other income deduction net see accompanying note pfizer inc form balance sheetspfizer inc and subsidiary companiesas of december million except per common share data and cash equivalent short term trade account receivable le allowance for doubtful account current tax other current total current equity method long term property plant and identifiable intangible noncurrent deferred tax asset and other noncurrent tax other noncurrent total asset liability and equity short term borrowing including current portion of long term debt trade account dividend income tax accrued compensation and related deferred other current total current long term pension benefit postretirement benefit noncurrent deferred tax other tax other noncurrent total commitment and contingenciespreferred stock no par value at stated value share authorized no share issued or outstanding at december and december common stock par value share authorized issued additional paid in treasury stock share at cost retained accumulated other comprehensive loss total pfizer inc shareholder equity attributable to noncontrolling total total liability and equity see accompanying note pfizer inc form statement of equitypfizer inc and subsidiary company pfizer inc shareholder preferred stockcommon stock treasury stock million except preferred share sharesstated valuesharespar valueadd lpaid incapitalsharescostretained earningsaccum othercomp lossshare holder equitynon controlling intereststotalequitybalance january net other comprehensive income loss net of tax cash dividend declared per share stock preferred stock noncontrolling interest share based payment purchase of common stock preferred stock conversion and redemption other balance december net other comprehensive income loss net of cash dividend declared per share stock preferred stock noncontrolling interest share based payment preferred stock conversion and redemption distribution of upjohn business other balance december net other comprehensive income loss net of tax cash dividend declared per share stock preferred stock noncontrolling interest share based payment other balance december see note see note see accompanying note pfizer inc form statement of cash flowspfizer inc and subsidiary company year ended december million activity net income before allocation to noncontrolling interest discontinued operation net of tax net income from continuing operation before allocation to noncontrolling adjustment to reconcile net income before allocation to noncontrolling interest to net cash provided by operating activity depreciation and asset write offs and tcja impact gain on completion of consumer healthcare jv transaction net of cash conveyed deferred tax from continuing operation share based compensation benefit plan contribution in excess of expense income other adjustment net other change in asset and liability net of acquisition and divestiture trade account receivable inventory other asset trade account other other tax account net net cash provided by operating activity from continuing net cash provided by used in operating activity from discontinued operation net cash provided by operating investing activity purchase of property plant and equipment purchase of short term investment proceeds from redemption sale of short term net purchase of proceeds from redemption sale of short term investment with original maturity of three month or le purchase of long term investment proceeds from redemption sale of long term acquisition of business net of cash acquired other investing activity net net cash provided by used in investing activity from continuing operation net cash provided by used in investing activity from discontinued operation net cash provided by used in investing activity financing activity proceeds from short term borrowing principal payment on short term borrowing net payment on proceeds from short term borrowing with original maturity of three month or le proceeds from issuance of long term principal payment on long term debt purchase of common stock cash dividend paid other financing activity net cash provided by used in financing activity from continuing operation net cash provided by used in financing activity from discontinued operation net cash provided by used in financing activity effect of exchange rate change on cash and cash equivalent and restricted cash and cash equivalent net increase decrease in cash and cash equivalent and restricted cash and cash cash and cash equivalent and restricted cash and cash equivalent at beginning of cash and cash equivalent and restricted cash and cash equivalent at end of period continued pfizer inc form statement of cash flowspfizer inc and subsidiary companiesyear ended december cash flow information cash paid received during the period for income tax interest interest rate hedge non cash transaction right of use asset obtained in exchange for lease liability equity method investment in the consumer healthcare jv received in exchange for contributing pfizer consumer healthcare business the billion gain on completion of consumer healthcare jv transaction net of cash conveyed reflects the receipt of equity method investment in the new company initially valued at billion in exchange for net asset contributed of billion and is presented in operating activity net of million cash conveyed that is reflected in other investing activity net see note see accompanying note pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesnote basis of presentation and significant accounting policiesa basis of presentationthe consolidated financial statement include the account of our parent company and all subsidiary and are prepared in accordance with gaap the decision of whether or not to consolidate an entity for financial reporting purpose requires consideration of majority voting interest well effective economic or other control over the entity typically we do not seek control by mean other than voting interest for subsidiary operating outside the the financial information is included of and for the year ended november for each year presented pfizer fiscal year end for subsidiary is of and for the year ended december for each year presented substantially all unremitted earnings of international subsidiary are free of legal and contractual restriction all significant transaction among our subsidiary have been eliminated at the beginning of our fiscal fourth quarter of we reorganized our commercial operation and began to manage our commercial operation through new global structure consisting of two operating segment each led by single manager biopharma our innovative science based biopharmaceutical business and our global contract development and manufacturing organization and leading supplier of specialty active pharmaceutical ingredient see note on december we completed the sale of our meridian subsidiary the manufacturer of epipen and other auto injector product prior to it sale meridian wa managed within the hospital therapeutic area beginning in the fourth quarter of the financial result of meridian are reflected discontinued operation for all period presented on december pfizer and viatris completed the termination of pre existing strategic collaboration between pfizer and mylan for generic drug in japan the mylan japan collaboration pursuant to an agreement dated november and we transferred related inventory and operation that were part of the mylan japan collaboration to viatris on november we completed the spin off and the combination of our upjohn business with mylan to form viatris beginning in the fourth quarter of the financial result of the upjohn business and the mylan japan collaboration were reflected discontinued operation for all period presented the asset and liability associated with meridian and the mylan japan collaboration are classified asset and liability of discontinued operation of december upon completion of the spin off of the upjohn business on november the upjohn asset and liability were derecognized from our consolidated balance sheet and are reflected in retained earnings distribution of upjohn business in the consolidated statement of equity prior to the spin off of the upjohn business in november the upjohn business the mylan japan collaboration and meridian were managed part of our former upjohn operating segment with the separation of the upjohn business the mylan japan collaboration and meridian well the formation of the consumer healthcare jv in pfizer transformed into more focused global leader in science based innovative medicine and vaccine certain prior year amount have been reclassified to conform with the current year presentation in addition other acquisition and business development activity completed in and impacted financial result in the period presented see note certain amount in the consolidated financial statement and associated note may not add due to rounding all percentage have been calculated using unrounded amount new accounting standard adopted in january we adopted new accounting standard for income tax that eliminates certain exception to the guidance related to the approach for intraperiod tax allocation the methodology for calculating income tax in an interim period and the recognition of deferred tax liability for outside basis difference the new guidance also simplifies aspect of the accounting for franchise tax and enacted change in tax law or rate and clarifies the accounting for transaction that result in step up in the tax basis of goodwill the adoption of this guidance did not have material impact on our consolidated financial statement change in accounting principlein the first quarter of we adopted change in accounting principle to more preferable policy under gaap to immediately recognize actuarial gain and loss arising from the remeasurement of our pension and postretirement plan mtm accounting under the prior policy we deferred recognition of these gain and loss in accumulated other comprehensive loss the accumulated actuarial gain loss outside of corridor were then amortized into net periodic benefit cost over the average remaining service period or the average life expectancy of participant this change ha been applied to all pension and postretirement plan on retrospective basis for all prior period presented and of january resulted in cumulative effect decrease to retained earnings of billion with corresponding offset to accumulated other comprehensive loss each time pension or postretirement plan is remeasured the actuarial gain or loss is recognized immediately and classified other income deduction net we believe that mtm accounting is more preferable policy it provides improved transparency of result and performance better alignment with fair value accounting principle and better reflection of current economic and interest rate trend on plan investment and assumption and the actuarial impact of plan remeasurements pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesthe impact of the adjustment on our consolidated financial statement are summarized follows year ended december million except per common share data previousaccountingprincipleimpact of changeas reportedprevious accounting principleimpact of changeas adjustedprevious accounting principleimpact of changeas adjustedconsolidated statement of income gain on completion of consumer healthcare jv transaction other income deduction net income from continuing operation before provision benefit for tax on provision benefit for tax on discontinued operation net of tax net income before allocation to noncontrolling net income attributable to pfizer inc common earnings per common share basic income from continuing operation attributable to pfizer inc common shareholder discontinued operation net of tax net income attributable to pfizer inc common earnings per common share diluted income from continuing operation attributable to pfizer inc common shareholder discontinued operation net of tax net income attributable to pfizer inc common year ended december million previousaccountingprincipleimpact of changeas reportedprevious accounting principleimpact of changeas adjustedprevious accounting principleimpact of changeas adjustedconsolidated statement of comprehensive income foreign currency translation adjustment net benefit plan actuarial gain loss reclassification adjustment related to reclassification adjustment related to settlement tax provision benefit on other comprehensive income loss consolidated statement of cash flow deferred tax from continuing operation benefit plan contribution in excess of expense income year ended december million previousaccountingprincipleimpact of changeas reportedprevious accounting principleimpact of changeas adjustedconsolidated balance sheet noncurrent deferred tax asset and other noncurrent tax asset other noncurrent pension benefit retained accumulated other comprehensive loss pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesd estimate and assumptionsin preparing these financial statement we use certain estimate and assumption that affect reported amount and disclosure these estimate and assumption can impact all element of our financial statement for example in the consolidated statement of income estimate are used when accounting for deduction from revenue determining the cost of inventory that is sold allocating cost in the form of depreciation and amortization and estimating restructuring charge and the impact of contingency well determining provision for tax on income on the consolidated balance sheet estimate are used in determining the valuation and recoverability of asset and in determining the reported amount of liability all of which also impact the consolidated statement of income certain estimate of fair value and amount recorded in connection with acquisition revenue deduction impairment review restructuring associated charge investment and financial instrument valuation allowance pension and postretirement benefit plan contingency share based compensation and other calculation can result from complex series of judgment about future event and uncertainty and can rely heavily on estimate and assumption our estimate are often based on complex judgment and assumption that we believe to be reasonable but that can be inherently uncertain and unpredictable if our estimate and assumption are not representative of actual outcome our result could be materially impacted future event and their effect can not be determined with precision our estimate and assumption may prove to be incomplete or inaccurate or unanticipated event and circumstance may occur that might cause to change those estimate and assumption we are subject to risk and uncertainty that may cause actual result to differ from estimated amount such change in the healthcare environment competition litigation legislation and regulation we regularly evaluate our estimate and assumption using historical experience and expectation about the future we adjust our estimate and assumption when fact and circumstance indicate the need for change acquisitionsour consolidated financial statement include the operation of acquired business after the completion of the acquisition we account for acquired business using the acquisition method of accounting which requires among other thing that most asset acquired and liability assumed be recognized at their estimated fair value of the acquisition date and that the fair value of acquired ipr be recorded on the balance sheet transaction cost are expensed incurred any excess of the consideration transferred over the assigned value of the net asset acquired is recorded goodwill when we acquire net asset that do not constitute business defined in gaap no goodwill is recognized and acquired ipr is expensed in research and development expense contingent consideration in business combination is included part of the acquisition cost and is recognized at fair value of the acquisition date fair value is generally estimated by using probability weighted discounted cash flow approach see note any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved these change in fair value are recognized in earnings in other income deduction net fair valuewe measure certain asset and liability at fair value either upon initial recognition or for subsequent accounting or reporting we estimate fair value using an exit price approach which requires among other thing that we determine the price that would be received to sell an asset or paid to transfer liability in an orderly market the determination of an exit price is considered from the perspective of market participant considering the highest and best use of non financial asset and for liability assuming that the risk of non performance will be the same before and after the transfer when estimating fair value depending on the nature and complexity of the asset or liability we may use one or all of the following technique income approach which is based on the present value of future stream of net cash flow market approach which is based on market price and other information from market transaction involving identical or comparable asset or liability cost approach which is based on the cost to acquire or construct comparable asset le an allowance for functional and or economic obsolescence our fair value methodology depend on the following type of input quoted price for identical asset or liability in active market level input quoted price for similar asset or liability in active market or quoted price for identical or similar asset or liability in market that are not active or input other than quoted price that are directly or indirectly observable or input that are derived principally from or corroborated by observable market data by correlation or other mean level input unobservable input that reflect estimate and assumption level input the following input and valuation technique are used to estimate the fair value of our financial asset and liability available for sale debt security third party matrix pricing model that us significant input derived from or corroborated by observable market data and credit adjusted yield curve equity security with readily determinable fair value quoted market price and observable nav price derivative asset and liability third party matrix pricing model that us input derived from or corroborated by observable market data where applicable these model use market based observable input including interest rate yield curve to discount future cash flow amount and forward and spot price for currency the credit risk impact to our derivative financial instrument wa not significant money market fund observable nav price we periodically review the methodology input and output of third party pricing service for reasonableness our procedure can include for example referencing other third party pricing model monitoring key observable input like benchmark interest rate and selectively performing test comparison of value with actual sale of financial instrument pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesg foreign currency translationfor most of our international operation local currency have been determined to be the functional currency we translate functional currency asset and liability to their dollar equivalent at exchange rate in effect of the balance sheet date and income and expense amount at average exchange rate for the period the dollar effect that arise from changing translation rate are recorded in other comprehensive income loss the effect of converting non functional currency monetary asset and liability into the functional currency are recorded in other income deduction net for operation in highly inflationary economy we translate monetary item at rate in effect of the balance sheet date with translation adjustment recorded in other income deduction net and we translate non monetary item at historical rate revenue and trade account receivablerevenue recognition we record revenue from product sale when there is transfer of control of the product from to the customer we typically determine transfer of control based on when the product is shipped or delivered and title pass to the customer our sale contract sale on credit are typically under short term contract collection are based on market payment cycle common in various market with shorter cycle in the sale are adjusted for sale allowance chargebacks rebate and sale return and cash discount sale return occur due to loe product recall or changing competitive environment deduction from revenue our gross product revenue are subject to variety of deduction which generally are estimated and recorded in the same period that the revenue are recognized such variable consideration represents chargebacks rebate sale allowance and sale return these deduction represent estimate of the related obligation and such knowledge and judgment is required when estimating the impact of these revenue deduction on gross sale for reporting period provision for pharmaceutical sale return provision are based on calculation for each market that incorporates the following appropriate local return policy and practice historical return percentage of sale an understanding of the reason for past return estimated shelf life by product an estimate of the amount of time between shipment and return or lag time and any other factor that could impact the estimate of future return such loe product recall or changing competitive environment generally returned product are destroyed and customer are refunded the sale price in the form of credit we record sale incentive reduction of revenue at the time the related revenue are recorded or when the incentive is offered whichever is later we estimate the cost of our sale incentive based on our historical experience with similar incentive program to predict customer behavior the following outline our common sale arrangement customer our prescription pharmaceutical product are sold principally to wholesaler but we also sell directly to retailer hospital clinic government agency and pharmacy in the we primarily sell our vaccine product directly to the federal government cdc wholesaler individual provider office retail pharmacy and integrated delivery network outside the we primarily sell our vaccine to government and non government institution prescription pharmaceutical product that ultimately are used by patient are generally covered under governmental program managed care program and insurance program including those managed through pbms and are subject to sale allowance and or rebate payable directly to those program those sale allowance and rebate are generally negotiated but government program may have legislated amount by type of product patented or unpatented specifically in the we sell our product principally to distributor and hospital we also have contract with managed care program or pbms and legislatively mandated contract with the federal and state government under which we provide rebate based on medicine utilized by the life they cover we record provision for medicare medicaid and performance based contract pharmaceutical rebate based upon our experience ratio of rebate paid and actual prescription written during prior period we apply the experience ratio to the respective period sale to determine the rebate accrual and related expense this experience ratio is evaluated regularly to ensure that the historical trend are current practicable we estimate discount on branded prescription drug sale to medicare part participant in the medicare coverage gap also known the doughnut hole based on the historical experience of beneficiary prescription and consideration of the utilization that is expected to result from the discount in the coverage gap we evaluate this estimate regularly to ensure that the historical trend and future expectation are current practicable for performance based contract rebate we also consider current contract term such change in formulary status and rebate rate outside the the majority of our pharmaceutical sale allowance are contractual or legislatively mandated and our estimate are based on actual invoiced sale within each period which reduces the risk of variation in the estimation process in certain european country rebate are calculated on the government total unbudgeted pharmaceutical spending or on specific product sale threshold and we apply an estimated allocation factor against our actual invoiced sale to project the expected level of reimbursement we obtain third party information that help to monitor the adequacy of these accrual provision for pharmaceutical chargebacks primarily reimbursement to wholesaler for honoring contracted price and legislated discount to third party closely approximate actual amount incurred we settle these deduction generally within two to five week of incurring the liability we recorded direct product sale and or alliance revenue of more than billion for each of nine product in for each of seven product in and for each of six product in in the aggregate these direct product sale and or alliance product revenue represented of our revenue in of our revenue in and of our revenue in see note for additional information the loss or expiration of intellectual property right can have significant adverse effect on our revenue our contract with customer will generally be at lower selling price and lower volume due to added generic competition we generally provide for higher sale return during the period in which individual market begin to near the loss or expiration of intellectual property right pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesour accrual for medicare medicaid and related state program and performance based contract rebate chargebacks sale allowance and sale return and cash discount are follows of december million against trade account receivable le allowance for doubtful account other current liability accrued other other noncurrent total accrued rebate and other sale related accrual tax collected from customer relating to product sale and remitted to governmental authority are excluded from revenue trade account receivable trade account receivable are stated at their net realizable value the allowance for credit loss reflects our best estimate of expected credit loss of the receivables portfolio determined on the basis of historical experience current information and forecast of future economic condition in developing the estimate for expected credit loss trade account receivables are segmented into pool of asset depending on market versus international delinquency status and customer type high risk versus low risk and government versus non government and fixed reserve percentage are established for each pool of trade account receivables in determining the reserve percentage for each pool of trade account receivables we considered our historical experience with certain customer and customer type regulatory and legal environment country and political risk and other relevant current and future forecasted macroeconomic factor these credit risk indicator are monitored on quarterly basis to determine whether there have been any change in the economic environment that would indicate the established reserve percentage should be adjusted and are considered on regional basis to reflect more geographic specific metric additionally write offs and recovery of customer receivables are tracked against collection on quarterly basis to determine whether the reserve percentage remain appropriate when management becomes aware of certain customer specific factor that impact credit risk specific allowance for these known troubled account are recorded trade account receivable are written off after all reasonable mean to collect the full amount including litigation where appropriate have been exhausted during and addition to the allowance for credit loss write offs and recovery of customer receivables were not material to our consolidated financial statement collaborative arrangementspayments to and from our collaboration partner are presented in our consolidated statement of income based on the nature of the arrangement including it contractual term the nature of the payment and applicable accounting guidance under co promotion agreement we record the amount received for our share of gross profit from our collaboration partner alliance revenue component of revenue when our collaboration partner are the principal in the transaction and we receive share of their net sale or profit alliance revenue are recorded we perform co promotion activity for the collaboration and the collaboration partner sell the product to their customer the related expense for selling and marketing these product including reimbursement to or from our collaboration partner for these cost are included in selling informational and administrative expense in collaborative arrangement where we manufacture product for our collaboration partner we record revenue when we transfer control of the product to our collaboration partner in collaboration arrangement where we are the principal in the transaction we record amount paid to collaboration partner for their share of net sale or profit earned and all royalty payment to collaboration partner cost of sale royalty payment received from collaboration partner are included in other income deduction net reimbursement to or from our collaboration partner for development cost are typically recorded in research and development expense upfront payment and pre approval milestone payment due from to our collaboration partner in development stage collaboration are recorded research and development expense milestone payment due from to our collaboration partner after regulatory approval ha been attained for medicine are recorded in identifiable intangible asset developed technology right upfront and pre approval milestone payment earned from our collaboration partner by are recognized in other income deduction net over the development period for the product when our performance obligation include providing service to our collaboration partner upfront pre approval and post approval milestone payment earned by may be recognized in other income deduction net immediately when earned or over other period depending upon the nature of our performance obligation in the applicable collaboration where the milestone event is regulatory approval for medicine we generally recognize milestone payment due to in the transaction price when regulatory approval in the applicable jurisdiction ha been attained we may recognize milestone payment due to in the transaction price earlier than the milestone event in certain circumstance when recognition of the income would not be probable of significant reversal cost of sale and inventoriesinventories are recorded at the lower of cost or net realizable value the cost of finished good work in process and raw material is determined using average actual cost we regularly review our inventory for impairment and reserve are established when necessary selling informational and administrative expensesselling informational and administrative cost are expensed incurred among other thing these expense include the internal and external cost of marketing advertising shipping and handling information technology and legal defense advertising expense totaled approximately billion in billion in and billion in production cost are expensed incurred and the cost of tv radio and other electronic medium and publication are expensed when the related advertising occurs pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesl research and development expensesr cost are expensed incurred these expense include the cost of our proprietary effort well cost incurred in connection with certain licensing arrangement before compound receives regulatory approval we record upfront and milestone payment we make to third party under licensing arrangement expense upfront payment are recorded when incurred and milestone payment are recorded when the specific milestone ha been achieved once compound receives regulatory approval we record any milestone payment in identifiable intangible asset le accumulated amortization and unless the asset is determined to have an indefinite life we typically amortize the payment on straight line basis over the remaining agreement term or the expected product life cycle whichever is shorter amortization of intangible asset depreciation and certain long lived assetslong lived asset include property plant and equipment le accumulated depreciation these asset are recorded at cost including any significant improvement after purchase le accumulated depreciation property plant and equipment asset other than land and construction in progress are depreciated on straight line basis over the estimated useful life of the individual asset depreciation begin when the asset is ready for it intended use for tax purpose accelerated depreciation method are used allowed by tax law identifiable intangible asset le accumulated amortization these asset are recorded at fair value at acquisition intangible asset with finite life are amortized on straight line basis over their estimated useful life intangible asset with indefinite life are not amortized until useful life can be determined goodwill goodwill represents the excess of the consideration transferred for an acquired business over the assigned value of it net asset goodwill is not amortized amortization of finite lived acquired intangible asset that contribute to our ability to sell manufacture research market and distribute product compound and intellectual property is included in amortization of intangible asset these intangible asset benefit multiple business function amortization of intangible asset that are for single function and depreciation of property plant and equipment are included in cost of sale selling informational and administrative expense and or research and development expense appropriate we review our long lived asset for impairment indicator throughout the year we perform impairment testing for indefinite lived intangible asset and goodwill at least annually and for all other long lived asset whenever impairment indicator are present when necessary we record impairment of long lived asset for the amount by which the fair value is le than the carrying value of these asset specifically for finite lived intangible asset such developed technology right and for other long lived asset such property plant and equipment whenever impairment indicator are present we calculate the undiscounted value of the projected cash flow for the asset or asset group and compare this estimated amount to the carrying amount if the carrying amount is greater we record an impairment loss for the excess of book value over fair value in addition in all case of an impairment review we reevaluate the remaining useful life of the asset and modify them appropriate for indefinite lived intangible asset such brand and ipr asset when necessary we determine the fair value of the asset and record an impairment loss if any for the excess of book value over fair value in addition in all case of an impairment review other than for ipr asset we re evaluate whether continuing to characterize the asset indefinite lived is appropriate for goodwill when necessary we determine the fair value of each reporting unit and record an impairment loss if any for the excess of the book value of the reporting unit over the implied fair value restructuring charge and other cost associated with acquisition and cost reduction productivity initiativeswe may incur restructuring charge in connection with acquisition when we implement plan to restructure and integrate the acquired operation or in connection with our cost reduction and productivity initiative in connection with acquisition activity we typically incur cost associated with executing the transaction integrating the acquired operation which may include expenditure for consulting and the integration of system and process and restructuring the combined company which may include charge related to employee asset and activity that will not continue in the combined company and in connection with our cost reduction productivity initiative we typically incur cost and charge for site closing and other facility rationalization action workforce reduction and the expansion of shared service including the development of global system included in restructuring charge and certain acquisition related cost are all restructuring charge well certain other cost associated with acquiring and integrating an acquired business if the restructuring action result in change in the estimated useful life of an asset that incremental impact is classified in cost of sale selling informational and administrative expense and or research and development expense appropriate employee termination cost are generally recorded when the action are probable and estimable and include accrued severance benefit pension and postretirement benefit many of which may be paid out during period after termination transaction cost such banking legal accounting and other similar cost incurred in connection with business acquisition are expensed incurred our business and platform function may be impacted by these action including sale and marketing manufacturing and well our corporate enabling function such digital global real estate operation legal finance human resource worldwide public affair compliance and worldwide procurement cash equivalent and statement of cash flowscash equivalent include item almost liquid cash such certificate of deposit and time deposit with maturity period of three month or le when purchased if item meeting this definition are part of larger investment pool we classify them short term investment pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiescash flow for financial instrument designated fair value or cash flow hedge may be included in operating investing or financing activity depending on the classification of the item being hedged cash flow for financial instrument designated net investment hedge are classified according to the nature of the hedging instrument cash flow for financial instrument that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature investment and derivative financial instrumentsthe classification of an investment depends on the nature of the investment our intent and ability to hold the investment and the degree to which we may exercise influence our investment are primarily comprised of the following public equity security with readily determinable fair value which are carried at fair value with change in fair value reported in other income deduction net available for sale debt security which are carried at fair value with change in fair value reported in other comprehensive income loss until realized held to maturity debt security which are carried at amortized cost private equity security without readily determinable fair value and where we have no significant influence are measured at cost minus any impairment and plus or minus change resulting from observable price change in orderly transaction for the identical or similar investment of the same issuer for equity investment in common stock or in substance common stock where we have significant influence over the financial and operating policy of the investee we use the equity method of accounting under the equity method we record our share of the investee income and expense in other income deduction net the excess of the cost of the investment over our share of the underlying equity in the net asset of the investee of the acquisition date is allocated to the identifiable asset and liability of the investee with any remaining excess amount allocated to goodwill such investment are initially recorded at cost which is the fair value of consideration paid and typically doe not include contingent consideration realized gain or loss on sale of investment are determined by using the specific identification cost method we regularly evaluate all of our financial asset for impairment for investment in debt and equity when decline in fair value if any is determined an impairment charge is recorded and new cost basis in the investment is established derivative financial instrument are carried at fair value in various balance sheet category see note with change in fair value reported in net income or for derivative financial instrument in certain qualifying hedging relationship in other comprehensive income loss see note tax asset and liability and income tax contingenciestax asset and liabilitiescurrent tax asset primarily include tax effect for intercompany transfer of inventory within our combined group which are recognized in the consolidated statement of income when the inventory is sold to third party and ii income tax receivables that are expected to be recovered either via refund from taxing authority or reduction to future tax obligation deferred tax asset and liability are recognized for the expected future tax consequence of difference between the financial reporting and tax base of asset and liability using enacted tax rate and law we provide valuation allowance when we believe that our deferred tax asset are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing prudent and feasible tax planning strategy that would be implemented if necessary to realize the deferred tax asset amount recorded for valuation allowance requires judgment about future income which can depend heavily on estimate and assumption all deferred tax asset and liability within the same tax jurisdiction are presented net amount in the noncurrent section of our consolidated balance sheet the tcja subject shareholder to current tax on global intangible low taxed income earned by certain foreign subsidiary the fasb staff topic no accounting for global intangible low taxed income state that we are permitted to make an accounting policy election to either recognize deferred tax for temporary basis difference expected to reverse global intangible low taxed income in future year or provide for the tax expense related to such income in the year the tax is incurred we elected to recognize deferred tax for temporary difference expected to reverse global intangible low taxed income in future year other non current tax asset primarily represent our estimate of the potential tax benefit in one tax jurisdiction that could result from the payment of income tax in another tax jurisdiction these potential benefit generally result from cooperative effort among taxing authority required by tax treaty to minimize double taxation commonly referred to the competent authority process the recoverability of these asset which we believe to be more likely than not is dependent upon the actual payment of tax in one tax jurisdiction and in some case the successful petition for recovery in another tax jurisdiction other tax payable of december and include liability for uncertain tax position and the noncurrent portion of the repatriation tax liability for which we elected payment over eight year through for additional information see note for uncertain tax position and note for the repatriation tax liability and other estimate and assumption in connection with the tcja income tax contingencieswe account for income tax contingency using benefit recognition model if we consider that tax position is more likely than not to be sustained upon audit based solely on the technical merit of the position we recognize all or portion of the benefit we measure the benefit by determining the amount that is greater than likely of being realized upon settlement presuming that the tax position is examined by the taxing authority with full knowledge of all relevant information pfizer inc form to consolidated financial statementspfizer inc and subsidiary companieswe regularly monitor our position and subsequently recognize the unrecognized tax benefit if there are change in tax law analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merit of the position to more likely than not ii if the statute of limitation expires or iii if there is completion of an audit resulting in favorable settlement of that tax year with the appropriate agency liability for uncertain tax position are classified current only when we expect to pay cash within the next month interest and penalty if any are recorded in provision benefit for tax on income and are classified on our consolidated balance sheet with the related tax liability our assessment are based on estimate and assumption that have been deemed reasonable by management but our estimate of unrecognized tax benefit and potential tax benefit may not be representative of actual outcome and variation from such estimate could materially affect our financial statement in the period of settlement or when the statute of limitation expire we treat these event discrete item in the period of resolution pension and postretirement benefit plansthe majority of our employee worldwide are covered by defined benefit pension plan defined contribution plan or both in the we have both irc qualified and supplemental non qualified defined benefit plan and defined contribution plan well other postretirement benefit plan consisting primarily of medical insurance for retiree and their eligible dependent we recognize the overfunded or underfunded status of each of our defined benefit plan an asset or liability the obligation are generally measured at the actuarial present value of all benefit attributable to employee service rendered provided by the applicable benefit formula our pension and other postretirement obligation may be determined using assumption such discount rate expected annual rate of return on plan asset expected employee turnover and participant mortality for our pension plan the obligation may also include assumption to future compensation level for our other postretirement benefit plan the obligation may include assumption to the expected cost of providing medical insurance benefit well the extent to which those cost are shared with the employee or others such governmental program plan asset are measured at fair value net periodic pension and postretirement benefit cost other than the service cost are recognized in other income deduction net legal and environmental contingencieswe and certain of our subsidiary are subject to numerous contingency arising in the ordinary course of business such patent litigation product liability and other product related litigation commercial litigation environmental claim and proceeding government investigation and guarantee and indemnification in assessing contingency related to legal and environmental proceeding that are pending against the company or unasserted claim that are probable of being asserted we record accrual for these contingency to the extent that we conclude that loss is both probable and reasonably estimable if some amount within range of loss appears to be better estimate than any other amount within the range we accrue that amount alternatively when no amount within range of loss appears to be better estimate than any other amount we accrue the lowest amount in the range we record anticipated recovery under existing insurance contract when recovery is assured share based paymentsour compensation program can include share based payment generally grant under share based payment program are accounted for at fair value and these fair value are generally amortized on straight line basis over the vesting term with the related cost recorded in cost of sale selling informational and administrative expense and or research and development expense appropriate note acquisition divestiture equity method investment licensing arrangement and collaborative arrangementsa acquisitionstrilliumon november we acquired all of the issued and outstanding common stock not already owned by pfizer of trillium clinical stage immuno oncology company developing therapy targeting cancer immune evasion pathway and specific cell targeting approach for price of per share in cash for total consideration of billion net of cash acquired result trillium became our wholly owned subsidiary we previously held ownership investment in trillium trillium lead program tti is an investigational fusion protein that is designed to block the inhibitory activity of molecule that is overexpressed by wide variety of tumor we accounted for the transaction an asset acquisition since the lead asset tti represented substantially all of the fair value of the gross asset acquired which exclude cash acquired at the acquisition date we recorded billion charge representing an acquired ipr asset with no alternative future use in research and development expense of which the billion net cash consideration is presented cash outflow from operating activity in connection with this acquisition we recorded million of asset acquired primarily consisting of cash and investment liability assumed were approximately million arrayon july we acquired array commercial stage biopharmaceutical company focused on the discovery development and commercialization of targeted small molecule medicine to treat cancer and other disease of high unmet need for per share in cash the total fair value of the consideration transferred wa billion billion net of cash acquired in addition million in payment to array employee for the fair value of previously unvested stock option wa recognized post closing compensation expense and recorded in restructuring charge and certain acquisition related cost see note we financed the majority of the transaction with debt and the balance with existing cash pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesarray portfolio includes braftovi encorafenib and mektovi binimetinib broad pipeline of targeted cancer medicine in different stage of well portfolio of out licensed medicine which may generate milestone and royalty over time the final allocation of the consideration transferred to the asset acquired and the liability assumed wa completed in in connection with this acquisition we recorded billion in identifiable intangible asset consisting of billion of developed technology right with useful life of year billion of ipr and billion of licensing agreement and other billion for technology in development indefinite lived licensing agreement and million for developed technology finite lived licensing agreement with useful life of year ii billion of goodwill iii billion of net deferred tax liability and iv million of assumed long term debt which wa paid in full in in we recorded measurement period adjustment to the estimated fair value initially recorded in which resulted in reduction in identifiable intangible asset of approximately million with corresponding change to goodwill and net deferred tax liability the measurement period adjustment were recorded to better reflect market participant assumption about fact and circumstance existing of the acquisition date and did not have material impact on our consolidated statement of income for the year ended december therachonon july we acquired all the remaining share of therachon privately held clinical stage biotechnology company focused on rare disease with asset in development for the treatment of achondroplasia genetic condition and the most common form of short limb dwarfism for million upfront plus potential milestone payment of up to million contingent on the achievement of key milestone in the development and commercialization of the lead asset we accounted for the transaction an asset acquisition since the lead asset represented substantially all the fair value of the gross asset acquired the total fair value of the consideration transferred for therachon wa million which consisted of million of cash and our previous million investment in therachon in connection with this asset acquisition we recorded charge of million in research and development expense divestituresmeridianon december we completed the sale of our meridian subsidiary for approximately million in cash and recognized loss of approximately million net of tax in discontinued operation net of tax in connection with the sale pfizer and the purchaser of meridian entered into various agreement to provide framework for our relationship after the sale including interim tsa and manufacturing supply agreement msa the tsa primarily involve pfizer providing service related to information technology among other activity and are generally expected to be for term of no more than to month post sale the msa is for term of three year post sale with two year extension period no amount were recorded under the above arrangement in upjohn separation and combination with mylanon november we completed the spin off and the combination of the upjohn business with mylan the transaction to form viatris the transaction were structured an all stock reverse morris trust transaction specifically we contributed the upjohn business to wholly owned subsidiary which wa renamed viatris so that the upjohn business wa separated from the remainder of our business the separation ii following the separation we distributed on pro rata basis all of the share of viatris common stock held by pfizer to pfizer stockholder of the november record date such that each pfizer stockholder of the record date received approximately share of viatris common stock per share of pfizer common stock the distribution and iii immediately after the distribution the upjohn business combined with mylan in series of transaction in which mylan shareholder received one share of viatris common stock for each mylan ordinary share held by such shareholder subject to any applicable withholding tax the combination prior to the distribution viatris made cash payment to pfizer equal to billion partial consideration for the contribution of the upjohn business to viatris of the closing of the combination pfizer stockholder owned approximately of the outstanding share of viatris common stock and mylan shareholder owned approximately of the outstanding share of viatris common stock in each case on fully diluted converted and exercised basis the transaction are generally expected to be tax free to pfizer and pfizer stockholder for tax purpose beginning november viatris operates both the upjohn business and mylan an independent publicly traded company which is traded under the symbol vtrs on the nasdaq in connection with the transaction in june upjohn inc and upjohn finance completed privately placed debt offering of billion and billion aggregate principal amount respectively approximately billion of senior unsecured note and entered into other financing arrangement including million delayed draw term loan agreement and revolving credit facility agreement for up to billion proceeds from the debt offering and other financing arrangement were used to fund the billion cash distribution viatris made to pfizer prior to the distribution we used the cash distribution proceeds to pay commercial paper borrowing and redeem the billion aggregate principal amount outstanding of our senior unsecured note that were due in june and million aggregate principal amount outstanding of our senior unsecured note that were due in august before the maturity date interest expense for the billion in debt security incurred during is included in discontinued operation net of tax following the separation and combination of the upjohn business with mylan we are no longer the obligor or guarantor of any upjohn debt or upjohn financing arrangement result of the spin off of the upjohn business we distributed net asset of billion of november which wa reflected reduction to retained earnings and reflects the change in accounting principle in the first quarter of to mtm accounting see note of this amount million represents cash transferred to the upjohn business with the remainder considered non cash activity in the consolidated statement of cash flow for the year ended december the spin off also resulted in net increase to accumulated other comprehensive loss of million for the derecognition of net gain on foreign currency translation adjustment of million and prior service net credit associated with benefit plan of million which were reclassified to retained earnings result of the separation of upjohn we incurred separation related cost of million in and million in which are included in discontinued operation net of tax these cost primarily relate to professional fee for regulatory filing and separation activity within finance tax legal and information system function well investment banking fee pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesin connection with the transaction pfizer and viatris entered into various agreement to effect the separation and combination to provide framework for our relationship after the combination including separation and distribution agreement interim operating model including agency arrangement msas tsa tax matter agreement and an employee matter agreement among others the interim agency operating model arrangement primarily include billing collection and remittance of rebate that we are performing on transitional basis on behalf of viatris under the msas pfizer or viatris the case may be manufacture label and package product for the other party the term of the msas range in initial duration from four to seven year post separation the tsa primarily involve pfizer providing service to viatris related to finance information technology and human resource infrastructure and are generally expected to be for term of no more than three year post separation the amount recorded under the above agreement were not material to our consolidated result of operation in and in addition pfizer and mylan had pre existing arm length commercial agreement which is continuing with viatris and is not material to pfizer consolidated financial statement net amount due from viatris under the above agreement were million of december and million of december the cash flow associated with the above agreement are included in net cash provided by operating activity from continuing operation except for million payment to viatris made in pursuant to term of the separation agreement which is reported in other financing activity net and wa recorded payable to viatris in other current liability of december component of discontinued operation net of tax year ended december million cost and expense cost of selling informational and administrative research and development amortization of intangible asset restructuring charge and certain acquisition related other income deduction pre tax income loss from discontinued operation provision benefit for tax on income income loss from discontinued operation net of tax pre tax loss on sale of discontinued operation benefit for tax on income loss on sale of discontinued operation net of tax discontinued operation net of tax in discontinued operation net of tax primarily includes the operation of meridian prior to it sale on december recognized in income loss from discontinued operation net of tax which includes pre tax amount for multi district litigation relating to epipen against the company in the district court for the district of kansa for million and ii the after tax loss of million related to the sale of meridian recognized in loss on sale of discontinued operation net of tax to much lesser extent discontinued operation net of tax in also includes the operation of the mylan japan collaboration prior to it termination on december and post closing adjustment directly related to our former upjohn and nutrition discontinued business including adjustment for tax benefit and legal related matter recognized in income loss from discontinued operation net of tax in and discontinued operation net of tax relates to the operation of the upjohn business meridian and the mylan japan collaboration and includes the change in accounting principle in the first quarter of to mtm accounting see note in discontinued operation net of tax includes pre tax interest expense of million associated with the dollar and euro denominated senior unsecured note issued by upjohn inc and upjohn finance in the second quarter of and pre tax charge of million related to the remeasurement of euro debt issued by upjohn finance in the second quarter of component of asset and liability of discontinued operation and other asset held for sale of december million asset of discontinued operation and other asset held for sale other current asset property plant and equipment identifiable intangible asset other noncurrent asset noncurrent asset of discontinued operation other noncurrent asset current liability of discontinued operation other current liability noncurrent liability of discontinued operation other noncurrent liability amount of december represent property plant and equipment held for sale amount of december primarily relate to discontinued operation of our former meridian subsidiary and the mylan japan collaboration pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesc equity method investmentsformation of consumer healthcare jvon july we completed transaction in which we and gsk combined our respective consumer healthcare business into new jv that operates globally under the gsk consumer healthcare name in exchange we received equity stake in the new company and gsk owns the remaining upon closing we deconsolidated our consumer healthcare business and recognized pre tax gain of billion billion net of tax in the third quarter of in gain on completion of consumer healthcare jv transaction for the difference in the fair value of our equity stake and the carrying value of our consumer healthcare business our financial result and our consumer healthcare segment operating result for reflect seven month of consumer healthcare segment domestic operation and eight month of consumer healthcare segment international operation the financial result for and do not reflect any contribution from the consumer healthcare business in valuing our investment in the consumer healthcare jv we used discounted cash flow technique some of the more significant estimate and assumption inherent in this approach include the amount and timing of the projected net cash flow which include the expected impact of competitive legal or regulatory force on the product the long term growth rate which seek to project the sustainable growth rate over the long term the discount rate which seek to reflect our best estimate of the various risk inherent in the projected cash flow and the tax rate which seek to incorporate the geographic diversity of the projected cash flow we are accounting for our interest in the consumer healthcare jv an equity method investment the carrying value of our investment in the consumer healthcare jv is billion of december and billion of december and is reported private equity investment in equity method investment of december and the consumer healthcare jv is foreign investee whose reporting currency is the pound and therefore we translate it financial statement into dollar and recognize the impact of foreign currency translation adjustment in the carrying value of our investment and in other comprehensive income the decrease in the value of our investment from december to december is primarily due to dividend totaling million well million in pre tax foreign currency translation adjustment see note partially offset by our share of the jv earnings we record our share of earnings from the consumer healthcare jv on quarterly basis on one quarter lag in other income deduction net commencing from august our total share of the jv earnings generated in the fourth quarter of and the first nine month of which we recorded in our operating result in wa million our total share of the jv earnings generated in the fourth quarter of and the first nine month of which we recorded in our operating result in wa million our total share of two month of the jv earnings generated in the third quarter of which we recorded in our operating result in the fourth quarter of wa million of the july closing date we estimated that the fair value of our investment in the consumer healthcare jv wa billion and that of the underlying equity in the carrying value of the net asset of the consumer healthcare jv wa billion resulting in an initial basis difference of approximately billion in the fourth quarter of we preliminarily completed the allocation of the basis difference which resulted from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net asset of the jv primarily to inventory definite lived intangible asset indefinite lived intangible asset related deferred tax liability and equity method goodwill within the investment account during the fourth quarter of the consumer healthcare jv revised the initial carrying value of the net asset of the jv and our share of the underlying equity in the carrying value of the net asset of the consumer healthcare jv wa reduced to billion and our initial basis difference wa increased to billion the adjustment wa allocated to equity method goodwill within the investment account we began recording the amortization of basis difference allocated to inventory definite lived intangible asset and related deferred tax liability in other income deduction net commencing august the total amortization and adjustment of basis difference resulting from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net asset of the jv is included in other income deduction net and wa not material to our result of operation in the period presented see note amortization of basis difference on inventory and related deferred tax liability wa completely recognized by the second quarter of basis difference on definite lived intangible asset and related deferred tax liability are being amortized over the life of the underlying asset which range from to year part of pfizer in pre tax income on management basis for the consumer healthcare business wa million through july summarized financial information for our equity method investee the consumer healthcare jv of september the most recent period available and of september and for the period ending september and is follows million september asset noncurrent total asset current liability noncurrent total liability equity attributable to shareholder equity attributable to noncontrolling total net equity pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesfor the twelve month endingfor the two month ending million september sale cost of sale gross profit income from continuing net income attributable to investment in viivin we and gsk created viiv which is focused on research development and commercialization of human immunodeficiency virus hiv medicine we own approximately of viiv and prior to we accounted for our investment under the equity method due to the significant influence that we have over the operation of viiv through our board representation and minority veto right we suspended application of the equity method to our investment in viiv in when the carrying value of our investment wa reduced to zero due to the recognition of cumulative equity method loss and dividend since we have recognized dividend from viiv income in other income deduction net when earned including dividend of million in million in and million in see note summarized financial information for our equity method investee viiv of december and and for the year ending december and is follows of december million asset noncurrent total asset current liability noncurrent total liability total net equity deficit attributable to shareholder year ended december million sale cost of sale gross profit income from continuing net income attributable to licensing arrangementsagreement with valnevaon april we signed an agreement to co develop and commercialize valneva lyme disease vaccine candidate which cover six serotypes that are prevalent in north america and europe valneva and pfizer will work closely together throughout the development of valneva is eligible to receive total of up to million in cash payment from consisting of million upfront payment which wa paid and recorded in research and development expense in our second quarter of well million in development milestone and million in early commercialization milestone under the term of the agreement valneva will fund of all development cost through completion of the development program and in return we will pay valneva tiered royalty we will lead late stage development and have sole control over commercialization agreement with akceaon october we entered into worldwide exclusive licensing agreement for akcea lrx an investigational antisense therapy being developed to treat patient with certain cardiovascular and metabolic disease with akcea wholly owned subsidiary of ionis the transaction closed in november and we made an upfront payment of million to akcea which wa recorded in research and development expense in our fourth quarter of on january we and ionis announced the discontinuation of the pfizer led clinical development program for the licensed product and that we would be returning the right to the licensed product to ionis pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiese collaborative arrangementswe enter into collaborative arrangement with respect to in line medicine well medicine in development that require completion of research and regulatory approval collaborative arrangement are contractual agreement with third party that involve joint operating activity typically research and or commercialization effort where both we and our partner are active participant in the activity and are exposed to the significant risk and reward of the activity our right and obligation under our collaborative arrangement vary for example we have agreement to co promote pharmaceutical product discovered by or other company and we have agreement where we partner to co develop and or participate together in commercializing marketing promoting manufacturing and or distributing drug product collaboration with beamon december we entered into multi year research collaboration with beam to utilize beam in vivo base editing program which use mrna and lipid nanoparticles for three target for rare genetic disease of the liver muscle and central nervous system under the term of the agreement beam conduct all research activity through development candidate selection for three undisclosed target which are not included in beam existing program and we may opt in to obtain exclusive license to each development candidate beam ha right to opt in at the end of phase study upon the payment by beam of an option exercise fee to global co development and co commercialization agreement with respect to one program licensed under the collaboration pursuant to which we and beam would share net profit well development and commercialization cost in ratio pfizer beam upon entering into the agreement we recorded million in research and development expense in the fourth quarter of for an upfront payment due to beam and if we exercise our opt in to license for all three target beam would be eligible for up to an additional billion in development regulatory and commercial milestone payment for potential total deal consideration of up to billion beam is also eligible to receive royalty on global net sale for each licensed program collaboration with arvinason july we entered into global collaboration with arvinas to develop and commercialize arv an investigational oral protac proteolysis targeting chimera estrogen receptor protein degrader the estrogen receptor is well known disease driver in most breast cancer in connection with the agreement we made an upfront cash payment of million to arvinas and we made million equity investment in the common stock of arvinas we recognized million for the upfront payment and premium paid on our equity investment in research and development expense in our third quarter of arvinas is also eligible to receive up to million in approval milestone and up to billion in commercial milestone the company will equally share worldwide development cost commercialization expense and profit of december we held equity stake of arvinas collaboration with myovanton december we entered into collaboration with myovant to jointly develop and commercialize orgovyx relugolix in advanced prostate cancer and myfembree relugolix mg estradiol mg and norethindrone acetate mg in woman health in the and canada we also received an exclusive option to commercialize relugolix in oncology outside the and canada excluding certain asian country which we declined to exercise under the term of the agreement the company will equally share profit and allowable expense for orgovyx and myfembree in the and canada with myovant bearing our share of allowable expense up to maximum of million in and up to maximum of million in we record our share of gross profit alliance revenue myovant remains responsible for regulatory interaction and drug supply and continues to lead clinical development for myfembree myovant is entitled to receive up to billion including an upfront payment of million which wa made in december million in potential regulatory milestone for fda approval for myfembree in woman health of which million wa paid to myovant in july and recognized identifiable intangible asset developed technology right and tiered sale milestone of up to billion in total for prostate cancer and for the combined woman health indication in connection with this transaction in we recognized million in identifiable intangible asset developed technology right and million in research and development expense representing the relative fair value of the portion of the upfront payment allocated to the approved indication and unapproved indication of the product respectively collaboration with cstoneon september we entered into strategic collaboration with cstone to address oncological need in china the collaboration encompasses our million upfront equity investment in cstone the development and commercialization of cstone sugemalimab pd antibody in mainland china and framework between the company to bring additional oncology asset to the greater china market the transaction closed on october of december we held equity stake of cstone collaboration with biontechon december we entered into new research development and commercialization agreement to develop potential first mrna based vaccine for the prevention of shingle herpes zoster virus based on biontech proprietary mrna technology and our antigen technology under the term of the agreement we agreed to pay biontech million including an upfront cash payment of million and an equity investment of million biontech is eligible to receive future regulatory and sale milestone payment of up to million in return biontech agreed to pay million for our proprietary antigen technology the net upfront payment to biontech wa recorded to research and development expense in our fourth quarter of we and biontech will share development cost we will have commercialization right to the potential vaccine worldwide excluding germany turkey and certain developing country where biontech will have commercialization right we and biontech will share gross profit from commercialization of any product on april we signed global agreement with biontech to co develop mrna based coronavirus vaccine program aimed at preventing covid infection in connection with the april agreement we made an upfront cash payment of million and an equity investment in the common stock of biontech of million we recognized million for the upfront payment and premium paid on the equity investment in research and development expense in our second quarter of biontech became eligible to receive potential milestone payment of up to million for total consideration of million under the term of this agreement we and biontech share gross profit and development cost equally after approval and successful commercialization of the vaccine and we were responsible for all of pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesthe development cost until commercialization of the vaccine thereafter biontech wa to repay it percent share of these development cost through reduction in gross profit sharing and milestone payment to biontech over time on january we and biontech signed an amended version of the april agreement under the january agreement biontech paid their percent share of prior development cost in lump sum payment during the first quarter of further cost are being shared equally we have commercialization right to the vaccine worldwide excluding germany and turkey where biontech market and distributes the vaccine under the agreement with and excluding china hong kong macau and taiwan which are subject to separate collaboration between biontech and shanghai fosun pharmaceutical group co ltd we recognize revenue and cost of sale on gross basis in market where we are commercializing the vaccine and we record our share of gross profit related to sale of the vaccine by biontech in germany and turkey in alliance revenue we made an additional investment of million in common stock of biontech part of an underwritten equity offering by biontech which closed in july of december we held an equity stake of of biontech summarized financial information for collaborative arrangementsthe following provides the amount and classification of payment income expense between and our collaboration partner year ended december million revenue revenue alliance revenue total revenue from collaborative arrangement cost of sale selling informational and administrative expense research and development expense other income deduction net represents sale to our partner of product manufactured by substantially all relates to amount earned from our partner under co promotion agreement the increase in reflects increase in alliance revenue from comirnaty eliquis and xtandi while the increase in reflects increase in alliance revenue from eliquis and xtandi primarily relates to amount paid to collaboration partner for their share of net sale or profit earned in collaboration arrangement where we are the principal in the transaction and cost of sale for inventory purchased from our partner the increase in is primarily related to comirnaty represents net reimbursement to our partner for selling informational and administrative expense incurred primarily relates to upfront payment and pre approval milestone payment earned by our partner well net reimbursement primarily relates to royalty from our collaboration partner the amount outlined in the above table do not include transaction with third party other than our collaboration partner or other cost for the product under the collaborative arrangement note restructuring charge and other cost associated with acquisition and cost reduction productivity initiativesin we substantially completed several multi year initiative focused on positioning for future growth and creating simpler more efficient operating structure within each business transforming to more focused company programwith the formation of the consumer healthcare jv in and the spin off of our upjohn business in the fourth quarter of pfizer ha transformed into more focused global leader in science based innovative medicine and vaccine we have undertaken effort to ensure our cost base and support model align appropriately with our new operating structure while certain direct cost transferred to the consumer healthcare jv and to the upjohn business in connection with the spin off there are indirect cost which did not transfer this program is primarily composed of the following three initiative we are taking step to restructure our corporate enabling function to appropriately support our business and pgs platform function we expect cost primarily related to restructuring our corporate enabling function to total billion with substantially all cost to be cash expenditure action include among others change in location of certain activity expanded use and co location of center of excellence and shared service and increased use of digital technology the associated action and the specific cost will primarily include severance and benefit plan impact exit cost well associated implementation cost in addition we are transforming our commercial go to market model in the way we engage patient and physician we expect cost of billion with substantially all cost to be cash expenditure action include among others centralization of certain activity and enhanced use of digital technology the cost for this effort primarily include severance and associated implementation cost we are also optimizing our manufacturing network under this program and incurring one time cost for cost reduction initiative related to our manufacturing operation we expect to incur cost of million with approximately of the cost to be non cash the cost for this effort include among other thing severance cost implementation cost product transfer cost site exit cost well accelerated depreciation the program cost discussed above are expected to be incurred primarily from through and may be rounded and represent approximation from the start of this program in the fourth quarter of through december we incurred cost of billion of which million is associated with biopharma million in million in and million in pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesb key activitiesin and we incurred cost of billion and million respectively composed primarily of the transforming to more focused company program in we incurred cost of million composed of million for the and organizing for growth initiative million for the integration of array million for the integration of hospira and million for the transforming to more focused company program partially offset by income of million primarily due to the reversal of certain accrual upon the effective favorable settlement of an irs audit for multiple tax year and other acquisition related initiative the following summarizes acquisition and cost reduction productivity initiative cost and credit year ended december million charge credit employee termination asset exit cost credit restructuring charge credit transaction cost integration cost and other restructuring charge and certain acquisition related net periodic benefit cost credit recorded in other income deduction net additional depreciation asset restructuring recorded in our consolidated statement of income follows cost of selling informational and administrative research and development expense total additional depreciation asset implementation cost recorded in our consolidated statement of income follows cost of selling informational and administrative research and development total implementation total cost associated with acquisition and cost reduction productivity initiative represents acquisition related cost million credit in and million credit in and cost reduction initiative million charge in million charge in and million charge in and charge mainly represent employee termination cost for our transforming to more focused company cost reduction program restructuring charge mainly represent employee termination cost for cost reduction and productivity initiative partially offset by the reversal of certain accrual related to our acquisition of wyeth upon the effective favorable settlement of an irs audit for multiple tax year see note the employee termination cost for were primarily for our improvement to operational effectiveness part of the realignment of our business structure and also included employee termination cost for the transforming to more focused company cost reduction program represents external cost for banking legal accounting and other similar service represents external incremental cost directly related to integrating acquired business such expenditure for consulting and the integration of system and process and certain other qualifying cost cost primarily related to our acquisition of trillium cost primarily related to our acquisition of array cost mainly related to our acquisition of array including million in payment to array employee for the fair value of previously unvested stock option that wa recognized post closing compensation expense see note and hospira amount include the impact of change in accounting principle see note represents the impact of change in the estimated useful life of asset involved in restructuring action represents external incremental cost directly related to implementing our non acquisition related cost reduction productivity initiative the following summarizes the component and change in restructuring accrual million employeeterminationcostsassetimpairmentchargesexit costsaccrualbalance january utilization and other balance december utilization and other balance december includes adjustment for foreign currency translation included in other current liability million and other noncurrent liability million included in other current liability million and other noncurrent liability million pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesnote other income deduction netcomponents of other income deduction net include year ended december million income interest expense net interest royalty related income net gain loss on asset disposal net gain loss recognized during the period on equity security income from collaboration out licensing arrangement and sale of compound product right net periodic benefit cost credit other than service cost certain legal matter net certain asset impairment business and legal entity alignment cost consumer healthcare jv equity method income loss other net other income deduction net capitalized interest totaled million in million in and million in gain include among other thing unrealized gain of billion related to investment in biontech and cerevel gain included among other thing unrealized gain of million related to investment in biontech and springworks therapeutic inc springworks gain included among other thing unrealized gain of million related to investment in cortexyme inc and springworks includes among other thing million of net collaboration income from biontech related to the covid vaccine and million of milestone income from multiple licensee included among other thing million upfront payment received from our sale of our asset to biogen ii million of milestone income from puma biotechnology inc related to neratinib regulatory approval in the eu iii million of milestone income from lilly related to the first commercial sale in the of loxo for the treatment of ret fusion positive nsclc and iv million in milestone income from multiple licensee included among other thing million in milestone income from mylan pharmaceutical inc related to the fda approval and launch of wixela inhub generic of advair diskus fluticasone propionate and salmeterol inhalation powder and million in milestone income from multiple licensee amount include the impact of change in accounting principle see note and in other non service cost component activity related to the consumer healthcare jv transaction such gain on settlement were recorded in gain on completion of consumer healthcare jv transaction includes legal reserve for certain pending legal matter represents intangible asset impairment charge associated with our biopharma segment million related to ipr asset for unapproved indication of certain cancer medicine acquired in our array acquisition and reflected among other thing updated commercial forecast ii million related to eucrisa finite lived developed technology right acquired in our anacor acquisition and reflected updated commercial forecast mainly reflecting competitive pressure and iii million related to finite lived developed technology right for certain generic sterile injectables acquired in our hospira acquisition and reflected updated commercial forecast mainly reflecting competitive pressure primarily included intangible asset impairment charge of billion mainly composed of billion related to eucrisa and reflected updated commercial forecast mainly reflecting competitive pressure mainly represents incremental cost for the design planning and implementation of our then new business structure effective in the beginning of and primarily includes consulting legal tax and other advisory service see note includes among other thing income net of cost associated with tsa of million ii dividend income of million from our investment in viiv and iii charge of million reflecting the change in the fair value of contingent consideration included among other thing dividend income of million from our investment in viiv ii income net of cost associated with tsa of million and iii charge of million reflecting the change in the fair value of contingent consideration included among other thing dividend income of million from our investment in viiv ii charge of million for external incremental cost such transaction cost and cost to separate our consumer healthcare business into separate legal entity associated with the formation of the consumer healthcare jv and iii net loss on early retirement of debt of million the asset impairment charge included in other income deduction net are based on estimate of fair value note tax mattersa tax on income from continuing operationscomponents of income from continuing operation before provision benefit for tax on income include year ended december million state income from continuing operation before provision benefit for tax on income pfizer inc form to consolidated financial statementspfizer inc and subsidiary company the domestic income in versus domestic loss in wa mainly related to comirnaty income lower asset impairment charge net periodic benefit credit in versus net periodic benefit cost in and higher net gain from equity security partially offset by higher expense the increase in the international income wa primarily related to comirnaty income net periodic benefit credit in versus net periodic benefit cost in and lower asset impairment charge the domestic loss in versus domestic income in wa mainly related to the non recurrence of the gain on the completion of the consumer healthcare jv transaction well higher asset impairment charge and higher expense the increase in the international income wa primarily related to the non recurrence of the write off of asset contributed to the consumer healthcare jv well lower asset impairment charge and lower amortization of intangible asset component of provision benefit for tax on income based on the location of the taxing authority include year ended december million statescurrent income tax federal state and deferred income tax federal state and local total tax benefit tcjacurrent income tax deferred income tax total tcja tax benefit internationalcurrent income deferred income total international tax provision benefit for tax on income amount discussed below are rounded to the nearest hundred million and represent approximation we elected with the filing of our federal consolidated income tax return to pay our initial estimated billion repatriation tax liability on accumulated post foreign earnings over eight year through the third annual installment of this liability wa paid by it april due date the fourth annual installment is due april and is reported in current income tax payable of december the remaining liability is reported in noncurrent other tax payable our obligation may vary result of change in our uncertain tax position and or availability of attribute such foreign tax and other credit carryforwards the change in provision benefit for tax on income impacting the effective tax rate year over year are summarized below higher effective tax rate in wa mainly the result of the change in the jurisdictional mix of earnings primarily related to comirnaty and lower tax benefit related to the impairment of intangible asset partially offset by certain initiative executed in the third quarter of associated with our investment in the consumer healthcare jv with gsk based on estimate and assumption that we believe to be reasonable higher effective tax rate in wa mainly the result of the non recurrence of the billion tax benefit representing tax and interest recorded in due to the favorable settlement of an irs audit for multiple tax year the non recurrence of the tax benefit related to certain tax initiative associated with the implementation of our then new business structure and the non recurrence of the tax benefit recorded in result of additional guidance issued by the department of treasury related to the tcja well lower tax benefit related to the impairment of intangible asset partially offset by the non recurrence of the tax expense of billion recorded in the third quarter of associated with the gain on the completion of the consumer healthcare jv transaction and the favorable change in the jurisdictional mix of earnings result of operating fluctuation in the normal course of business in all year federal state and international net tax liability assumed or established part of business acquisition are not included in provision benefit for tax on income see note pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesb tax rate reconciliationthe reconciliation of the statutory income tax rate to our effective tax rate for income from continuing operation follows year ended december statutory income tax tcja impact taxation of non operation tax settlement and resolution of certain tax position completion of consumer healthcare jv transaction certain consumer healthcare jv initiative tax credit interest all other net effective tax rate for income from continuing see note for taxation of non operation this rate impact reflects the income tax rate and relative earnings in the location where we do business outside the together with the tax cost on our international operation change in uncertain tax position not included in the reconciling item called tax settlement and resolution of certain tax position well change in valuation allowance specifically the jurisdictional location of earnings is significant component of our effective tax rate each year and the rate impact of this component is influenced by the specific location of non earnings and the level of such earnings compared to our total earnings ii the tax implication of our foreign operation is significant component of our effective tax rate each year and generally offset some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings iii the impact of certain tax initiative and iv the impact of change in uncertain tax position not included in the reconciling item called tax settlement and resolution of certain tax position is component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate the jurisdictional mix of earnings which includes the impact of the location of earnings well the tax cost on our international operation can vary result of operating fluctuation in the normal course of business and result of the extent and location of other income and expense item such restructuring charge asset impairment and gain and loss on strategic business decision see also note for the component of pre tax income and provision benefit for tax on income which is based on the location of the taxing authority and for information about settlement and other item impacting provision benefit for tax on income in all year the reduction in our effective tax rate is result of the jurisdictional location of earnings and is largely due to lower tax rate in certain jurisdiction well manufacturing and other incentive for our subsidiary in singapore and to lesser extent in puerto rico we benefit from puerto rican tax incentive pursuant to grant that expires during under such grant we are partially exempt from income property and municipal tax in singapore we benefit from incentive tax rate effective through on income from manufacturing and other operation includes change in interest related to our uncertain tax position not included in the reconciling item called tax settlement and resolution of certain tax position all other net is primarily due to routine business operation deferred taxescomponents of our deferred tax asset and liability shown before jurisdictional netting follow deferred tax deferred tax million asset liability asset liability prepaid deferred item intangible asset property plant and equipment employee benefit restructurings and other legal and product liability net operating loss tax credit carryforwards unremitted earnings state and local tax investment all valuation allowance total deferred tax net deferred tax asset liability the deferred tax asset and liability associated with global intangible low taxed income are included in the relevant category see note the increase in net deferred tax asset in is primarily related to temporary difference associated with comirnaty royalty accrual and the result of operating lease rou liability recognized during the period the increase in the deferred tax asset is primarily due to the acquisition of intangible asset relating to trillium and the decrease in the deferred tax liability is primarily the result of amortization of intangible asset pfizer inc form to consolidated financial statementspfizer inc and subsidiary company the increase in net deferred tax liability in is primarily the result of operating lease rou asset recognized during the period see note the decrease in net deferred tax asset in is primarily the result of favorable pension plan asset performance reported in the period see note the amount in and are reduced for unrecognized tax benefit of billion and billion respectively where we have net operating loss carryforwards similar tax loss and or tax credit carryforwards that are available under the tax law of the applicable jurisdiction to settle any additional income tax that would result from the disallowance of tax position the decrease in net deferred tax liability in is primarily due to certain initiative executed in the third quarter of associated with our investment in the consumer healthcare jv in noncurrent deferred tax asset and other noncurrent tax asset billion and noncurrent deferred tax liability billion in noncurrent deferred tax asset and other noncurrent tax asset billion and noncurrent deferred tax liability billion we have carryforwards primarily related to net operating and capital loss general business credit foreign tax credit and charitable contribution which are available to reduce future federal and or state well international income tax payable with either an indefinite life or expiring at various time from to certain of our net operating loss and general business credit are subject to limitation under irc section of december we have not made tax provision on billion of unremitted earnings of our international subsidiary these earnings are intended to be indefinitely reinvested overseas the determination of hypothetical unrecognized deferred tax liability of december is not practicable the amount of indefinitely reinvested earnings is based on estimate and assumption and subject to management evaluation and is subject to change in the normal course of business based on operational cash flow completion of local statutory financial statement and the finalization of tax return and audit among other thing accordingly we regularly update our earnings and profit analysis for such event tax contingenciesfor description of our accounting policy associated with accounting for income tax contingency see note uncertain tax positionsas tax law is complex and often subject to varied interpretation it is uncertain whether some of our tax position will be sustained upon audit of december we had billion and of december we had billion in net unrecognized tax benefit excluding associated interest tax asset for uncertain tax position primarily represent our estimate of the potential tax benefit in one tax jurisdiction that could result from the payment of income tax in another tax jurisdiction these potential benefit generally result from cooperative effort among taxing authority required by tax treaty to minimize double taxation commonly referred to the competent authority process the recoverability of these asset which we believe to be more likely than not is dependent upon the actual payment of tax in one tax jurisdiction and in some case the successful petition for recovery in another tax jurisdiction of december we had billion in asset associated with uncertain tax position these amount were included in noncurrent deferred tax asset and other noncurrent tax asset billion and other tax payable million of december we had billion in asset associated with uncertain tax position these amount were included in noncurrent deferred tax asset and other noncurrent tax asset billion noncurrent deferred tax liability million and other tax payable million substantially all of these unrecognized tax benefit if recognized would impact our effective income tax rate the reconciliation of the beginning and ending amount of gross unrecognized tax benefit follows million beginning acquisition divestiture increase based on tax position taken during prior period decrease based on tax position taken during prior period decrease based on settlement for prior period increase based on tax position taken during the current period impact of foreign other net balance ending for related to the separation of upjohn see note primarily included in provision benefit for tax on income primarily related to effectively settling certain issue with the and foreign tax authority see note primarily related to cash payment and reduction of tax attribute primarily related to decrease result of lapse of applicable statute of limitation in included in income tax payable million other current asset million noncurrent deferred tax asset and other noncurrent tax asset billion noncurrent deferred tax liability million and other tax payable billion in included in income tax payable million noncurrent deferred tax asset and other noncurrent tax asset million noncurrent deferred tax liability billion and other tax payable billion interest related to our unrecognized tax benefit is recorded in accordance with the law of each jurisdiction and is recorded primarily in provision benefit for tax on income in and we recorded net increase in interest of million and million respectively in we recorded net decrease in interest of million resulting primarily from settlement with the irs gross accrued interest totaled million of december reflecting decrease of million result of cash payment and gross pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesaccrued interest totaled million of december reflecting decrease of million result of cash payment and decrease of million relating to the separation of upjohn in and these amount were substantially all included in other tax payable accrued penalty are not significant see also note status of tax audit and potential impact on accrual for uncertain tax positionsthe is one of our major tax jurisdiction and we are regularly audited by the irs with respect to pfizer the irs ha issued revenue agent report rars for tax year and we are not in agreement with the rars and are currently appealing certain disputed issue tax year are currently under audit tax year are open but not under audit all other tax year are closed in addition to the open audit year in the we have open audit year in certain major international tax jurisdiction such canada europe primarily reflecting ireland the france italy spain and germany asia pacific primarily reflecting china japan and singapore and latin america primarily reflecting brazil any settlement or statute of limitation expiration could result in significant decrease in our uncertain tax position we estimate that it is reasonably possible that within the next month our gross unrecognized tax benefit exclusive of interest could decrease by much million result of settlement with taxing authority or the expiration of the statute of limitation our assessment are based on estimate and assumption that have been deemed reasonable by management but our estimate of unrecognized tax benefit and potential tax benefit may not be representative of actual outcome and variation from such estimate could materially affect our financial statement in the period of settlement or when the statute of limitation expire we treat these event discrete item in the period of resolution finalizing audit with the relevant taxing authority can include formal administrative and legal proceeding and result it is difficult to estimate the timing and range of possible change related to our uncertain tax position and such change could be significant tax provision benefit on other comprehensive income loss component of the tax provision benefit on other comprehensive income loss include year ended december million currency translation adjustment net unrealized holding gain loss on derivative financial instrument reclassification adjustment for gain loss included in net unrealized holding gain loss on available for sale security net reclassification adjustment for gain loss included in net income benefit plan prior service cost credit and other reclassification adjustment related to amortization of prior service cost and other net reclassification adjustment related to curtailment of prior service cost and other net other tax provision benefit on other comprehensive income loss tax are not provided for foreign currency translation adjustment relating to investment in international subsidiary that are expected to be held indefinitely note accumulated other comprehensive loss excluding noncontrolling intereststhe following summarizes the change net of tax in accumulated other comprehensive loss net unrealized gain loss benefit plan million foreign currency translation adjustment derivative financial instrumentsavailable for sale securitiesprior service cost credit and otheraccumulated other comprehensive income loss balance january other comprehensive income loss balance december other comprehensive income loss distribution of upjohn business balance december other comprehensive income loss balance december amount include the impact of change in accounting principle see note amount do not include foreign currency translation adjustment attributable to noncontrolling interest foreign currency translation adjustment include net loss in and net gain in and related to our equity method investment in the consumer healthcare jv see note and the impact of our net investment hedging program for more information see note pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesnote financial instrumentsa fair value measurementsfinancial asset and liability measured at fair value on recurring basis and fair value hierarchy using market approach of december of december million totallevel asset short term investmentsclassified equity security with readily determinable fair value money market fund classified available for sale debt security government and agency non government and agency corporate and total short term other current assetsderivative asset interest rate foreign exchange total other current long term investmentsclassified equity security with readily determinable fair value classified available for sale debt security government and agency non government and agency corporate and total long term other noncurrent assetsderivative asset interest rate foreign exchange total derivative insurance contract total other noncurrent total asset financial liability other current liabilitiesderivative liability foreign exchange contract total other current other noncurrent liabilitiesderivative liability foreign exchange total other noncurrent total liability long term equity security of million of december and million of december were held in restricted trust for non qualified employee benefit plan includes life insurance policy held in restricted trust for non qualified employee benefit plan the underlying invested asset in these contract are marketable security which are carried at fair value with change in fair value recognized in other income deduction net see note financial asset and liability not measured at fair value on recurring basisthe carrying value of long term debt excluding the current portion wa billion of december and billion of december the estimated fair value of such debt using market approach and level input wa billion of december and billion of december pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesthe difference between the estimated fair value and carrying value of held to maturity debt security private equity security long term receivables and short term borrowing not measured at fair value on recurring basis were not significant of december and the fair value measurement of our held to maturity debt security and short term borrowing are based on level input the fair value measurement of our long term receivables and private equity security are based on level input investmentstotal short term long term and equity method investmentsthe following summarizes our investment by classification type of december million term investmentsequity security with readily determinable fair value available for sale debt held to maturity debt total short term investment long term investmentsequity security with readily determinable fair value available for sale debt held to maturity debt private equity security at cost total long term investment equity method total long term investment and equity method investment held to maturity cash equivalent of december and includes money market fund primarily invested in treasury and government debt represent investment in the life science sector debt securitiesat december our investment portfolio consisted of debt security issued across diverse government corporate and financial institution which are investment grade the contractual or estimated maturity are follows of december of december unrealizedmaturities in year gross unrealized million amortized costgainslossesfair valuewithin costgainslossesfair valueavailable for sale debt securitiesgovernment and agency non government and agency corporate and held to maturity debt securitiestime deposit and government and agency non total debt security any expected credit loss to these portfolio would be immaterial to our financial statement equity securitiesthe following present the calculation of the portion of unrealized gain loss that relates to equity security excluding equity method investment held at the reporting date year ended december million gain loss recognized during the period on equity security le net gain loss recognized during the period on equity security sold during the period net unrealized gain loss during the reporting period on equity security still held at the reporting date reported in other income deduction net see note included in net unrealized gain are observable price change on equity security without readily determinable fair value of december there were cumulative impairment and downward adjustment of million and upward adjustment of million impairment downward and upward adjustment were not significant in and pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesc short term borrowingsshort term borrowing include of december million paper current portion of long term debt principal other short term borrowing principal amount total short term borrowing principal net unamortized discount premium and debt issuance cost total short term borrowing including current portion of long term debt carried at historical proceeds adjusted primarily includes cash collateral see note the weighted average effective interest rate on commercial paper outstanding wa approximately of december of december we had access to billion committed revolving credit facility expiring in which may be used for general corporate purpose including to support our commercial paper borrowing in addition to the revolving credit facility our lender have provided an additional million in line of credit of which million expire within one year essentially all line of credit were unused of december long term debtthe following outline our senior unsecured long term debt and the weighted average stated interest rate by maturity of december million due for note due for and note due for and note due for and note due for and note due for and for note due for and for note due for and note due for and note due for and note due for and total long term debt principal net fair value adjustment related to hedging and purchase net unamortized discount premium and debt issuance cost other long term total long term debt carried at historical proceeds adjusted current portion of long term debt carried at historical proceeds adjusted not included above for and for reclassified to the current portion of long term debt our long term debt outlined in the above table is generally redeemable by at any time at varying redemption price plus accrued and unpaid interest issuancesin august we issued the following senior unsecured note at an effective interest rate of million principalinterest ratematurity dateas of december august the note may be redeemed by at any time in whole or in part at redemption price plus accrued and unpaid interest in may we completed public offering of billion aggregate principal amount of senior unsecured note with weighted average effective interest rate of and in march we completed public offering of billion aggregate principal amount of senior unsecured note with weighted average effective interest rate of in march we completed public offering of billion aggregate principal amount of senior unsecured note with weighted average effective interest rate of pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesretirementsin november we repurchased all billion and million principal amount outstanding of the senior unsecured note due june and senior unsecured note due august and recorded total net loss of million in other income deduction net see note in march we repurchased at par all billion principal amount outstanding of our senior unsecured note due in in january we repurchased all billion billion principal amount outstanding of the euro denominated debt due june at redemption value of billion billion we recorded net loss of million in other income deduction net which included the related termination of cross currency swap derivative financial instrument and hedging activitiesforeign exchange riska significant portion of our revenue earnings and net investment in foreign affiliate is exposed to change in foreign exchange rate where foreign exchange risk is not offset by other exposure we manage our foreign exchange risk principally through the use of derivative financial instrument and foreign currency debt these financial instrument serve to mitigate the impact on net income result of remeasurement into another currency or against the impact of translation into dollar of certain foreign exchange denominated transaction the derivative financial instrument primarily hedge or offset exposure in the euro pound japanese yen and canadian dollar we hedge portion of our forecasted intercompany inventory sale denominated in euro japanese yen canadian dollar chinese renminbi pound and australian dollar for up to two year under certain market condition we may seek to protect against possible decline in the reported net investment of our foreign business entity change in fair value are reported in earnings or in other comprehensive income loss depending on the nature and purpose of the financial instrument hedge or offset relationship for certain foreign exchange contract we exclude an amount from the assessment of hedge effectiveness and recognize the excluded amount through an amortization approach in earnings the hedge relationship are follows generally we recognize the gain and loss on foreign exchange contract that are designated fair value hedge in earnings upon the recognition of the change in fair value of the hedged item we also recognize the offsetting foreign exchange impact attributable to the hedged item in earnings generally we record in other comprehensive income loss gain or loss on foreign exchange contract that are designated cash flow hedge and reclassify those amount into earnings in the same period or period during which the hedged transaction affect earnings we record in other comprehensive income loss foreign currency translation adjustment net the foreign exchange gain and loss related to foreign exchange denominated debt and foreign exchange contract designated hedge of our net investment in foreign subsidiary and reclassify those amount into earnings upon the sale or substantial liquidation of our net investment for foreign exchange contract not designated hedging instrument we recognize the gain and loss immediately into earnings along with the earnings impact of the item they generally offset these contract take the opposite currency position of that reflected on the balance sheet to counterbalance the effect of any currency movement interest rate riskour interest bearing investment and borrowing are subject to interest rate risk depending on market condition we may change the profile of our outstanding debt or investment by entering into derivative financial instrument like interest rate swap either to hedge or offset the exposure to change in the fair value of hedged item with fixed interest rate or to convert variable rate debt or investment to fixed rate the derivative financial instrument primarily hedge dollar fixed rate debt we recognize the change in fair value on interest rate contract that are designated fair value hedge in earnings well the offsetting earnings impact of the hedged risk attributable to the hedged item the following summarizes the fair value of the derivative financial instrument and notional amount including those reported part of discontinued operation million of december of december valuefair valuenotionalassetliabilitynotionalassetliabilityderivatives designated hedging instrument foreign exchange contract interest rate derivative not designated hedging instrument foreign exchange contract total the notional amount of outstanding foreign exchange contract hedging our intercompany forecasted inventory sale wa billion of december and billion of december pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesthe following summarizes information about the gain loss incurred to hedge or offset operational foreign exchange or interest rate risk exposure including those reported part of discontinued operation gain loss recognized in oid gain loss recognized in oci gain loss reclassified fromoci into oid and co year ended december million financial instrument in cash flow hedge relationship foreign exchange contract amount excluded from effectiveness testing and amortized into earnings derivative financial instrument in fair value hedge relationship interest rate contract hedged item derivative financial instrument in net investment hedge relationship foreign exchange contract amount excluded from effectiveness testing and amortized into earnings non derivative financial instrument in net investment hedge relationship foreign currency short term borrowing foreign currency long term debt derivative financial instrument not designated hedge foreign exchange contract all other net oid other income deduction net included in other income deduction net in the consolidated statement of income co cost of sale included in cost of sale in the consolidated statement of income oci other comprehensive income loss included in the consolidated statement of comprehensive income the amount reclassified from oci into co were net loss of million in and net gain of million in including gain of million reported in discontinued operation net of tax the remaining amount were reclassified from oci into oid based on year end foreign exchange rate that are subject to change we expect to reclassify pre tax gain of million within the next month into income the maximum length of time over which we are hedging our exposure to the variability in future foreign exchange cash flow is approximately year and relates to foreign currency debt the amount reclassified from oci were reclassified into oid short term borrowing and long term debt include foreign currency borrowing which are used net investment hedge the short term borrowing carrying value of december wa billion the long term debt carrying value of december and december were million and billion respectively the following summarizes cumulative basis adjustment to our long term debt in fair value hedge of december of december amount of fairvalue hedging adjustmentincrease decrease to carrying amountcumulative amount of fair value hedging adjustment increase decrease to carrying amount million carrying amount of hedged asset liability activehedgingrelationshipsdiscontinued hedging relationshipscarrying amount of hedged asset liability active hedging relationshipsdiscontinued hedging relationshipslong term debt carrying amount exclude the cumulative amount of fair value hedging adjustment credit riskon an ongoing basis we monitor and review the credit risk of our customer financial institution and exposure in our investment portfolio with respect to our trade account receivable we monitor the creditworthiness of our customer to which we grant credit in the normal course of business in general there is no requirement for collateral from customer for additional information on our trade account receivable and pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesallowance for credit loss see note significant portion of our trade account receivable balance are due from wholesaler and government for additional information on our trade account receivables with significant customer see note with respect to our investment we monitor concentration of credit risk associated with government government agency and corporate issuer of security investment are placed in instrument that are investment grade and are primarily short in duration exposure limit are established to limit concentration with any single credit counterparty of december the largest investment exposure in our portfolio represent primarily sovereign debt instrument issued by the canada japan germany france australia and switzerland with respect to our derivative financial instrument agreement with financial institution we do not expect to incur significant loss from failure of any counterparty derivative financial instrument are executed under international swap and derivative association isda master agreement with credit support annex that contain zero threshold provision requiring collateral to be exchanged daily depending on level of exposure result there are no significant concentration of credit risk with any individual financial institution of december the aggregate fair value of these derivative financial instrument that are in net payable position wa million for which we have posted collateral of million with corresponding amount reported in short term investment of december the aggregate fair value of our derivative financial instrument that are in net receivable position wa million for which we have received collateral of million with corresponding amount reported in short term borrowing including current portion of long term debt note other financial informationa inventoriesthe following summarizes the component of inventory of december million good work in raw material and inventory noncurrent inventory not included above the change from december reflects increase for certain product including inventory build for new product launch primarily comirnaty network strategy and supply recovery partially offset by decrease due to market demand included in other noncurrent asset there are no recoverability issue for these amount other current liabilitiesother current liability includes among other thing amount payable to biontech for the gross profit split for comirnaty which totaled billion of december and million of december note property plant and equipment pp the following summarizes the component of property plant and equipment useful livesas of december million year machinery and furniture fixture and construction in progress le accumulated property plant and equipment the following provides long lived asset by geographic area of december million plant and equipmentunited state developed developed rest of emerging property plant and equipment pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesnote identifiable intangible asset and goodwilla identifiable intangible assetsthe following summarizes the component of identifiable intangible asset of december of december million grosscarryingamountaccumulatedamortizationidentifiableintangibleassets lessaccumulatedamortizationgrosscarryingamountaccumulatedamortizationidentifiableintangibleassets lessaccumulatedamortizationfinite lived intangible assetsdeveloped technology right licensing agreement and indefinite lived intangible ipr licensing agreement and identifiable intangible asset the increase in the gross carrying amount primarily reflects million of capitalized comirnaty sale milestone to biontech partially offset by net loss from foreign currency translation adjustment the decrease is primarily due to amortization partially offset by the capitalization of the comirnaty milestone described above developed technology rightsdeveloped technology right represent the cost for developed technology acquired from third party and can include the right to develop use market sell and or offer for sale the product compound and intellectual property that we have acquired with respect to product compound and or process that have been completed we posse well diversified portfolio of hundred of developed technology right across therapeutic category representing our commercialized product the significant component of developed technology right are the following xtandi prevnar prevenar infant braftovi mektovi premarin prevnar prevenar adult eucrisa orgovyx zavicefta tygacil bavencio merrem meronem and comirnaty also included in this category are the post approval milestone payment made under our alliance agreement for certain prescription pharmaceutical product brandsbrands represent the cost for tradenames and know how the product do not receive patent protection indefinite lived brand include medrol and depo medrol while finite lived brand include zavedos and depo provera ipr dipr asset represent asset that have not yet received regulatory approval in major market the significant component of ipr are the following the program for the oral poly adenosine diphosphate adp ribose polymerase inhibitor for the treatment of patient with germline brca mutated advanced breast cancer acquired part of the medivation acquisition and asset acquired in connection with the array acquisition ipr asset are required to be classified indefinite lived asset until the successful completion or the abandonment of the associated effort accordingly during the development period after the date of acquisition these asset are not amortized until approval is obtained in major market typically either the or the eu or in series of other country subject to certain specified condition and management judgment at that time we will determine the useful life of the asset reclassify it out of ipr and begin amortization if the associated effort is abandoned the related ipr asset will likely be written off and we will record an impairment charge ipr asset are high risk asset given the uncertain nature of accordingly we expect that many of these ipr asset will become impaired and be written off at some time in the future licensing agreementslicensing agreement for developed technology and for technology in development primarily relate to out licensing arrangement acquired from third party including the array acquisition these asset represent the cost for the license where we acquired the right to future royalty and or milestone upon development or commercialization by the licensing partner significant component of the licensing arrangement are for out licensing arrangement with number of partner for oncology technology in varying stage of development that have not yet received regulatory approval in major market accordingly during the development period after the date of acquisition each of these asset is classified indefinite lived intangible asset and will not be amortized until approval is obtained in major market at that time we will determine the useful life of the asset reclassify the respective licensing arrangement asset to finite lived intangible asset and begin amortization if the development effort is abandoned the related licensing asset will likely be written off and we will record an impairment charge pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesamortizationthe weighted average life for each of our total finite lived intangible asset is approximately year and for the largest component developed technology right is approximately year total amortization expense for finite lived intangible asset wa billion in billion in and billion in the following provides the expected annual amortization expense million expense goodwillthe following summarizes the component and change in the carrying amount of goodwill million total balance january addition other balance december addition other balance december result of the reorganization of our commercial operation during the fourth quarter of see note we were required to estimate the relative fair value of our and hospital organization to determine any reallocation of goodwill we completed this analysis and determined that no goodwill wa required to be reallocated result our entire goodwill balance continues to be assigned within the biopharma reportable segment addition primarily represent the impact of measurement period adjustment related to our array acquisition see note other represents the impact of foreign exchange note pension and postretirement benefit plan and defined contribution plansthe majority of our employee worldwide are eligible for retirement benefit provided through defined benefit pension plan defined contribution plan or both in the we sponsor both irc qualified and supplemental non qualified defined benefit plan and defined contribution plan qualified plan meet the requirement of certain section of the irc and generally contribution to qualified plan are tax deductible qualified plan typically provides benefit to broad group of employee with restriction on discriminating in favor of highly compensated employee with regard to coverage benefit and contribution supplemental non qualified plan provides additional benefit to certain employee in addition we provide medical insurance benefit to certain retiree and their eligible dependent through our postretirement plan discussed in note we adopted change in accounting principle to more preferable policy under gaap to immediately recognize actuarial gain and loss arising from the remeasurement of pension and postretirement plan this change ha been applied to all pension and postretirement plan on retrospective basis for all prior period presented component of net periodic benefit cost and change in other comprehensive income loss the following summarizes the component of net periodic benefit cost credit including those reported part of discontinued operation for and and the change in other comprehensive income loss for our benefit plan pension plan postretirement plansu internationalyear ended december million cost interest expected return on plan asset amortization of prior service cost credit actuarial gain loss curtailment special termination net periodic benefit cost credit reported in income cost credit reported in other comprehensive income loss cost credit recognized in comprehensive income reflects actuarial remeasurement gain in primarily due to favorable plan asset performance and increase in discount rate and actuarial remeasurement loss in and primarily due to decrease in discount rate partially offset by favorable plan asset performance pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesthe component of net periodic benefit cost credit other than the service cost component are included in other income deduction net see note actuarial assumptionspension planspostretirement plansu internationalyear ended december percentage average assumption used to determine net periodic benefit cost discount rate pension plan postretirement interest service expected return on plan rate of compensation increase weighted average assumption used to determine benefit obligation at fiscal year end discount rate of compensation increase the rate of compensation increase is not used to determine the net periodic benefit cost and benefit obligation for the pension plan these plan are frozen all of the assumption are reviewed on at least an annual basis we revise these assumption based on an annual evaluation of long term trend well market condition that may have an impact on the cost of providing retirement benefit the weighted average discount rate for our defined benefit plan is determined annually and evaluated and modified to reflect at year end the prevailing market rate of portfolio of high quality fixed income investment rated aa aa or better that reflect the rate at which the pension benefit could be effectively settled for our international plan the discount rate are set by benchmarking against investment grade corporate bond rated aa aa or better including when there is sufficient data yield curve approach these rate determination are made consistent with local requirement overall the yield curve used to measure the benefit obligation at year end resulted in higher discount rate compared to the prior year the following provides the healthcare cost trend rate assumption for our postretirement benefit plan of december cost trend rate assumed for next year rate to which the cost trend rate is assumed to year that the rate reach the ultimate trend pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesc obligation and funded statusthe following provides an analysis of the change in our benefit obligation plan asset and funded status of our benefit plan including those reported part of discontinued operation for ii the funded status recognized in our consolidated balance sheet and iii the pre tax component of cumulative amount recognized in accumulated other comprehensive loss pension plan postretirement plan internationalyear ended december million in benefit obligation benefit obligation beginning service cost interest employee contribution plan amendment change in actuarial assumption and other foreign exchange impact upjohn spin off acquisition divestiture other net curtailment and special termination settlement benefit paid benefit obligation ending change in plan assetsfair value of plan asset actual return on plan company employee contribution foreign exchange impact upjohn spin off acquisition divestiture net settlement benefit paid fair value of plan asset funded status plan asset le than benefit obligation amount recorded in our consolidated balance sheet noncurrent asset current liability noncurrent liability funded status pre tax component of cumulative amount recognized in accumulated other comprehensive loss prior service cost credit information related to the funded status of pension plan with an abo in excess of plan asset fair value of plan asset information related to the funded status of pension plan with pbo in excess of plan asset fair value of plan asset for the pension plan the benefit obligation is both the pbo and abo these plan are frozen and future benefit accrual no longer increase with future compensation increase for the international pension plan the benefit obligation is the pbo the abo for our international pension plan wa billion in and billion in for the postretirement plan the benefit obligation is the abo primarily includes actuarial gain resulting from increase in discount rate in offset by increase in inflation assumption in for the international plan and actuarial loss resulting from decrease in discount rate in for more information see note our main qualified plan and many of our international plan were overfunded of december pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesd plan assetsthe following provides the component of plan asset including those reported part of discontinued operation for of december of december fair valuefair value million except target allocation percentage target allocation percentagetotallevel measured at nav totallevel measured at nav pension planscash and cash equity security global equity equity commingled fixed income security corporate debt government and agency obligation fixed income commingled other investment partnership investment insurance other commingled fund international pension planscash and cash equity security equity commingled fixed income security corporate debt government and agency obligation fixed income commingled other investment partnership investment insurance other postretirement plan cash and cash insurance certain investment that are measured at nav per share or it equivalent have not been classified in the fair value hierarchy the nav amount presented in this table are intended to permit reconciliation of the fair value hierarchy to the amount presented for the total pension benefit plan asset government and agency obligation are inclusive of repurchase agreement mainly includes investment in private equity private debt public equity limited partnership and to lesser extent real estate and venture capital mostly includes investment in hedge fund and real estate reflects postretirement plan asset which support portion of our retiree medical plan the following provides an analysis of the change in our more significant investment valued using significant unobservable input including those reported part of discontinued operation for international pension plansyear ended december million value beginning actual return on plan asset asset held purchase sale and settlement transfer into out of level exchange rate change fair value ending pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesthe following method and assumption were used to estimate the fair value of our pension and postretirement plan asset cash and cash equivalent level investment may include cash cash equivalent and foreign currency valued using exchange rate level investment may include short term investment fund which are commingled fund priced at stable nav by the administrator of the fund equity security level investment may include individual security that are valued at the closing price or last trade reported on the major market on which they are traded level and level investment may include commingled fund that have readily determinable fair value based on quoted price on an exchange or published nav derived from the quoted price in active market of the underlying security level investment may include individual security that are unlisted delisted suspended or illiquid and are typically valued using their last available price fixed income security level investment may include individual security that are valued at the closing price or last trade reported on the major market on which they are traded level investment may include commingled fund that have readily determinable fair value based on observable price of the underlying security level investment may include corporate bond government and government agency obligation and other fixed income security valued using bid evaluation pricing model or quoted price of security with similar characteristic level investment may include security that are valued using alternative pricing source such investment manager or broker which use proprietary pricing model that incorporate unobservable input other investment level investment may include individual security that are valued at the closing price or last trade reported on the major market on which they are traded level investment may include insurance contract which invest in interest bearing cash government security and corporate debt instrument level investment may include security or insurance contract that are valued using alternative pricing source such investment manager or broker which use proprietary pricing model that incorporate unobservable input equity security fixed income security and other investment may each be combined into commingled fund most commingled fund are valued to reflect the interest in the fund based on the reported year end nav partnership and other investment are valued based on year end reported nav or it equivalent with adjustment appropriate for lagged reporting of up to three month certain investment are authorized to include derivative such equity or bond future swap option and currency future or forward for managing risk and exposure global plan asset are managed with the objective of generating return that will enable the plan to meet their future obligation while seeking to manage net periodic benefit cost and cash contribution over the long term we utilize long term asset allocation range in the management of our plan invested asset our long term return expectation are developed based on diversified global investment strategy that take into account historical experience well the impact of portfolio diversification active portfolio management and our view of current and future economic and financial market condition market condition and other factor change we may adjust our target accordingly and our asset allocation may vary from the target allocation cash flowsit is our practice to fund amount for our qualified pension plan that are at least sufficient to meet the minimum requirement set forth in applicable employee benefit law and local tax law the following provides the expected future cash flow information related to our benefit plan pension planspostretirement plan million internationalexpected employer contribution expected benefit payment the above table reflects the total and international plan benefit projected to be paid from the plan or from our general asset under the current actuarial assumption used for the calculation of the benefit obligation defined contribution planswe have defined contribution plan in the and other country for the majority of the defined contribution plan employee may contribute portion of their salary and bonus to the plan and we match in cash portion of the employee contribution we also offer retirement saving contribution rsc which is an annual non contributory employer contribution in the and puerto rico we recorded charge related to the employer contribution to global defined contribution plan of million in million in and million in pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesnote equitya common stock purchaseswe purchase our common stock through privately negotiated transaction or in the open market circumstance and price warrant purchased share under each of the share purchase plan which are authorized by our bod are available for general corporate purpose in december the bod authorized billion share repurchase program which wa exhausted in the first quarter of in december the bod authorized another billion share repurchase program to be utilized over time and share repurchase commenced thereunder in the first quarter of in february we entered into an asr with goldman sachs co llc to repurchase billion of our common stock pursuant to our previously announced share repurchase authorization we paid billion and received an initial delivery of million share of common stock which represented approximately of the notional amount of the asr in august the asr with goldman sachs co llc wa completed resulting in goldman sachs co llc owing an additional million share of our common stock the average price paid for all of the share delivered under the asr wa per share the common stock received is included in treasury stock the following provides the number of share of our common stock purchased and the cost of purchase under our publicly announced share purchase plan including our asr year ended december share in million dollar in billion share of common stock purchased cost of purchase represents share purchased pursuant to the asr with goldman sachs co llc entered into in february well open market share repurchase of billion our remaining share purchase authorization wa approximately billion at december preferred stock and employee stock ownership plansprior to may we had outstanding series convertible perpetual preferred stock the series preferred stock that wa held by an esop trust the trust all outstanding share of series preferred stock were converted at the direction of the independent fiduciary under the trust and in accordance with the certificate of designation for the series preferred stock into share of our common stock on may the trust received an aggregate of share of our common stock upon conversion with zero share of series preferred stock remaining outstanding result of the conversion in december we filed certificate of elimination and restated certificate of incorporation with the delaware secretary of state which eliminated the series preferred stock since may we have one esop that hold common stock of the company common esop of december all share of common stock held by the common esop have been allocated to the pfizer defined contribution plan participant the compensation cost related to the common esop wa million in million in and million in note share based paymentsour compensation program can include share based payment award with value that is determined by reference to the fair value of our share and that provide for the grant of share or option to acquire share or similar arrangement our share based award are designed based on competitive survey data or industry peer group used for compensation purpose and are allocated between different long term incentive award generally in the form of total shareholder return unit tsrus restricted stock unit rsus portfolio performance share ppss performance share award psa breakthrough performance award bpas and stock option determined by the compensation committee the stock plan plan replaced and superseded the plan it provides for million share in addition to share remaining under the plan to be authorized for grant the plan provides that the number of stock option tsrus rsus or performance based award that may be granted to any one individual during any month period is limited to million share and that rsus count three share ppss psa and bpas count three share time the maximum potential payout while tsrus and stock option count one share toward the maximum share available under the plan of december million share were available for award although not required to do so we have used authorized and unissued share and to lesser extent treasury stock to satisfy our obligation under these program pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesa summary of the award and valuation detail awarded totermsvaluationrecognition and presentationtotal shareholder return unit tsrus senior and other key management and select employee entitle the holder to receive share of our common stock with value equal to the difference between the defined settlement price and the grant price plus the dividend equivalent accumulated during the five or seven year term if and to the extent the total value is positive settlement price is the average closing price of our common stock during the trading day ending on the fifth or seventh anniversary of the grant applicable the grant price is the closing price of our common stock on the date of the grant automatically settle on the fifth or seventh anniversary of the grant but vest on the third anniversary of the grant of the grant date using monte carlo simulation modelamortized on straight line basis over the vesting term into cost of sale selling informational and administrative expense and or research and development expense appropriate restricted stock unit rsus select employee entitle the holder to receive specified number of share of our common stock including dividend equivalent that are reinvested into additional rsus for rsus granted in virtually all instance the unit vest on the third anniversary of the grant date assuming continuous service from the grant date of the grant date using the closing price of our common stockamortized on straight line basis over the vesting term into cost of sale selling informational and administrative expense and or research and development expense appropriate portfolio performance share ppss select employee entitle the holder to receive at the end of the performance period share of our common stock if any including share resulting from dividend equivalent earned on such share for ppss granted the award vest on the third anniversary of the grant assuming continuous service from the grant date and the number of share paid if any depends on the achievement of predetermined goal related to pfizer long term product portfolio during three or five year performance period from the year of the grant date applicable the number of share that may be earned range from to of the initial award depending on goal achievement over the performance period of the grant date using the intrinsic value method using the closing price of our common stockamortized on straight line basis over the vesting term into cost of sale selling informational and administrative expense and or research and development expense appropriate and adjusted each reporting period necessary to reflect change in the price of our common stock the number of share that are probable of being earned and management assessment of the probability that the specified performance criterion will be achieved performance share award psa senior and other key management entitle the holder to receive at the end of the performance period share of our common stock retiree earned if any or an equal value in cash active colleague including dividend equivalent on share earned dependent upon the achievement of predetermined goal related to two measure adjusted net income over three one year period andb tsr compared to the nyse arca pharmaceutical index drg index over the three year performance period psa vest on the third anniversary of the grant assuming continuous service from the grant date the award that may be earned range from to of the target award depending on goal achievement over the performance period of the grant date using the intrinsic value method using the closing price of our common stockamortized on straight line basis over the vesting term into cost of sale selling informational and administrative expense and or research and development expense appropriate and adjusted each reporting period necessary to reflect change in the price of our common stock the number of share that are probable of being earned and management assessment of the probability that the specified performance criterion will be achieved breakthrough performance award bpas select employee identified instrumental in delivering medicine to patient excluding executive officer entitle the holder to receive at the end of the performance period share of our common stock if any including share resulting from dividend equivalent earned on such share for bpas granted the award if earned vested are settled at the end of the performance period but no earlier than the one year anniversary of the date of grant and dependent upon the achievement of the respective predetermined performance goal related to advancing pfizer product pipeline during the performance period the number of share that may be earned range from to of the target award depending on the level and timing of goal achievement over the performance period of the grant date using the intrinsic value method using the closing price of our common stockamortized on straight line basis over the probable vesting term into cost of sale selling informational and administrative expense and or research and development expense appropriate and adjusted each reporting period necessary to reflect change in the price of our common stock the number of share that are probable of being earned and management assessment of the probability that the specified performance criterion will be achieved and or management assessment of the probable vesting term pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesawarded totermsvaluationrecognition and presentationstock optionsselect employee entitle the holder to purchase specified number of share of our common stock at price per share equal to the closing market price of our common stock on the date of grant for period of time when vested since only limited set of non employee received stock option grant no stock option were awarded to senior and other key management in any period presented stock option vest on the third anniversary of the grant assuming continuous service from the grant date and have contractual term of year of the grant date using the black scholes merton option pricing modelamortized on straight line basis over the vesting term into cost of sale selling informational and administrative expense and or research and development expense appropriate retirement eligible holder defined in the grant term can convert their tsrus when vested into profit unit ptus with conversion ratio based on calculation used to determine the share at tsru settlement the ptus are entitled to earn dividend equivalent unit deus and the ptus and deus will be settled in our common stock on the tsrus original settlement date and will be subject to the term and condition of the original grant including forfeiture provision in performance total shareholder return unit ptsrus were awarded to the former chairman and chief executive officer ptsrus and ptsrus were awarded to the group president chief business officer former role group president pfizer innovative health at grant price of and at gdfv of per ptsru in addition to having the same characteristic and valuation methodology of tsrus ptsru grant require special service and performance condition the following provides data related to all tsru rsu pps psa and stock option activity million except fair value of share vested per tsru and stock option tsrusrsusppsspsasstock optionsyear ended december fair value of share vested intrinsic value of option exercised or share unit converted received upon exercise benefit realized from exercise cost recognized pre tax compensation cost related to nonvested award not yet recognized pre tax average period over which cost is expected to be recognized year weighted average gdfv per tsrus and stock option tsru includes expense for ptsrus which is not significant for all year presented total share based payment expense wa billion million and million in and respectively which includes pre tax share based payment expense included in discontinued operation net of tax of million million and million in and respectively tax benefit for share based compensation expense wa million million and million in and respectively the table above excludes total expense due to the modification for share based award in connection with our cost reduction productivity initiative which wa not significant for all year presented and is recorded in restructuring charge and certain acquisition related cost see note amount capitalized part of inventory cost were not significant for any period presented summary of the weighted average assumption used in the valuation of tsrus and stock option tsrusstock optionsyear ended december dividend yield based on constant dividend yield during the expected term risk free interest rate based on interpolated yield on treasury zero coupon issue expected stock price volatility based on implied volatility after consideration of historical volatility tsrus contractual stock option expected term year based on historical exercise and post vesting termination pattern for stock option inc form to consolidated financial statementspfizer inc and subsidiary companiessummary of all tsru rsu pps psa and bpa activity during with the share granted representing the maximum award that could be achieved for ppss psa and bpas tsrusrsusppss psasbpastsrus per tsru weighted averageshares weighted avg gdfv per shareshares weighted avg intrinsic value per shareshares weighted avg intrinsic value per shareshares weighted avg intrinsic value per share thousand gdfvgrant price thousand thousand thousand thousand nonvested december vested reinvested dividend forfeited nonvested december vested and non vested share outstanding but not paid of december were million summary of tsru and ptu information of december tsrus thousand ptus thousand weighted averagegrant priceper tsruweighted averageremaining contractual term year aggregate intrinsic value million tsrus tsrus tsrus expected to vest tsrus exercised and converted to ptus in we settled tsrus with weighted average grant price of per unit in tsrus with weighted average grant price of per unit were converted into ptus the number of tsrus expected to vest take into account an estimate of expected forfeiture summary of all stock option activity during share thousand weighted averageexercise priceper shareweighted averageremaining contractual term year aggregateintrinsic value million outstanding december exercised forfeited expired outstanding december vested and expected to vest december exercisable december market price of our underlying common stock le exercise price the number of option expected to vest take into account an estimate of expected forfeiture pfizer inc form to consolidated financial statementspfizer inc and subsidiary company note earnings per common share attributable to pfizer inc common shareholdersthe following present the detailed calculation of eps year ended december in million numerator basic income from continuing operation attributable to pfizer inc le preferred stock dividend net of tax income from continuing operation attributable to pfizer inc common discontinued operation net of tax net income attributable to pfizer inc common shareholder eps numerator diluted income from continuing operation attributable to pfizer inc common shareholder and assumed conversion discontinued operation net of tax attributable to pfizer inc common shareholder and assumed conversion net income attributable to pfizer inc common shareholder and assumed conversion eps denominator weighted average number of common share outstanding common share equivalent stock option stock issuable under employee compensation plan convertible preferred stock and accelerated share repurchase weighted average number of common share outstanding anti dilutive common stock equivalent these common stock equivalent were outstanding for the period presented but were not included in the computation of diluted eps for those period because their inclusion would have had an anti dilutive effect allocated share held by the common esop including reinvested dividend are considered outstanding for eps calculation and the eventual conversion of allocated preferred share held by the preferred esop wa assumed in the diluted eps calculation until the conversion date which occurred in may see note note leaseswe lease real estate fleet and equipment for use in our operation our lease generally have lease term of to year some of which include option to terminate or extend lease for up to to year or on month to month basis we include option that are reasonably certain to be exercised part of the determination of lease term we may negotiate termination clause in anticipation of any change in market condition but generally these termination option have not been exercised residual value guarantee are generally not included within our operating lease with the exception of some fleet lease in addition to base rent payment the lease may require to pay directly for tax and other non lease component such insurance maintenance and other operating expense which may be dependent on usage or vary month to month variable lease payment amounted to million in million in and million in we elected the practical expedient to not separate non lease component from lease component in calculating the amount of rou asset and lease liability for all underlying asset class we determine if an arrangement is lease at inception of the contract and we perform the lease classification test of the lease commencement date rou asset represent our right to use an underlying asset for the lease term and lease liability represent our obligation to make lease payment arising from the lease operating lease rou asset and liability are recognized at commencement date based on the present value of lease payment over the lease term most of our lease do not provide an implicit rate we use our estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payment for operating lease the rou asset and liability in our consolidated balance sheet follows of december million balance sheet assetsother noncurrent asset lease liability short term other current lease liability long term other noncurrent component of total lease cost includes year ended december million lease cost variable lease sublease income total lease cost pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesother supplemental information follows of december million leasesweighted average remaining contractual lease term year average discount year ended december million paid for amount included in the measurement of lease liability operating cash flow from operating lease gain loss on sale and leaseback transaction the following reconciles the undiscounted cash flow for the first five year and total of the remaining year to the operating lease liability recorded in the consolidated balance sheet of december million periodoperating lease liabilitiesnext one year total undiscounted lease le imputed present value of minimum lease le current noncurrent portion reflects lease payment due within month subsequent to the balance sheet date note contingency and certain commitmentswe and certain of our subsidiary are subject to numerous contingency arising in the ordinary course of business including tax and legal contingency the following outline our legal contingency for discussion of our tax contingency see note legal proceedingsour legal contingency include but are not limited to the following patent litigation which typically involves challenge to the coverage and or validity of patent on various product process or dosage form an adverse outcome could result in loss of patent protection for product significant loss of revenue from that product or impairment of the value of associated asset we are the plaintiff in the majority of these action product liability and other product related litigation related to current or former product which can include personal injury consumer off label promotion security antitrust and breach of contract claim among others and often involves highly complex issue relating to medical causation label warning and reliance on those warning scientific evidence and finding actual provable injury and other matter commercial and other asserted or unasserted matter which can include acquisition licensing intellectual property collaboration or co promotion related and product pricing claim and environmental claim and proceeding can involve complexity that will vary from matter to matter government investigation which often are related to the extensive regulation of pharmaceutical company by national state and local government agency in the and in other jurisdiction certain of these contingency could result in increased expense and or loss including damage royalty payment fine and or civil penalty which could be substantial and or criminal charge we believe that our claim and defense in matter in which we are defendant are substantial but litigation is inherently unpredictable and excessive verdict do occur we do not believe that any of these matter will have material adverse effect on our financial position however we could incur judgment enter into settlement or revise our expectation regarding the outcome of matter which could have material adverse effect on our result of operation and or our cash flow in the period in which the amount are accrued or paid we have accrued for loss that are both probable and reasonably estimable substantially all of our contingency are subject to significant uncertainty and therefore determining the likelihood of loss and or the measurement of any loss can be complex consequently we are unable to estimate the range of reasonably possible loss in excess of amount accrued our assessment which result from complex series of judgment about future event and uncertainty are based on estimate and assumption that have been deemed reasonable by management but that may prove to be incomplete or inaccurate and unanticipated event and circumstance may occur that might cause to change those estimate and assumption pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesamounts recorded for legal and environmental contingency can result from complex series of judgment about future event and uncertainty and can rely heavily on estimate and assumption for proceeding under environmental law to which governmental authority is party we have adopted disclosure threshold of million in potential or actual governmental monetary sanction the principal pending matter to which we are party are discussed below in determining whether pending matter is principal matter we consider both quantitative and qualitative factor to ass materiality such among others the amount of damage and the nature of other relief sought if specified our view of the merit of the claim and of the strength of our defense whether the action purport to be or is class action and if not certified our view of the likelihood that class will be certified by the court the jurisdiction in which the proceeding is pending whether related action have been transferred to multidistrict litigation any experience that we or to our knowledge other company have had in similar proceeding whether disclosure of the action would be important to reader of our financial statement including whether disclosure might change reader judgment about our financial statement in light of all of the information that is available to the reader the potential impact of the proceeding on our reputation and the extent of public interest in the matter in addition with respect to patent matter in which we are the plaintiff we consider among other thing the financial significance of the product protected by the patent at issue some of the matter discussed below include those which management belief that the likelihood of possible loss in excess of amount accrued is remote legal proceeding patent litigationwe are involved in suit relating to our patent including but not limited to those discussed below most involve claim by generic drug manufacturer that patent covering our product or those of our collaboration licensing partner to which we have license or co promotion right and to which we may or may not be party process or dosage form are invalid and or do not cover the product of the generic drug manufacturer also counterclaim well various independent action have been filed alleging that our assertion of or attempt to enforce patent right with respect to certain product constitute unfair competition and or violation of antitrust law in addition to the challenge to the patent that are discussed below patent right to certain of our product or those of our collaboration licensing partner are being challenged in various other jurisdiction for example some of our collaboration or licensing partner face challenge to the validity of their patent right in non jurisdiction we are also party to patent damage suit in various jurisdiction pursuant to which generic drug manufacturer payer government or other party are seeking damage from for allegedly causing delay of generic entry we also are often involved in other proceeding such inter partes review post grant review re examination or opposition proceeding before the patent and trademark office the european patent office or other foreign counterpart relating to our intellectual property or the intellectual property right of others also if one of our patent is found to be invalid by such proceeding generic or competitive product could be introduced into the market resulting in the erosion of sale of our existing product for example several of the patent in our pneumococcal vaccine portfolio were challenged in inter partes review and post grant review proceeding in the in the patent trial and appeal board ptab initiated proceeding with respect to two of our pneumococcal vaccine patent however the ptab declined to initiate proceeding to two other pneumococcal vaccine patent those two patent and one other patent were challenged in federal court in delaware in september pfizer and challenger entered into settlement and license agreement resolving all worldwide legal proceeding involving that challenger related to our pneumococcal vaccine patent other challenge to pneumococcal vaccine patent remain pending at the ptab and outside the the invalidation of any of the patent in our pneumococcal portfolio could potentially allow additional competitor vaccine into the marketplace in the event that any of the patent are found valid and infringed competitor vaccine might be prohibited from entering the market or competitor might be required to pay royalty we are also subject to patent litigation pursuant to which one or more third party seek damage and or injunctive relief to compensate for alleged infringement of it patent by our commercial or other activity for example our hospira subsidiary are involved in patent and patent related dispute over their attempt to bring generic pharmaceutical and biosimilar product to market if one of our marketed product is found to infringe valid patent right of third party such third party may be awarded significant damage or royalty payment or we may be prevented from further sale of that product such damage may be enhanced much three fold if we or one of our subsidiary is found to have willfully infringed valid patent right of third party action in which we are the plaintiffepipenin king which we acquired in and is wholly owned subsidiary brought patent infringement action against sandoz in the district court for the district of new jersey in connection with sandoz abbreviated new drug application anda filed with the fda seeking approval to market an epinephrine injectable product sandoz is challenging patent which expire in covering the next generation autoinjector for use with epinephrine that is sold under the epipen brand name xeljanz tofacitinib beginning in we brought patent infringement action against several generic manufacturer that filed separate andas with the fda seeking approval to market their generic version of tofacitinib tablet in one or both of mg and mg dosage strength and in both immediate and extended release form to date we have settled action with several manufacturer on term not material to the remaining action continue in the district court for the district of delaware described below in january we brought separate patent infringement action against aurobindo pharma limited aurobindo asserting the infringement and validity of the patent covering the active ingredient expiring in december and the patent covering polymorphic form of tofacitinib expiring in which aurobindo challenged in it anda seeking approval to market generic version of tofacitinib mg and mg tablet in october we brought separate patent infringement action against sinotherapeutics inc sinotherapeutics asserting the infringement and validity of our patent covering extended release formulation of tofacitinib that wa challenged by sinotherapeutics in it anda seeking approval to market generic version of tofacitinib mg extended release tablet in february we brought separate patent infringement action against teva pharmaceutical usa inc teva asserting the infringement and validity of our patent covering extended release formulation of tofacitinib that wa challenged by teva in it anda seeking approval to market generic version of tofacitinib mg extended release tablet pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesin february we brought separate patent infringement action against slayback pharma llc slayback asserting the infringement and validity of our compound patent covering the active ingredient that wa challenged by slayback in it anda seeking approval to market generic version of tofacitinib oral solution mg ml inlyta axitinib in glenmark pharmaceutical ltd glenmark notified that it had filed an anda with the fda seeking approval to market generic version of inlyta glenmark asserts the invalidity and non infringement of the crystalline form patent for inlyta that expires in in we filed suit against glenmark in the district court for the district of delaware asserting the validity and infringement of the crystalline form patent for inlyta ibrance palbociclib beginning in september we received correspondence from several generic company notifying that they would seek approval to market generic version of ibrance capsule the generic company assert the invalidity and non infringement of our crystalline form patent which expires in beginning in october we brought patent infringement action against each of these generic company in various federal court asserting the validity and infringement of the crystalline form patent we have settled with one of these generic company on term not material to the company beginning in january several generic company notified that they had filed andas with the fda seeking approval to market generic version of ibrance tablet the generic company are challenging some or all of the following patent the composition of matter patent expiring in ii the composition of matter patent expiring in iii the method of use patent expiring in iv the crystalline form patent expiring in and tablet formulation patent expiring in we brought patent infringement action against each of the generic filer in various federal court asserting the validity and infringement of the patent challenged by the generic company eucrisabeginning in september several generic company notified that they had filed andas with the fda seeking approval to market generic version of eucrisa the company assert the invalidity and non infringement of composition of matter patent expiring in two method of use patent expiring in and one other method of use patent expiring in in september we brought patent infringement action against the generic filer in the district court for the district of delaware asserting the validity and infringement of the patent challenged by the generic company matter involving our collaboration licensing partnerseliquisin twenty five generic company sent bm paragraph iv certification letter informing bm that they had filed andas seeking approval of generic version of eliquis challenging the validity and infringement of one or more of the three patent listed in the orange book for eliquis one of the patent expired in december and the remaining patent currently are set to expire in and eliquis ha been jointly developed and is being commercialized by bm and pfizer bm and pfizer filed patent infringement action against all generic filer in the district court for the district of delaware and the district court for the district of west virginia asserting that each of the generic company proposed product would infringe each of the patent that each generic filer challenged some generic filer challenged only the patent some challenged both the and patent and one generic company challenged all three patent in august the district court for the district of delaware ruled that both the patent and the patent are valid and infringed by the proposed generic product in august and september the generic filer appealed the district court decision to the court of appeal for the federal circuit prior to the august ruling we and bm settled with certain of the company on term not material to and we and bm may settle with other generic company in the future in september the court of appeal for the federal circuit affirmed the district court decision legal proceeding product litigationwe are defendant in numerous case including but not limited to those discussed below related to our pharmaceutical and other product plaintiff in these case seek damage and other relief on various ground for alleged personal injury and economic loss asbestosbetween and warner lambert owned american optical corporation american optical which manufactured and sold respiratory protective device and asbestos safety clothing in connection with the sale of american optical in warner lambert agreed to indemnify the purchaser for certain liability including certain asbestos related and other claim warner lambert wa acquired by pfizer in and is wholly owned subsidiary of pfizer warner lambert is actively engaged in the defense of and will continue to explore various mean of resolving these claim numerous lawsuit against american optical pfizer and certain of it previously owned subsidiary are pending in various federal and state court seeking damage for alleged personal injury from exposure to product allegedly containing asbestos and other allegedly hazardous material sold by pfizer and certain of it previously owned subsidiary there also are small number of lawsuit pending in various federal and state court seeking damage for alleged exposure to asbestos in facility owned or formerly owned by pfizer or it subsidiary effexorbeginning in action including purported class action were filed in various federal court against wyeth and in certain of the action affiliate of wyeth and certain other defendant relating to effexor xr which is the extended release formulation of effexor the plaintiff in each of the class action seek to represent class consisting of all person in the and it territory who directly purchased indirectly purchased or reimbursed patient for the purchase of effexor xr or generic effexor xr from any of the defendant from june until the time the defendant allegedly unlawful conduct ceased the plaintiff in all of the action allege delay in the launch of generic effexor xr in the and it territory in violation of federal antitrust law and in certain of the action the antitrust consumer protection and various other law of certain state the result of wyeth fraudulently obtaining and improperly listing certain patent for effexor xr in the orange book enforcing certain patent for effexor xr and entering into litigation settlement agreement with generic drug manufacturer with respect to effexor xr each of the plaintiff seek treble damage for in the individual action or on behalf of the putative class in the pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiespurported class action for alleged price overcharge for effexor xr or generic effexor xr in the and it territory since june all of these action have been consolidated in the district court for the district of new jersey in the district court dismissed the direct purchaser plaintiff claim based on the litigation settlement agreement but declined to dismiss the other direct purchaser plaintiff claim in the district court entered partial final judgment to all settlement agreement claim including those asserted by direct purchaser and end payer plaintiff which plaintiff appealed to the court of appeal for the third circuit in the court of appeal for the third circuit reversed the district court decision and remanded the claim to the district court lipitorbeginning in purported class action relating to lipitor were filed in various federal court against among others pfizer certain pfizer affiliate and in most of the action ranbaxy laboratory ltd ranbaxy and certain ranbaxy affiliate the plaintiff in these various action seek to represent nationwide multi state or statewide class consisting of person or entity who directly purchased indirectly purchased or reimbursed patient for the purchase of lipitor or in certain of the action generic lipitor from any of the defendant from march until the cessation of the defendant allegedly unlawful conduct the class period the plaintiff allege delay in the launch of generic lipitor in violation of federal antitrust law and or state antitrust consumer protection and various other law resulting from the agreement pursuant to which pfizer and ranbaxy settled certain patent litigation involving lipitor and pfizer granted ranbaxy license to sell generic version of lipitor in various market beginning on varying date and ii in certain of the action the procurement and or enforcement of certain patent for lipitor each of the action seek among other thing treble damage on behalf of the putative class for alleged price overcharge for lipitor or in certain of the action generic lipitor during the class period in addition individual action have been filed against pfizer ranbaxy and certain of their affiliate among others that assert claim and seek relief for the plaintiff that are substantially similar to the claim asserted and the relief sought in the purported class action described above these various action have been consolidated for pre trial proceeding in multi district litigation in the district court for the district of new jersey in september and the district court dismissed with prejudice the claim of the direct purchaser in october and november the district court dismissed with prejudice the claim of all other multi district litigation plaintiff all plaintiff have appealed the district court order dismissing their claim with prejudice to the court of appeal for the third circuit in addition the direct purchaser class plaintiff appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the court of appeal in the court of appeal reversed the district court decision and remanded the claim to the district court also in the state of west virginia filed an action in west virginia state court against pfizer and ranbaxy among others that asserts claim and seek relief on behalf of the state of west virginia and resident of that state that are substantially similar to the claim asserted and the relief sought in the purported class action described above epipen direct purchaser in february lawsuit wa filed in the district court for the district of kansa against pfizer it affiliate king and meridian and various mylan entity on behalf of purported nationwide class of direct purchaser plaintiff who purchased epipen device directly from the defendant plaintiff in this action generally allege that pfizer and mylan conspired to delay market entry of generic epipen through the settlement of patent litigation regarding epipen and thereby delayed market entry of generic epipen in violation of federal antitrust law plaintiff seek treble damage for alleged overcharge for epipen since in july the district court granted defendant motion to dismiss the direct purchaser complaint without prejudice in september plaintiff filed an amended complaint nexium and protonixa number of individual and multi plaintiff lawsuit have been filed against pfizer certain of it subsidiary and or other pharmaceutical manufacturer in various federal and state court alleging that the plaintiff developed kidney related injury purportedly result of the ingestion of certain proton pump inhibitor the case against pfizer involve protonix and or nexium and seek compensatory and punitive damage and in some case treble damage restitution or disgorgement in the federal action were ordered transferred for coordinated pre trial proceeding to multi district litigation in the district court for the district of new jersey part of our consumer healthcare jv transaction with gsk the jv ha agreed to assume and to indemnify pfizer for liability arising out of such litigation to the extent related to nexium docetaxel personal injury actionsa number of lawsuit have been filed against hospira and pfizer in various federal and state court alleging that plaintiff who were treated with docetaxel developed permanent hair loss the significant majority of the case also name other defendant including the manufacturer of the branded product taxotere plaintiff seek compensatory and punitive damage in the federal case were transferred for coordinated pre trial proceeding to multi district litigation in the district court for the eastern district of louisiana mississippi attorney general government actionin the attorney general of mississippi filed complaint in mississippi state court against the manufacturer of the branded product and eight other manufacturer including pfizer and hospira alleging with respect to pfizer and hospira failure to warn about risk of permanent hair loss in violation of the mississippi consumer protection act the action seek civil penalty and injunctive relief zantaca number of lawsuit have been filed against pfizer in various federal and state court alleging that plaintiff developed various type of cancer or face an increased risk of developing cancer purportedly result of the ingestion of zantac the significant majority of these case also name other defendant that have historically manufactured and or sold zantac pfizer ha not sold zantac since and only sold an otc version of the product plaintiff seek compensatory and punitive damage in february the federal action were transferred for coordinated pre trial proceeding to multi district litigation in the district court for the southern district of florida plaintiff in the multi district litigation have filed against pfizer and many other defendant master personal injury complaint consolidated consumer class action complaint alleging among other thing claim under consumer protection pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesstatutes of all state and medical monitoring complaint seeking to certify medical monitoring class under the law of state plaintiff previously had filed consolidated third party payor class action complaint alleging violation of the federal racketeer influenced and corrupt organization act rico statute and seeking reimbursement for payment made for the prescription version of zantac but the multi district litigation court dismissed that complaint plaintiff have appealed the dismissal to the court of appeal for the eleventh circuit in addition pfizer ha received service of canadian class action complaint naming pfizer and other defendant and seeking compensatory and punitive damage for personal injury and economic loss allegedly arising from the defendant sale of zantac in canada and ii the state of new mexico and the mayor and city council of baltimore separately filed civil action against pfizer and many other defendant in state court alleging various state statutory and common law claim in connection with the defendant alleged sale of zantac in those jurisdiction in april judicial council coordinated proceeding wa created in the superior court of california in alameda county to coordinate personal injury action against pfizer and other defendant filed in california state court chantixbeginning in august number of putative class action have been filed against pfizer in various federal court following pfizer voluntary recall of chantix due to the presence of nitrosamine nitroso varenicline plaintiff assert that they suffered economic harm purportedly result of purchasing chantix or generic varenicline medicine sold by pfizer plaintiff seek to represent nationwide and state specific class and seek various remedy including damage and medical monitoring similar putative class action have been filed in canada and israel where the product brand is champix legal proceeding commercial and other mattersmonsanto related mattersin monsanto company former monsanto contributed certain chemical manufacturing operation and facility to newly formed corporation solutia inc solutia and spun off the share of solutia in former monsanto merged with pharmacia upjohn company to form pharmacia pharmacia then transferred it agricultural operation to newly created subsidiary named monsanto company new monsanto which it spun off in two stage process that wa completed in pharmacia wa acquired by pfizer in and is wholly owned subsidiary of pfizer in connection with it spin off that wa completed in new monsanto assumed and agreed to indemnify pharmacia for any liability related to pharmacia former agricultural business new monsanto ha defended and or is defending pharmacia in connection with various claim and litigation arising out of or related to the agricultural business and ha been indemnifying pharmacia when liability ha been imposed or settlement ha been reached regarding such claim and litigation in connection with it spin off in solutia assumed and agreed to indemnify pharmacia for liability related to former monsanto chemical business the result of it reorganization under chapter of the bankruptcy code solutia indemnification obligation relating to former monsanto chemical business are primarily limited to site that solutia ha owned or operated in addition in connection with it spin off that wa completed in new monsanto assumed and agreed to indemnify pharmacia for any liability primarily related to former monsanto chemical business including but not limited to any such liability that solutia assumed solutia and new monsanto assumption of and agreement to indemnify pharmacia for these liability apply to pending action and any future action related to former monsanto chemical business in which pharmacia is named defendant including without limitation action asserting environmental claim including alleged exposure to polychlorinated biphenyls solutia and or new monsanto are defending pharmacia in connection with various claim and litigation arising out of or related to former monsanto chemical business and have been indemnifying pharmacia when liability ha been imposed or settlement ha been reached regarding such claim and litigation environmental mattersin we submitted revised site wide feasibility study with regard to the wyeth holding corporation formerly american cyanamid company discontinued industrial chemical facility in bound brook new jersey in wyeth holding corporation executed an administrative settlement agreement and order on consent for removal action the administrative settlement agreement with the environmental protection agency epa with regard to the bound brook facility in accordance with the administrative settlement agreement we completed construction of an interim remedy in the epa issued final remediation plan for the bound brook facility main plant area in wyeth holding corporation now wyeth holding llc entered into an administrative settlement agreement and order on consent with the epa to allow to undertake detailed engineering design of the remedy for the main plant area and to perform focused feasibility study for two adjacent lagoon in the on behalf of the epa filed complaint and consent decree with the federal district court for the district of new jersey that allows wyeth holding llc to complete the design and to implement the remedy for the main plant area the consent decree which supersedes the administrative settlement agreement wa entered by the district court in in the epa issued final remediation plan for the two adjacent lagoon in wyeth holding llc entered into an administrative settlement agreement and order on consent with the epa to allow to undertake detailed engineering design of the remedy for the lagoon in september the on behalf of the epa filed complaint and consent decree with the federal district court for the district of new jersey which the court approved in november that will allow wyeth holding llc to complete the design and implement the remedy for the two adjacent lagoon we have accrued for the estimated cost of the site remedy for the bound brook facility we are party to number of other proceeding brought under the comprehensive environmental response compensation and liability act of amended and other state local or foreign law in which the primary relief sought is the cost of past and or future remediation contract with iraqi ministry of healthin number of service member civilian and their family brought complaint in the district court for the district of columbia against number of pharmaceutical and medical device company including pfizer and certain of it subsidiary alleging that the defendant violated the anti terrorism act the complaint alleges that the defendant provided funding for terrorist organization through their sale practice pursuant to pharmaceutical and medical device contract with the iraqi ministry of health and seek monetary relief in july the district court granted defendant motion to dismiss and dismissed all of plaintiff claim in january the court of appeal reversed the district court decision in february the defendant filed for en banc review of the court of appeal decision pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesallergan complaint for indemnityin pfizer wa named defendant in complaint along with king filed by allergan finance llc allergan in the supreme court of the state of new york asserting claim for indemnity related to kadian which wa owned for short period by king in prior to pfizer acquisition of king in this suit wa voluntarily discontinued without prejudice in january breach of contract xalkori lorbrenawe are defendant in breach of contract action brought by new york university nyu in the supreme court of the state of new york supreme court nyu alleges that it is entitled to royalty on pfizer sale of xalkori under the term of research and license agreement between nyu and sugen inc sugen inc wa acquired by pharmacia in august and pharmacia wa acquired by pfizer in and is wholly owned subsidiary of pfizer the action wa originally filed in in the supreme court dismissed the action and in the new york state appellate division reversed the decision and remanded the proceeding to the supreme court in january the supreme court denied both party summary judgment motion in october nyu filed separate breach of contract action against pfizer alleging that it is entitled to royalty on sale of lorbrena under the term of the same nyu sugen inc research and licensing agreement in february the party reached an agreement to settle both breach of contract action on term not material to pfizer viatris security litigationin october putative class action wa filed in the court of common plea of allegheny county pennsylvania on behalf of former mylan shareholder who received viatris common stock in exchange for mylan share in connection with the spin off of the upjohn business and it combination with mylan the transaction viatris pfizer and certain of each company current and former officer director and employee are named defendant the complaint alleges that the defendant violated certain provision of the security act of in connection with certain disclosure made in or omitted from the registration statement and related prospectus issued in connection with the transaction plaintiff seek damage cost and expense and other equitable and injunctive relief legal proceeding government investigationswe are subject to extensive regulation by government agency in the other developed market and multiple emerging market in which we operate criminal charge substantial fine and or civil penalty limitation on our ability to conduct business in applicable jurisdiction corporate integrity or deferred prosecution agreement well reputational harm and increased public interest in the matter could result from government investigation in the and other jurisdiction in which we do business in addition in qui tam lawsuit in which the government decline to intervene the relator may still pursue suit for the recovery of civil damage and penalty on behalf of the government among the investigation by government agency are the matter discussed below greenstone investigation department of justice antitrust division investigationsince july the department of justice antitrust division ha been investigating our former greenstone generic business we believe this is related to an ongoing broader antitrust investigation of the generic pharmaceutical industry we have produced record relating to this investigation state attorney general and multi district generic antitrust litigationin april greenstone received request for information from the antitrust department of the connecticut office of the attorney general in may attorney general of more than state plus the district of columbia and puerto rico filed complaint against number of pharmaceutical company including greenstone and pfizer the matter ha been consolidated with multi district litigation in the eastern district of pennsylvania to greenstone and pfizer the complaint alleges anticompetitive conduct in violation of federal and state antitrust law and state consumer protection law in june the state attorney general filed new complaint against large number of company including greenstone and pfizer making similar allegation but concerning new set of drug this complaint wa transferred to the multi district litigation in july the multi district litigation also includes civil complaint filed by private plaintiff and state county against pfizer greenstone and significant number of other defendant asserting allegation that generally overlap with those asserted by the state attorney general subpoena relating to manufacturing of quillivant xrin october we received subpoena from the attorney office for the southern district of new york sdny seeking record relating to our relationship with another drug manufacturer and it production and manufacturing of drug including but not limited to quillivant xr we have produced record pursuant to the subpoena government inquiry relating to meridian medical technology in february we received civil investigative demand from the attorney office for the sdny the civil investigative demand seek record and information related to alleged quality issue involving the manufacture of auto injector at the meridian site in august we received hipaa subpoena from the attorney office for the eastern district of missouri seeking similar record and information we are producing record in response to these request department of justice sec inquiry relating to russian operationsin june we received an informal request from the department of justice fcpa unit seeking document relating to our operation in russia in september we received similar request from the sec fcpa unit we have produced record pursuant to these request docetaxel mississippi attorney general government investigationsee legal proceeding product litigation docetaxel mississippi attorney general government investigation above for information regarding government investigation related to docetaxel marketing practice pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesu department of justice inquiry relating to india operationsin march we received an informal request from the department of justice consumer protection branch seeking document relating to our manufacturing operation in india including at our former facility located at irrungattukottai in india in april we received similar request from the attorney office for the sdny regarding civil investigation concerning operation at our facility in india we are producing record pursuant to these request department of justice sec inquiry relating to china operationsin june we received an informal request from the department of justice fcpa unit seeking document relating to our operation in china in august we received similar request from the sec fcpa unit we are producing record pursuant to these request zantac state of new mexico and mayor and city council of baltimore civil actionssee legal proceeding product litigation zantac above for information regarding civil action separately filed by the state of new mexico and the mayor and city council of baltimore alleging various state statutory and common law claim in connection with the defendant alleged sale of zantac in those jurisdiction legal proceeding matter resolved during certain matter including the matter discussed below were resolved or became the subject of definitive settlement agreement or settlement agreement in principle epipenbeginning in purported class action were filed in various federal court by indirect purchaser of epipen against pfizer and or it current and former affiliate king and meridian and or various entity affiliated with mylan and mylan former chief executive officer heather bresch the plaintiff in these action represent nationwide class comprising person or entity who paid for any portion of the end user purchase price of an epipen between until the cessation of the defendant allegedly unlawful conduct against pfizer and or it affiliate plaintiff in these action generally allege that pfizer and or it affiliate settlement of patent litigation regarding epipen delayed market entry of generic epipen in violation of federal and various state antitrust law at least one lawsuit also alleges that pfizer and or mylan violated rico plaintiff also filed various federal antitrust state consumer protection and unjust enrichment claim against and relating to conduct attributable solely to mylan and or it affiliate regarding epipen plaintiff seek treble damage for alleged overcharge for epipen since in all of these indirect purchase action were consolidated for coordinated pre trial proceeding in multi district litigation in the district court for the district of kansa with other epipen related action against mylan and or it affiliate to which pfizer king and meridian are not party in july pfizer and plaintiff filed stipulation of settlement to resolve the multi district litigation for million the district court approved the settlement in november and the payment wa made in accordance with the term of the settlement agreement guarantee and indemnificationsin the ordinary course of business and in connection with the sale of asset and business and other transaction we often indemnify our counterparties against certain liability that may arise in connection with the transaction or that are related to event and activity prior to or following transaction if the indemnified party were to make successful claim pursuant to the term of the indemnification we may be required to reimburse the loss these indemnification are generally subject to various restriction and limitation historically we have not paid significant amount under these provision and of december the estimated fair value of these indemnification obligation ha been included in our financial statement and is not material to pfizer in addition in connection with our entry into certain agreement and other transaction our counterparties may agree to indemnify for example in november we and mylan completed the transaction to spin off our upjohn business and combine it with mylan to form viatris part of the transaction and previously disclosed viatris ha agreed to assume and to indemnify pfizer for liability arising out of certain matter we have also guaranteed the long term debt of certain company that we acquired and that now are subsidiary of pfizer see note certain commitmentsas of december we had commitment totaling billion that are legally binding and enforceable these commitment include payment relating to potential milestone payment deemed reasonably likely to occur and purchase obligation for good and service see note for information on the tcja repatriation tax liability contingent consideration for acquisitionswe may be required to make payment to seller for certain prior business combination that are contingent upon future event or outcome see note the estimated fair value of contingent consideration of december is million of which million is recorded in other current liability and million in other noncurrent liability and of december is million of which million is recorded in other current liability and million in other noncurrent liability the increase in the contingent consideration balance from december is primarily due to fair value adjustment partially offset by payment made upon the achievement of certain sale based milestone insuranceour insurance coverage reflects market condition including cost and availability existing at the time it is written and our decision to obtain insurance coverage or to self insure varies accordingly depending upon the cost and availability of insurance and the nature of the risk involved the amount of self insurance may be significant the cost and availability of coverage have resulted in self insuring certain exposure including product liability if we incur substantial liability that are not covered by insurance or substantially exceed insurance pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiescoverage and that are in excess of existing accrual there could be material adverse effect on our cash flow or result of operation in the period in which the amount are paid and or accrued note segment geographic and other revenue informationa segment informationwe regularly review our operating segment and the approach used by management to evaluate performance and allocate resource with the formation of the consumer healthcare jv in and the completion of the spin off of our upjohn business in the fourth quarter of pfizer transformed into more focused global leader in science based innovative medicine and vaccine and beginning in the fourth quarter of operated single operating segment engaged in the discovery development manufacturing marketing sale and distribution of biopharmaceutical product worldwide at the beginning of our fiscal fourth quarter of we reorganized our commercial operation and began to manage our commercial operation through new global structure consisting of two operating segment each led by single manager biopharma our innovative science based biopharmaceutical business and our global contract development and manufacturing organization and leading supplier of specialty active pharmaceutical ingredient biopharma is science based medicine business that includes six therapeutic area oncology inflammation immunology rare disease hospital vaccine and internal medicine the hospital therapeutic area commercializes our global portfolio of sterile injectable and anti infective medicine each operating segment ha responsibility for it commercial activity regional commercial organization market distribute and sell our product and are supported by global platform function that are responsible for the research development manufacturing and supply of our product and global corporate enabling function biopharma receives it service from gpd and wrdm these service include ipr project for new investigational product and additional indication for in line product each business ha geographic footprint across developed and emerging market our chief operating decision maker us the revenue and earnings of the operating segment among other factor for performance evaluation and resource allocation biopharma is the only reportable segment we have revised prior period information revenue and earnings defined by management to conform to the current management structure other cost and business activitiescertain pre tax cost are not allocated to our operating segment result such cost associated with the following wrdm the and medical expense managed by our wrdm organization which is generally responsible for research project for our biopharma portfolio until proof of concept is achieved and then for transitioning those project to the gpd organization for possible clinical and commercial development spending may include upfront and milestone payment for intellectual property right the wrdm organization also ha responsibility for certain science based and other platform service organization which provide end to end technical expertise and other service to the various project well the worldwide medical and safety group which ensures that pfizer provides all stakeholder including patient healthcare provider pharmacist payer and health authority with complete and up to date information on the risk and benefit associated with pfizer product so that they can make appropriate decision on how and when to use pfizer medicine gpd the cost associated with our gpd organization which is generally responsible for clinical trial from wrdm in the biopharma portfolio including late stage portfolio spend gpd also provides technical support and other service to pfizer project gpd is responsible for facilitating all regulatory submission and interaction with regulatory agency corporate and other unallocated the cost associated with corporate enabling function such digital global real estate operation legal finance human resource worldwide public affair compliance and worldwide procurement among others all strategy business development portfolio management and valuation capability patient advocacy activity and certain compensation and other corporate cost such interest income and expense and gain and loss on investment ii overhead expense primarily associated with our manufacturing which include manufacturing variance associated with production operation that are not directly assessed to an operating segment business unit segment management doe not manage these cost and iii our share of earnings from the consumer healthcare jv certain transaction and event such purchase accounting adjustment where we incur expense associated with the amortization of fair value adjustment to inventory intangible asset and pp ii acquisition related item where we incur cost for executing the transaction integrating the acquired operation and restructuring the combined company and iii certain significant item representing substantive and or unusual and in some case recurring item such pension and postretirement actuarial remeasurement gain and loss gain on the completion of joint venture transaction restructuring charge legal charge or net gain and loss on investment in equity security that are evaluated on an individual basis by management and that either result of their nature or size would not be expected to occur part of our normal business on regular basis such item can include but are not limited to non acquisition related restructuring cost well cost incurred for legal settlement asset impairment and disposal of asset or business including applicable any associated transition activity the operating result of our global contract development and manufacturing organization and through july our former consumer healthcare business are included in other business activity segment assetswe manage our asset on total company basis not by operating segment our operating asset are shared or commingled therefore our chief operating decision maker doe not regularly review any asset information by operating segment and accordingly we do not report asset information by operating segment total asset were billion of december and billion of december pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesselected income statement informationthe following table provides selected income statement information by reportable segment revenuesearnings depreciation and amortization year ended december year ended december year ended december million of dollar segment biopharma other business activity reconciling item purchase accounting adjustment acquisition related cost certain significant item income from continuing operation before provision benefit for tax on income biopharma earnings include dividend income from our investment in viiv of million in million in and million in certain production facility are shared depreciation is allocated based on estimate of physical production amount relate solely to the depreciation and amortization associated with continuing operation other business activity include revenue and cost associated with well cost associated with global wrdm and gpd platform function global corporate enabling function and other corporate item noted above that we do not allocate to our operating segment in other business activity also include revenue and cost associated with our former consumer healthcare business through july see note certain significant item are substantive and or unusual and in some case recurring item noted above that either result of their nature or size would not be expected to occur part of our normal business on regular basis for earnings in includes among other item billion charge for ipr related to our acquisition of trillium which wa accounted for an asset acquisition and recorded in research and development expense ii restructuring charge credit and implementation cost and additional depreciation asset restructuring of billion million recorded in selling informational and administrative expense and the remaining amount primarily recorded in restructuring charge and certain acquisition related cost and iii upfront and milestone payment on collaborative and licensing arrangement of billion recorded in research and development expense partially offset by iv actuarial valuation and other pension and postretirement plan gain of billion recorded in other income deduction net and gain on equity security of billion recorded in other income deduction net for earnings in includes among other item charge of billion related to certain asset impairment recorded in other income deduction net ii actuarial valuation and other pension and postretirement plan loss of billion recorded in other income deduction net and iii restructuring charge credit and implementation cost and additional depreciation asset restructuring of million million recorded in selling informational and administrative expense and the remaining amount primarily recorded in restructuring charge and certain acquisition related cost for earnings in includes among other item pre tax gain of billion recorded in gain on completion of consumer healthcare jv transaction associated with the completion of the consumer healthcare jv transaction partially offset by ii charge of billion related to certain asset impairment recorded in other income deduction net and iii actuarial valuation and other pension and postretirement plan loss of million recorded in other income deduction net for additional information see note and geographic informationthe following summarizes revenue by geographic area year ended december million state developed developed rest of emerging revenue revenue exceeded million in each of and country outside the in and respectively the is the only country to contribute more than of total revenue in and percentage of revenue our largest national market outside the wa japan which contributed of total revenue in and in each of and we and our collaboration partner biontech have entered into agreement to supply pre specified dos of comirnaty with multiple developed and emerging nation around the world and are continuing to deliver dos of comirnaty under such agreement we currently sell the comirnaty vaccine directly to government and government sponsored customer this includes supply agreement entered into in november and february and may with the ec on behalf of the different eu member state and certain other country each eu member state submits it own comirnaty vaccine order to and is responsible for payment pursuant to term of the supply agreement negotiated by the ec other revenue informationsignificant customersour prescription pharmaceutical product are sold principally to wholesaler but we also sell directly to retailer hospital clinic government agency and pharmacy in the we primarily sell our vaccine product directly to the federal government cdc wholesaler individual provider office retail pharmacy and integrated delivery network outside the we primarily sell our vaccine to government and non government institution pfizer inc form to consolidated financial statementspfizer inc and subsidiary companiesthe following summarizes revenue percentage of total revenue for our three largest wholesaler customer year ended december inc amerisourcebergen cardinal health inc collectively our three largest wholesaler customer represented and of total trade account receivable of december and additionally revenue from the government represented of total revenue for and primarily represent sale of comirnaty account receivable from the government represented of total trade account receivable of december and primarily relate to sale of comirnaty significant product revenuesthe following provides detailed revenue information for several of our major product million year ended december productprimary indication or revenue pfizer biopharmaceuticals group biopharma vaccine comirnaty direct sale and alliance revenuesactive immunization to prevent covid prevnar family pneumococcal nimenrixmeningococcal acwy fsme immun ticovactick borne encephalitis trumenbameningococcal all other oncology ibrancehr positive negative metastatic breast xtandi alliance revenuesmcrpc nmcrpc inlytaadvanced sutentadvanced and or metastatic rcc adjuvant rcc refractory gist after disease progression on or intolerance to imatinib mesylate and advanced pancreatic neuroendocrine bosulifphiladelphia chromosome positive chronic myelogenous xalkorialk positive and positive advanced ruxience non hodgkin lymphoma chronic lymphocytic leukemia granulomatosis with polyangiitis wegener granulomatosis and microscopic retacrit zirabev treatment of mcrc unresectable locally advanced recurrent or metastatic nsclc recurrent glioblastoma metastatic rcc and persistent recurrent or metastatic cervical lorbrenaalk positive metastatic aromasinpost menopausal early and advanced breast trazimera her positive breast cancer and metastatic stomach besponsarelapsed or refractory cell acute lymphoblastic leukemia braftoviin combination with mektovi for metastatic melanoma in patient with mutation and in combination with erbitux cetuximab for the treatment of mutant mcrc after prior bavencio alliance revenueslocally advanced or metastatic urothelial carcinoma metastatic merkel cell carcinoma immunotherapy and tyrosine kinase inhibitor combination for patient with advanced mektoviin combination with braftovi for metastatic melanoma in patient with all other internal medicine eliquis alliance revenue and direct salesnonvalvular atrial fibrillation deep vein thrombosis pulmonary premarin familysymptoms of chantix champixan aid to smoking cessation treatment in adult year of age or of bone and toviazoveractive all other internal pfizer inc form to consolidated financial statementspfizer inc and subsidiary company million year ended december productprimary indication or sulperazonbacterial medrolanti inflammatory zaviceftabacterial fragmintreatment prevention of venous zithromaxbacterial vfendfungal tygacilbacterial precedexsedation agent in surgery or intensive zyvoxbacterial paxlovidcovid infection high risk population ivig product all other anti all other inflammation immunology xeljanzra psa uc active polyarticular course juvenile idiopathic arthritis ankylosing enbrel outside the and canada ra juvenile idiopathic arthritis psa plaque psoriasis pediatric plaque psoriasis ankylosing spondylitis and nonradiographic axial inflectra remsima crohn disease pediatric crohn disease uc pediatric uc ra in combination with methotrexate ankylosing spondylitis psa and plaque all other rare disease vyndaqel vyndamaxattr cardiomyopathy and benefixhemophilia genotropinreplacement of human growth refacto af xynthahemophilia all other rare pfizer centreone consumer healthcare business total alliance revenue total biosimilars total sterile injectable pharmaceutical on december we completed the sale of our meridian subsidiary prior to it sale meridian wa managed part of the hospital therapeutic area on november we completed the spin off and the combination of our upjohn business with mylan to form viatris on december pfizer and viatris completed the termination of the mylan japan collaboration beginning in the fourth quarter of the financial result of meridian are reflected discontinued operation for all period presented beginning in the fourth quarter of the financial result of the upjohn business and mylan japan collaboration were reflected discontinued operation for all period presented prior period financial information ha been restated appropriate see note at the beginning of our fiscal fourth quarter of we reorganized our commercial operation and began to manage our commercial operation through new global structure consisting of two operating segment each led by single manager biopharma our innovative science based biopharmaceutical business and which previously had been managed within the hospital therapeutic area includes revenue from our contract manufacturing including certain comirnaty related manufacturing activity performed on behalf of biontech million for and million for and and active pharmaceutical ingredient sale operation well revenue related to our manufacturing and supply agreement with former legacy pfizer business partnership including but not limited to transitional manufacturing and supply agreement with viatris following the spin off of the upjohn business we have revised prior period information to conform to the current management structure prevnar family include revenue from prevnar prevenar pediatric and adult and prevnar adult biosimilars are highly similar version of approved and authorized biological medicine and primarily include revenue from inflectra remsima ruxience retacrit zirabev and trazimera intravenous immunoglobulin ivig product include the revenue from panzyga octagam and cutaquig on july our consumer healthcare business an otc medicine business wa combined with gsk consumer healthcare business to form new consumer healthcare jv see note total sterile injectable pharmaceutical represents the total of all branded and generic injectable product in the hospital therapeutic area including anti infective sterile injectable pharmaceutical remaining performance obligationscontracted revenue expected to be recognized from remaining performance obligation for firm order in long term contract to supply comirnaty to our customer total billion of december which includes amount received in advance and deferred and amount that will be invoiced we deliver the product to our customer in future period of this amount we expect to recognize revenue of pfizer inc form to consolidated financial statementspfizer inc and subsidiary company billion in billion in and million in remaining performance obligation exclude arrangement with an original expected contract duration of le than one year deferred revenuesour deferred revenue primarily relate to advance payment received or receivable in connection with contract that we entered into during and with various government or government sponsored customer in international market for supply of comirnaty the deferred revenue associated with the advance payment related to comirnaty total billion of december and million of december with billion and million recorded in current liability and noncurrent liability respectively of december and million recorded in current liability of december the increase in the comirnaty deferred revenue during wa the result of additional advance payment received we entered into new or amended contract or we invoiced customer in advance of vaccine delivery le amount recognized in revenue we delivered dos to our customer during we recognized in revenue substantially all of the balance of comirnaty deferred revenue of december the comirnaty deferred revenue of december will be recognized in revenue proportionately we deliver dos of the vaccine to our customer and satisfy our performance obligation under the contract with the amount included in current liability expected to be recognized in revenue within the next month and the amount included in noncurrent liability expected to be recognized in revenue in and in the first quarter of deferred revenue associated with contract for other product were not significant of december or pfizer inc form quarterly financial data unaudited pfizer inc and subsidiary company quarter million except per common share data revenue cost and expense restructuring charge and certain acquisition related cost income loss from continuing operation before provision benefit for tax on income loss provision benefit for tax on income loss income loss from continuing discontinued operation net of tax net income loss before allocation to noncontrolling le net income attributable to noncontrolling net income loss attributable to pfizer inc common shareholder earnings loss per common share basic income loss from continuing operation attributable to pfizer inc common shareholder discontinued operation net of tax net income loss attributable to pfizer inc common shareholder earnings loss per common share diluted income loss from continuing operation attributable to pfizer inc common shareholder discontinued operation net of tax net income loss attributable to pfizer inc common shareholder business development activity impacted our result of operation in see note the fourth quarter historically reflects higher cost in cost of sale selling informational and administrative expense and research and development expense cost of sale for all quarter reflects higher cost for comirnaty the fourth quarter includes billion charge for ipr expense associated with the acquisition of trillium well other upfront and milestone payment on collaboration and licensing arrangement see note and the third and fourth quarter of primarily include employee termination cost associated with our transforming to more focused company program see note all period reflect change in the jurisdictional mix of earnings primarily related to comirnaty the third quarter of reflects benefit resulting from certain initiative executed in the third quarter of associated with our investment in the consumer healthcare jv with gsk see note all period include the operating result of meridian prior to it sale on december and to lesser extent post closing adjustment directly related to prior discontinued business the second quarter of includes pre tax charge of million to resolve legal matter related to meridian and the fourth quarter of includes an after tax loss of million related to the sale of meridian see note basic and diluted eps are computed independently for each of the period presented accordingly the sum of the quarterly eps amount may not agree to the total for the year pfizer inc form quarterly financial data unaudited pfizer inc and subsidiary companiesquarter million except per common share data revenue cost and expense restructuring charge and certain acquisition related gain on completion of consumer healthcare jv transaction income loss from continuing operation before provision benefit for tax on income loss provision benefit for tax on income loss income loss from continuing discontinued operation net of tax net income loss before allocation to noncontrolling le net income attributable to noncontrolling net income loss attributable to pfizer inc common shareholder earnings loss per common share basic income loss from continuing operation attributable to pfizer inc common shareholder discontinued operation net of net income loss attributable to pfizer inc common shareholder earnings loss per common share diluted income loss from continuing operation attributable to pfizer inc common shareholder discontinued operation net of net income loss attributable to pfizer inc common shareholder business development activity impacted our result of operation in see note the fourth quarter historically reflects higher cost in cost of sale selling informational and administrative expense and research and development expense certain asset impairment totaled million in the third quarter of and million in the fourth quarter of recorded in other income deduction net see note operating result of the upjohn business through november the date of the spin off and combination with mylan the mylan japan collaboration and meridian are presented discontinued operation in all period presented see note basic and diluted eps are computed independently for each of the period presented accordingly the sum of the quarterly eps amount may not agree to the total for the year item change in and disagreement with accountant on accounting and financial disclosurenone item control and proceduresdisclosure control and proceduresas of the end of the period covered by this form we carried out an evaluation under the supervision and with the participation of our principal executive officer and principal financial officer of the effectiveness of the design and operation of our disclosure control and procedure such term is defined in rule and under the exchange act based on this evaluation our principal executive officer and principal financial officer concluded that our disclosure control and procedure are effective in alerting them in timely manner to material information required to be disclosed in our periodic report filed with the sec change in internal controlsduring our most recent fiscal quarter there ha not been any change in the company internal control over financial reporting such term is defined in rule and under the exchange act that ha materially affected or is reasonably likely to materially affect the company internal control over financial reporting pfizer inc form of independent registered public accounting firm to the board of director and shareholderspfizer inc opinion on internal control over financial reportingwe have audited pfizer inc and subsidiary company the company internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission in our opinion the company maintained in all material respect effective internal control over financial reporting of december based on criterion established in internal control integrated framework issued by the committee of sponsoring organization of the treadway commission we also have audited in accordance with the standard of the public company accounting oversight board united state pcaob the consolidated balance sheet of the company of december and the related consolidated statement of income comprehensive income equity and cash flow for each of the year in the three year period ended december and the related note collectively the consolidated financial statement and our report dated february expressed an unqualified opinion on those consolidated financial statement basis for opinionthe company management is responsible for maintaining effective internal control over financial reporting and for it assessment of the effectiveness of internal control over financial reporting included in the accompanying management report on internal control over financial reporting our responsibility is to express an opinion on the company internal control over financial reporting based on our audit we are public accounting firm registered with the pcaob and are required to be independent with respect to the company in accordance with the federal security law and the applicable rule and regulation of the security and exchange commission and the pcaob we conducted our audit in accordance with the standard of the pcaob those standard require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting wa maintained in all material respect our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting assessing the risk that material weakness exists and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk our audit also included performing such other procedure we considered necessary in the circumstance we believe that our audit provides reasonable basis for our opinion definition and limitation of internal control over financial reporting company internal control over financial reporting is process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle company internal control over financial reporting includes those policy and procedure that pertain to the maintenance of record that in reasonable detail accurately and fairly reflect the transaction and disposition of the asset of the company provide reasonable assurance that transaction are recorded necessary to permit preparation of financial statement in accordance with generally accepted accounting principle and that receipt and expenditure of the company are being made only in accordance with authorization of management and director of the company and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition use or disposition of the company asset that could have material effect on the financial statement because of it inherent limitation internal control over financial reporting may not prevent or detect misstatement also projection of any evaluation of effectiveness to future period are subject to the risk that control may become inadequate because of change in condition or that the degree of compliance with the policy or procedure may deteriorate new york new yorkfebruary inc form report on internal control over financial reportingmanagement reportwe prepared and are responsible for the financial statement that appear in this form these financial statement are in conformity with accounting principle generally accepted in the united state of america and therefore include amount based on informed judgment and estimate we also accept responsibility for the preparation of other financial information that is included in this document report on internal control over financial reportingthe management of the company is responsible for establishing and maintaining adequate internal control over financial reporting defined in rule and under the security exchange act of the company internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statement for external purpose in accordance with generally accepted accounting principle in the united state of america the company internal control over financial reporting includes those policy and procedure that pertain to the maintenance of record that in reasonable detail accurately and fairly reflect the transaction and disposition of the asset of the company ii provide reasonable assurance that transaction are recorded necessary to permit preparation of financial statement in accordance with generally accepted accounting principle and that receipt and expenditure of the company are being made only in accordance with authorization of management and director of the company and iii provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition use or disposition of the company asset that could have material effect on the financial statement because of it inherent limitation internal control over financial reporting may not prevent or detect misstatement also projection of any evaluation of effectiveness to future period are subject to the risk that control may become inadequate because of change in condition or that the degree of compliance with the policy or procedure may deteriorate management assessed the effectiveness of the company internal control over financial reporting of december in making this assessment management used the criterion set forth by the committee of sponsoring organization of the treadway commission in internal control integrated framework based on our assessment and those criterion management belief that the company maintained effective internal control over financial reporting of december the company independent auditor have issued their auditor report on the company internal control over financial reporting that report appears above in this form albert bourla chairman and chief executive officer frank amelio jennifer damicoprincipal financial officer principal accounting officerfebruary inc form iiiitem director executive officer and corporate governanceinformation about our director is incorporated by reference from the discussion under the heading item election of director in our proxy statement information about the pfizer policy on business conduct governing our employee including our chief executive officer chief financial officer and principal accounting officer and the code of business conduct and ethic for member of the board of director is incorporated by reference from the discussion under the heading governance pfizer policy on business conduct and code of conduct for director in our proxy statement information regarding the procedure by which our shareholder may recommend nominee to our board of director is incorporated by reference from the discussion under the heading item election of director criterion for board membership and annual meeting information submitting proxy proposal and director nomination for the annual meeting in our proxy statement information about our audit committee including the member of the committee and our audit committee financial expert is incorporated by reference from the discussion under the heading governance board and committee information board committee the audit committee in our proxy statement the balance of the information required by this item is contained in the discussion entitled information about our executive officer in this form item executive compensationinformation about director and executive compensation is incorporated by reference from the discussion under the heading non employee director compensation executive compensation and governance board and committee information board committee the compensation committee compensation committee interlock and insider participation in our proxy statement item security ownership of certain beneficial owner and management and related stockholder mattersinformation required by this item is incorporated by reference from the discussion under the heading executive compensation compensation table equity compensation plan information and security ownership in our proxy statement item certain relationship and related transaction and director independenceinformation about certain relationship and transaction with related party is incorporated by reference from the discussion under the heading governance other governance practice and policy related person transaction and indemnification and transaction with related person in our proxy statement information about director independence is incorporated by reference from the discussion under the heading item election of director director independence in our proxy statement item principal accounting fee and servicesour independent registered public accounting firm is kpmg llp new york ny auditor firm id information about the fee for professional service rendered by our independent registered public accounting firm in and is incorporated by reference from the discussion under the heading item ratification of selection of independent registered public accounting firm audit and non audit fee in our proxy statement our audit committee policy on pre approval of audit and permissible non audit service of our independent registered public accounting firm is incorporated by reference from the discussion under the heading item ratification of selection of independent registered public accounting firm policy on audit committee pre approval of audit and permissible non audit service in our proxy statement pfizer inc form ivitem exhibit financial statement financial statement the following consolidated financial statement related note report of independent registered public accounting firm and supplementary data are set forth in item financial statement and supplementary data in this form report of independent registered public accounting firm on the consolidated financial statement consolidated statement of income consolidated statement of comprehensive income consolidated balance sheet consolidated statement of equity consolidated statement of cash flow note to consolidated financial statement selected quarterly financial data unaudited financial statement schedule schedule are omitted because they are not required or because the information is provided elsewhere in the financial statement the financial statement of unconsolidated subsidiary are omitted because considered in the aggregate they would not constitute significant subsidiary exhibit these exhibit are available upon request request should be directed to our corporate secretary pfizer inc east street new york new york the exhibit number preceded by an asterisk indicate exhibit filed with this form all other exhibit number indicate exhibit filed by incorporation by reference exhibit number through are management contract or compensatory plan or arrangement and asset purchase agreement dated december by and among glaxosmithkline plc and glaxosmithkline consumer healthcare holding limited is incorporated by reference from our annual report on form pursuant to item of regulation the registrant hereby agrees to supplementally furnish to the sec upon request any omitted schedule or exhibit to the stock and asset purchase agreement combination agreement dated of july by and among upjohn inc utah acquisition sub inc mylan mylan and mylan ii is incorporated by reference from our current report on form filed on july pursuant to item of regulation the registrant hereby agrees to supplementally furnish to the sec upon request any omitted schedule or exhibit to the business combination agreement no to the business combination agreement dated of may by and among upjohn inc utah acquisition sub inc mylan mylan and mylan ii is incorporated by reference from our current report on form filed on june pursuant to item of regulation the registrant hereby agrees to supplementally furnish to the sec upon request any omitted schedule or exhibit to the amendment no to the business combination agreement and distribution agreement dated of july by and between and upjohn inc is incorporated by reference from our current report on form filed on july pursuant to item of regulation the registrant hereby agrees to supplementally furnish to the sec upon request any omitted schedule or exhibit to the separation and distribution agreement no to the separation and distribution agreement dated of february by and between and upjohn inc is incorporated by reference from our annual report on form pursuant to item of regulation the registrant hereby agrees to supplementally furnish to the sec upon request any omitted schedule or exhibit to the amendment no to the separation and distribution agreement no to the separation and distribution agreement dated of may by and between and upjohn inc is incorporated by reference from our current report on form filed on june pursuant to item of regulation the registrant hereby agrees to supplementally furnish to the sec upon request any omitted schedule or exhibit to the amendment no to the separation and distribution agreement no to the separation and distribution agreement dated of september by and between and upjohn inc is incorporated by reference from our quarterly report on form for the period ended september pursuant to item of regulation the registrant hereby agrees to supplementally furnish to the sec upon request any omitted schedule or exhibit to the amendment no to the separation and distribution agreement no to the separation and distribution agreement dated of november by and between and upjohn inc is incorporated by reference from our annual report on form pursuant to item of regulation the registrant hereby agrees to supplementally furnish to the sec upon request any omitted schedule or exhibit to the amendment no to the separation and distribution agreement restated certificate of incorporation dated december is incorporated by reference from our current report on form filed on december by law amended december are incorporated by reference from our current report on form filed ondecember dated of january between and the chase manhattan bank is incorporated by reference from our current report on form filed on january pfizer inc form supplemental indenture dated of march between and the bank of new york mellon successor to jpmorgan chase bank formerly jpmorgan chase bank formerly the chase manhattan bank trustee to indenture dated of january is incorporated by reference from our quarterly report on form for the period ended june supplemental indenture dated of june between and the bank of new york mellon successor to jpmorgan chase bank formerly jpmorgan chase bank formerly the chase manhattan bank trustee to indenture dated of january is incorporated by reference from our current report on form filed on june supplemental indenture dated of june between and the bank of new york mellon successor to jpmorgan chase bank formerly jpmorgan chase bank formerly the chase manhattan bank trustee to indenture dated of january is incorporated by reference from our current report on form filed on june supplemental indenture dated of may between and the bank of new york mellon successor to jpmorgan chase bank formerly jpmorgan chase bank formerly the chase manhattan bank trustee to indenture dated of january is incorporated by reference from our current report on form report filed on may supplemental indenture dated of october between and the bank of new york mellon successor to jpmorgan chase bank formerly jpmorgan chase bank formerly the chase manhattan bank trustee to indenture dated of january is incorporated by reference from our current report on form report filed on october supplemental indenture dated of june between and the bank of new york mellon formerly the bank of new york successor to jpmorgan chase bank formerly jpmorgan chase bank formerly the chase manhattan bank national association trustee to indenture dated of january is incorporated by reference from our current report on form report filed on june supplemental indenture dated of november between and the bank of new york mellon formerly the bank of new york successor to jpmorgan chase bank formerly jpmorgan chase bank formerly the chase manhattan bank national association trustee to indenture dated of january is incorporated by reference from our current report on form report filed on november supplemental indenture dated of march among the bank of new york mellon formerly the bank of new york successor to jpmorgan chase bank formerly jpmorgan chase bank formerly the chase manhattan bank successor to the chase manhattan bank national association trustee and the bank of new york mellon london branch paying agent to indenture dated of january is incorporated by reference from our current report on form report filed on march supplemental indenture dated of march among the bank of new york mellon formerly the bank of new york successor to jpmorgan chase bank formerly jpmorgan chase bank formerly the chase manhattan bank national association trustee and the bank of new york mellon london branch paying agent and calculation agent to indenture dated of january is incorporated by reference from our current report on form report filed on march supplemental indenture dated of december among the bank of new york mellon formerly the bank of new york successor to jpmorgan chase bank formerly jpmorgan chase bank formerly the chase manhattan bank national association trustee and the bank of new york mellon london branch paying agent to indenture dated of january is incorporated by reference from our current report on form report filed on december dated of april between wyeth formerly american home product corporation and the bank of new york mellon successor to jpmorgan chase bank trustee is incorporated by reference from wyeth registration statement on form filed on january indenture dated of october between wyeth and the bank of new york mellon successor to jpmorgan chase bank trustee is incorporated by reference from wyeth registration statement on form filed on january supplemental indenture dated of december between wyeth and the bank of new york mellon successor to jpmorgan chase bank trustee is incorporated by reference from wyeth annual report on form supplemental indenture dated of november between wyeth and the bank of new york mellon successor to jpmorgan chase bank trustee is incorporated by reference from wyeth current report on form filed on november supplemental indenture dated of march between wyeth and the bank of new york mellon successor to jpmorgan chase bank trustee is incorporated by reference from wyeth current report on form filed on march supplemental indenture dated of october between wyeth and the bank of new york mellon successor to jpmorgan chase bank formerly the chase manhattan bank trustee to indenture dated of april amended on october is incorporated by reference from our current report on form filed on november dated of september between and the bank of new york mellon trustee is incorporated by reference from our current report on form filed on september supplemental indenture dated of september between and the bank of new york mellon trustee is incorporated by reference from our current report on form filed on september supplemental indenture dated of march between and the bank of new york mellon trustee is incorporated by reference from our current report on form filed on march supplemental indenture dated of march between and the bank of new york mellon trustee is incorporated by reference from our current report on form filed on march pfizer inc form supplemental indenture dated of may between and the bank of new york mellon trustee is incorporated by reference from our current report on form filed on may supplemental indenture dated of august between and the bank of new york mellon trustee is incorporated by reference from our current report on form filed on august of pfizer security set forth in exhibit above the instrument defining the right of holder of long term debt security of the company and it subsidiary have been omitted we agree to furnish to the sec upon request copy of each instrument with respect to issuance of long term debt of the company and it subsidiary stock and incentive plan is incorporated by reference from our proxy statement for the annual meeting of shareholder inc stock plan amended and restated is incorporated by reference from our annual report on form no to pfizer stock plan is incorporated by reference from our annual report on form inc stock plan is incorporated by reference from our proxy statement for the annual meeting of shareholder no to pfizer inc stock plan is incorporated by reference from our annual report on form of acknowledgment and consent and summary of key term for grant of rsus tsrus ppss and psa is incorporated by reference from our quarterly report on form for the period ended march of executive grant letter is incorporated by reference from our annual report on form consolidated supplemental pension plan for united state and puerto rico employee is incorporated by reference from our annual report on form no to the pfizer consolidated supplemental pension plan for united state and puerto rico employee is incorporated by reference from our annual report on form no to the pfizer consolidated supplemental pension plan for united state and puerto rico employee is incorporated by reference from our annual report on form supplemental saving plan is incorporated by reference from our quarterly report on form for the period ended april no to the pfizer supplemental saving plan amended and restated of january is incorporated by reference from our quarterly report on form for the period ended october no to the pfizer supplemental saving plan is incorporated by reference from our annual report on form no to the pfizer supplemental saving plan is incorporated by reference from our quarterly report on form for the period ended september no to the pfizer supplemental saving plan is incorporated by reference from our annual report on form no to the pfizer supplemental saving plan is incorporated by reference from our annual report on form no to the pfizer supplemental saving plan is incorporated by reference from our quarterly report on form for the period ended june no to the pfizer supplemental saving plan is incorporated by reference from our annual report on form no to the pfizer supplemental saving plan is incorporated by reference from our annual report on form no to the pfizer supplemental saving plan is incorporated by reference from our annual report on form and restated pfizer inc global performance plan is incorporated by reference from our annual report on form and restated deferred compensation plan is incorporated by reference from our annual report on form to amended and restated deferred compensation plan dated june is incorporated by reference from our annual report on form no to amended and restated deferred compensation plan dated april is incorporated by reference from our quarterly report on form for the period ended july no to amended and restated deferred compensation plan is incorporated by reference from our annual report on form deferred compensation plan frozen of january together with certain amendment is incorporated by reference from our annual report on form no to wyeth deferred compensation plan is incorporated by reference from our annual report on form and restated wyeth supplemental employee saving plan effective of january and frozen of january together with all material amendment is incorporated by reference from our annual report on form to amended and restated wyeth supplemental employee saving plan dated june is incorporated by reference from our annual report on form form of indemnification agreement with each of our non employee director is incorporated by reference from our annual report on form pfizer inc form form of indemnification agreement with each of the named executive officer identified in our proxy statement for the annual meeting of shareholder is incorporated by reference from our annual report on form to frank amelio regarding replacement pension benefit dated august is incorporated by reference from our current report on form filed on august inc executive severance plan is incorporated by referenced from our current report on form filed on february no to the pfizer inc executive severance plan is incorporated by reference from our annual report on form no to the pfizer inc executive severance plan is incorporated by reference from our annual report on form no to the pfizer inc executive severance plan is incorporated by reference from our annual report on form retainer unit award plan for non employee director frozen of march amended is incorporated by reference from our annual report on form deferred compensation and unit award plan for non employee director amended is incorporated by reference from our quarterly report on form for the period ended september of special award letter agreement is incorporated by reference from our current report on form filed on october letter to mikael dolsten dated april is incorporated by reference from our quarterly report on form for the period ended april of special performance based incentive award letter is incorporated by reference from our annual report onform of special performance based incentive grant letter is incorporated by reference from our annual report on form inc stock plan is incorporated by reference from our proxy statement for the annual meeting of shareholder sharing agreement dated july between pfizer inc and albert bourla is incorporated by reference from our quarterly report on form for the period ended june of the company issuer of guaranteed security is incorporated by reference from our quarterly report on form for the period ended april of independent registered public accounting firm of attorney included part of signature page by the chief executive officer pursuant to section of the sarbanes oxley act of by the chief financial officer pursuant to section of the sarbanes oxley act of by the chief executive officer pursuant to section adopted pursuant to section of the sarbanes oxley act of by the chief financial officer pursuant to section adopted pursuant to section of the sarbanes oxley act of exhibit insxbrl instance document the instance document doe not appear in the interactive data file because it xbrl tag are embedded within the inline xbrl document schinline xbrl taxonomy extension schema calinline xbrl taxonomy extension calculation linkbase labinline xbrl taxonomy extension label linkbase preinline xbrl taxonomy extension presentation linkbase definline xbrl taxonomy extension definition page interactive data file the cover page interactive data file doe not appear in the interactive data file because it xbrl tag are embedded within the inline xbrl document item form summarynone pfizer inc form the requirement of section or of the security exchange act of this report wa signed on behalf of the registrant by the authorized person named below pfizer inc dated february margaret maddenmargaret maddensenior vice president and corporate secretarychief governance counselwe the undersigned director and officer of pfizer inc hereby severally constitute douglas lankler and margaret madden and each of them singly our true and lawful attorney with full power to them and each of them to sign for in our name in the capacity indicated below any and all amendment to this annual report on form filed with the security and exchange commission under the requirement of the security exchange act of this report wa signed by the following person on behalf of the registrant and in the capacity and on the date indicated signaturetitledate albert bourlaalbert bourlachairman and chief executive officer principal executive officer february frank ameliofrank ameliochief financial officer executive vice president principal financial officer february jennifer damicojennifer damicosenior vice president and controller principal accounting officer february ronald blaylockronald blaylockdirectorfebruary susan desmond hellmannsusan desmond hellmanndirectorfebruary joseph echevarriajoseph echevarriadirectorfebruary scott gottliebscott gottliebdirectorfebruary helen hobbshelen hobbsdirectorfebruary susan hockfieldsusan hockfielddirectorfebruary dan littmandan littmandirectorfebruary shantanu narayenshantanu narayendirectorfebruary suzanne nora johnsonsuzanne nora johnsondirectorfebruary james quinceyjames quinceydirectorfebruary james smithjames smithdirectorfebruary inc form copy and paste below content previous next setting hover over fact for quick information on off auto scrolling position top center selecting fact from the section menu or the fact menu will automatically scroll that element to the top or middle of the viewer window this setting will have no use on ie or safari tagged data savereset search result savereset selected fact savereset tag shading hover savereset copy and paste below content previous next nested fact previous next copy and paste below content previous next